CONFIDENTIAL –FOIA Exemptions Apply in U.S. 1
Status: A p
proved,  Date: 25 November 2021Janssen Research & Development *
Clinical Protocol
A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess
Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response
to Combination Regimens Containing JNJ-73763989 and Nucleos(t)ide Analog With or
Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection
The INSIG
HT Study
Protocol
73763989HPB2003; Phase 2
AMENDMENT 6
JNJ-73763989 and JNJ-56136379
*Janssen Research & Development is a global organization that operates through different legal entities in
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen
Biologics, BV; Janssen-Cilag International NV; Janssen, Inc; Janssen Pharmaceutica NV; Janssen
Sciences Ireland UC; Janssen Biopharma Inc.; or Janssen Research & Development, LLC. The term
“sponsor” is used throughout the protocol to represent these various legal entities; the sponsor is
identified on the Contact Information page that accompanies the protocol.
United States (US)sites of this study will be conducted under US Food & Drug Administration
Investigational New Drug (IND) regulations (21 CFR Part 312) .
EudraCT NUMBER:2019-004475-39
Status: Approved
Date: 25 November 2021
Prepared by: Janssen Research & Development, a division of Janssen Pharmaceutica NV
EDMS number: EDMS-ERI-200320376, 16.0
GCP Compliance:  This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory
requirements.
Confidentiality Statement
The info
rmation provided herein contains Company trade secrets, commercial or financial information that the Company
customarily holds close and treats as confidential.  The information is being provided under the assurance that the recipient
will maintain the confidentiality of the information under applicable statutes, regulations, rules, protective orders or
otherwise.
[STUDY_ID_REMOVED]
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 2
Status: 
Approved,  Date: 25 November 2021PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE
DOCUMENT HISTORY
Documen
t Date
Amendm
ent 6 This document
Amendm
ent 5 01 October 2021
Amendm
ent 4 30 July 2021
Amendm
ent 3 14 August 2020
Amendm
ent 2 07 May 2020
Amendm
ent 1 10 April 2020
Origina
l Protocol 12 February 2020
Amendm
ent 6 (This document)
Overall Rationale for the Amendment: The primary reason for this amendment is to update the criteria
for post-treatment monitoring and for nucleos(t) ide analog (NA)  re-treatment for participants who
discontinued NA treatment at Week 48.
With Amendment 5, changes were introduced to the criteria for post-treatment monitoring and NA re-
treatment for patients who discontinued NA treatment. These changes were triggered by a case of
hepatitis B reactivation with subacute hepatic failure (initially reported as severe clinical ALT flare)
following NA treatment cessation as per protocol in the REEF-2 (73763989PAHPB2002)  study which led
to listing of the patient for high urgency liver transplantation. The patient received a donor liver at Week
14 post-stopping NA and has since then showed an uneventful post-operative recovery.
To further protect the safety of study participants, the current amendment includes additional changes to
the criteria for post-treatment monitoring and for NA re-treatment for participants who discontinued NA
treatment.
These changes are based on additional follow-up information from participants in the REEF-2 study who
stopped all treatment including NA per protocol and is incorporating recommendations from Health
Authorities and the independent data monitoring committee.
Description of Change Brief Rationale Section Number and Name
Update
 of criteria for post- 
treatment monitoring and for 
NA re-treatment In further off-treatment analysis of 
REEF-2 with all participants 
having reached at least 12 weeks of 
follow-up post stopping NA, some 
participants show a pattern of fast 
increase of HBV DNA followed by 
significant elevations of ALT that 
improved after re-starting of NA 
treatment. Based on these 
observations it was decided to
implement more conservative rules
for post-treatment monitoring and
re-treatment criteria for all
participants who met NA treatment
completion criteria and stopped NA
treatment.1.1 Synopsis
1.3.2 Schedule of Activities - Follow-up
Phase
2.3.3 Benefit-risk Assessment for Study
Participation
4.2 Scientific Rationale for Study Design
6.6.2 NA Re-treatment Criteria
10.12 Appendix 12: NA Re-treatment and
Monitoring After Stopping of NA
Minor e
rrors were corrected
and minor clarifications
were made.Correction and clarification. Throughout the protocol 
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 3
Status: 
Approved,  Date: 25 November 2021TABLE OF CONTENTS
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE ............................................................... 2
TABLE OF CONTENTS ............................................................................................................................... 3
LIST OF IN-TEXT TABLES AND FIGURES................................................................................................ 6
1. PROTOCOL SUMMARY..................................................................................................................... 7
1.1. Synopsis........................................................................................................................................... 7
1.2. Schema.......................................................................................................................................... 23
1.3. Schedule of Activities..................................................................................................................... 25
1.3.1. Schedule of Activities - Screening and Study Intervention Phase ............................................. 25
1.3.2. Schedule of Activities - Follow-up Phase ................................................................................... 31
1.3.3. Schedule of Activities –Optional PegIFN-α2a Treatment.......................................................... 36
2. INTRODUCTION................................................................................................................................ 38
2.1. Study Rationale.............................................................................................................................. 40
2.2. Background.................................................................................................................................... 41
2.2.1. Nonclinical Studies ..................................................................................................................... 41
2.2.1.1. JNJ-3989 and JNJ-6379.......................................................................................................... 41
2.2.1.2. Combination of JNJ-3989 or JNJ-6379 with Entecavir, Tenofovir Disoproxil, or
Tenofovir Alafenamide............................................................................................................. 46
2.2.1.3. Combination of JNJ-3989 with PegIFN-α2a............................................................................ 48
2.2.1.4. Combination of JNJ-6379 with PegIFN-α2a............................................................................ 49
2.2.2. Clinical Studies ........................................................................................................................... 49
2.2.2.1. JNJ-3989 and JNJ-6379.......................................................................................................... 49
2.2.2.2. Combination of JNJ-3989 and JNJ-6379 with Entecavir, Tenofovir Disoproxil, or
Tenofovir Alafenamide............................................................................................................. 54
2.2.2.3. Combination of JNJ-3989 and JNJ-6379 with PegIFN-α2a.................................................... 56
2.3. Benefit-Risk Assessment............................................................................................................... 57
2.3.1. Benefits for Study Participation .................................................................................................. 57
2.3.1.1. Known Benefits........................................................................................................................ 57
2.3.1.2. Potential Benefits..................................................................................................................... 57
2.3.2. Risks for Study Participation....................................................................................................... 58
2.3.2.1. Known Risks............................................................................................................................ 58
2.3.2.2. Potential Risks......................................................................................................................... 58
2.3.2.2.1. Potential Risks for JNJ-3989................................................................................................ 58
2.3.2.2.2. Potential Risks for JNJ-6379................................................................................................ 59
2.3.2.2.3. Potential Risks for Tenofovir Disoproxil and PegIFN-α2a.................................................... 61
2.3.2.3. Risks Due to Study Procedures............................................................................................... 61
2.3.2.3.1. Potential Risks and Inconvenience Associated with the Liver Biopsy Procedures.............. 61
2.3.2.3.2. Potential Risks and Inconvenience Associated with the Optional Leukapheresis
Procedure............................................................................................................................. 62
2.3.3. Benefit-risk Assessment for Study Participation......................................................................... 62
3. OBJECTIVES AND ENDPOINTS ..................................................................................................... 64
4 . STUDY DESIGN................................................................................................................................ 66
4.1. Overall Design................................................................................................................................ 66
4.2. Scientific Rationale for Study Design............................................................................................. 69
4.2.1. Study-Specific Ethical Design Considerations ........................................................................... 73
4.3. Justification for Dose...................................................................................................................... 74
4.3.1. JNJ-3989 .................................................................................................................................... 74
4.3.2. JNJ-6379 .................................................................................................................................... 75
4.4. End of Study Definition................................................................................................................... 76
5. STUDY POPULATION ...................................................................................................................... 76
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 4
Status: 
Approved,  Date: 25 November 20215.1. Inclusion Criteria............................................................................................................................ 76
5.2. Exclusion Criteria........................................................................................................................... 79
5.3. Lifestyle Considerations................................................................................................................. 84
5.4. Screen Failures.............................................................................................................................. 84
6. STUDY INTERVENTION................................................................................................................... 85
6.1. Study Intervention(s) Administered................................................................................................ 85
6.2. Preparation/Handling/Storage/Accountability ................................................................................ 89
6.3. Measures to Minimize Bias: Randomization and Blinding............................................................. 90
6.4. Study Intervention Compliance...................................................................................................... 90
6.5. Concomitant Therapy..................................................................................................................... 91
6.6. Dose Modification........................................................................................................................... 93
6.6.1. Study Intervention Completion at Week 48................................................................................ 93
6.6.2. NA Re-treatment Criteria and Monitoring after Stopping of NA.................................................. 94
6.7. Study Intervention After the End of the Study................................................................................ 96
7. DISCONTINUATION OF INVESTIGATIONAL INTERVENTION AND PARTICIPANT
DISCONTINUATION/WITHDRAWAL............................................................................................... 96
7.1. Discontinuation of Study Intervention ............................................................................................ 96
7.2. Participant Discontinuation/Withdrawal From the Study................................................................ 98
7.2.1. Withdrawal From the Use of Research Samples ....................................................................... 98
7.3. Lost to Follow-up............................................................................................................................ 99
8. STUDY ASSESSMENTS AND PROCEDURES ............................................................................... 99
8.1. Liver Biopsy and Fine Needle Aspiration Biopsy......................................................................... 101
8.2. Blood Efficacy Assessments........................................................................................................ 102
8.2.1. Sequencing............................................................................................................................... 103
8.3. Blood Immune Assessments ....................................................................................................... 103
8.3.1. Peripheral Blood Mononuclear Cell Immune Analyses ............................................................ 103
8.3.2. Leukapheresis (Optional With Separate Consent)................................................................... 104
8.4. Safety Assessments..................................................................................................................... 104
8.4.1. Physical Examinations.............................................................................................................. 105
8.4.2. Vital Signs................................................................................................................................. 105
8.4.3. Electrocardiograms................................................................................................................... 105
8.4.4. Clinical Safety Laboratory Assessments.................................................................................. 106
8.5. Adverse Events and Serious Adverse Events ............................................................................. 106
8.5.1. Time Period and Frequency for Collecting Adverse Event and Serious Adverse Event
Information................................................................................................................................ 107
8.5.2. Method of Detecting Adverse Events and Serious Adverse Events ........................................ 107
8.5.3. Follow-up of Adverse Events and Serious Adverse Events..................................................... 108
8.5.4. Regulatory Reporting Requirements for Serious Adverse Events ........................................... 108
8.5.5. Pregnancy................................................................................................................................. 108
8.5.6. Adverse Events of Special Interest........................................................................................... 108
8.5.6.1. Injection Site Reactions......................................................................................................... 109
8.5.6.2. Intervention-emergent ALT/AST Elevations.......................................................................... 109
8.5.6.3. Complications From Liver Biopsy.......................................................................................... 110
8.5.6.4. Renal Complications.............................................................................................................. 110
8.5.6.5. Hematologic Abnormalities.................................................................................................... 111
8.5.7. Other Toxicities......................................................................................................................... 111
8.5.7.1. Rash ...................................................................................................................................... 111
8.5.7.2. Acute Systemic Allergic Reactions........................................................................................ 112
8.6. Treatment of Overdose................................................................................................................ 113
8.7. Pharmacokinetics......................................................................................................................... 113
8.7.1. Evaluations ............................................................................................................................... 113
8.7.2. Analytical Procedures............................................................................................................... 114
8.7.3. Pharmacokinetic Parameters and Evaluations......................................................................... 114
8.8. Pharmacokinetics/Pharmacodynamics........................................................................................ 114
8.9. Host Genetics............................................................................................................................... 114
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 5
Status: 
Approved,  Date: 25 November 20218.10. Host Biomarkers........................................................................................................................... 115
8.11. Medical Encounters...................................................................................................................... 115
9. STATISTICAL CONSIDERATIONS................................................................................................ 115
9.1. Statistical Hypotheses.................................................................................................................. 115
9.2. Sample Size Determination ......................................................................................................... 115
9.3. Populations for Analyses.............................................................................................................. 116
9.4. Statistical Analyses ...................................................................................................................... 116
9.4.1. Analysis of Efficacy and Antiviral Activity ................................................................................. 116
9.4.1.1. Analysis of the Primary Endpoint........................................................................................... 117
9.4.1.2. Analysis of Secondary Endpoints.......................................................................................... 117
9.4.1.3. Analysis of Exploratory Endpoints......................................................................................... 118
9.4.2. Safety Analyses........................................................................................................................ 118
9.4.3. Other Analyses ......................................................................................................................... 120
9.5. Interim Analysis............................................................................................................................ 121
9.6. Independent Flare Expert Panel .................................................................................................. 122
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS.......................... 123
10.1. Appendix 1: Abbreviations and Definitions of Terms................................................................... 123
10.2. Appendix 2: Clinical Laboratory Tests ......................................................................................... 126
10.3. Appendix 3: Regulatory, Ethical, and Study Oversight Considerations....................................... 128
REGULATORY AND ETHICAL CONSIDERATIONS............................................................................... 128
FINANCIAL DISCLOSURE....................................................................................................................... 131
INFORMED CONSENT PROCESS.......................................................................................................... 131
DATA PROTECTION................................................................................................................................ 132
LONG-TERM RETENTION OF SAMPLES FOR ADDITIONAL FUTURE RESEARCH .......................... 133
COMMITTEES STRUCTURE................................................................................................................... 133
PUBLICATION POLICY/DISSEMINATION OF CLINICAL STUDY DATA............................................... 133
DATA QUALITY ASSURANCE................................................................................................................. 135
CASE REPORT FORM COMPLETION.................................................................................................... 135
SOURCE DOCUMENTS........................................................................................................................... 136
MONITORING........................................................................................................................................... 137
ON-SITE AUDITS ..................................................................................................................................... 137
RECORD RETENTION............................................................................................................................. 138
STUDY AND SITE START AND CLOSURE ............................................................................................ 138
10.4. Appendix 4: Adverse Events: Definitions and Procedures for Recording, Evaluating,
Follow-up, and Reporting............................................................................................................. 140
ADVERSE EVENT DEFINITIONS AND CLASSIFICATIONS .................................................................. 140
ATTRIBUTION DEFINITIONS .................................................................................................................. 141
SEVERITY CRITERIA............................................................................................................................... 141
SPECIAL REPORTING SITUATIONS...................................................................................................... 141
PROCEDURES......................................................................................................................................... 142
CONTACTING SPONSOR REGARDING SAFETY ................................................................................. 143
PRODUCT QUALITY COMPLAINT HANDLING ...................................................................................... 143
10.5. Appendix 5: Rash Management................................................................................................... 144
10.6. Appendix 6: Intervention-emergent ALT/AST Elevations ............................................................ 147
10.7. Appendix 7: Cardiovascular Safety Abnormalities....................................................................... 148
10.8. Appendix 8: Contraceptive and Barrier Guidance and Collection of Pregnancy Information...... 149
10.9. Appendix 9: DAIDS Table............................................................................................................ 151
10.10. Appendix 10: Protocol Amendment History................................................................................. 174
10.11. Appendix 11: Covid Appendix...................................................................................................... 183
10.12. Appendix 12: NA Re-treatment and Monitoring After Stopping of NA......................................... 187
11. REFERENCES................................................................................................................................. 188
INVESTIGATOR AGREEMENT............................................................................................................... 191
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 6
Status: 
Approved,  Date: 25 November 2021LIST OF IN-TEXT TABLES AND FIGURES
TABLES
Table 1: Various Stages of HBV Infection –Terminology and Characteristics (EASL 2017)5 ............... 38
Table 2: Animal/Human Exposure Ratios at NOAEL for JNJ-3989........................................................ 42
Table 3: Animal/Human Ratios at the NOAEL in Rat and Dog (Human Exposure at 250mg
JNJ-6379 Once Daily for 28 Days [Study 56136379HPB1001]) .............................................. 44
Table 4: Disallowed Medication.............................................................................................................. 92
Table 5: PegIFN-α2a Hematological Dose Modification Guidelines....................................................... 93
Table 6: Management of Rash Events by Severity Grade ................................................................... 144
FIGURES
Figure 1: Schematic Overview of the Study –Prior to Protocol Amendment 5....................................... 23
Figure 2: Schematic Overview of the Study –As of Protocol Amendment 5........................................... 24
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 7
Status: 
Approved,  Date: 25 November 20211. PROTOCOL SUMMARY
1.1. Synopsis
A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and
Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens
Containing JNJ-73763989 and Nucleos(t) ide Analog With or Without JNJ-56136379 in Patients With
Chronic Hepatitis B Virus Infection.
JNJ-73763989 (JNJ-3989)  is a liver-targeted antiviral therapeutic for subcutaneous (SC)injection designed
to treat chronic hepatitis B virus (HBV) infection via a ribonucleic acid interference (RNAi)  mechanism.
Engagement of the cellular RNAi machinery by JNJ-3989 results in specific cleavage of HBV ribonucleic
acid (RNA)  transcripts, thereby reducing the levels of HBV proteins and the pre-genomic RNA (pgRNA) ,
the precursor of viral relaxed circular deoxyribonucleic acid (DNA) . The RNAi triggers in JNJ-3989, JNJ-
73763976 (JNJ-3976)  and JNJ-73763924 (JNJ-3924) , are designed to target all HBV RNA transcripts
derived from covalently closed circular DNA (cccDNA) , as well as transcripts derived from integrated viral
DNA. The latter has been suggested to be a significant source of hepatitis B surface antigen (HBsAg) in
hepatitis B e antigen (HBeAg) negative patients or patients on long term treatment with nucleos(t) ide
analogs (NAs) , the current standard of care.35
JNJ-56136379 (JNJ-6379)  is an orally administered capsid assembly modulator (CAM)  that is being
developed for the treatment of chronic HBV infection. JNJ-6379 binds to hepatitis B core protein (HBc)
and interferes with the viral capsid assembly process, thereby preventing the polymerase-bound pgRNA
encapsidation. This results in the formation of HBV capsids, devoid of HBV DNA or RNA (non-functional
capsids) , and ultimately in the inhibition of HBV replication. In addition, JNJ-6379 also acts at an early
stage of the viral life cycle by inhibiting the de-novo formation of cccDNA potentially by interfering with
the capsid disassembly process. JNJ-6379 was initially part of the study intervention for participants but
has been removed as study intervention with the implementation of an urgent safety measure, as described
in Protocol Amendment 5.
Prior to Protocol Amendment 5: The term “study intervention” throughout the protocol, refers to JNJ-3989,
JNJ-6379, NA, and optional PegIFN-α2aa.
As of Protocol Amendment 5: The term “study intervention” throughout the protocol, refers to JNJ-3989,
NA, and optional PegIFN α2a.
OBJECTIVES AND ENDPOINTS
The study will be conducted in 3 phases for all participants: a screening phase (4 weeks) , an open-label
study intervention phase (48 weeks) , and a follow-up phase (48 weeks) . Note that the follow-up period will
be extended for participants who are receiving optional treatment with PegIFN-α2a and who meet NA
treatment completion criteria at the end of treatment with NA and PegIFN-α2a to ensure all participants
have at least one year of follow-up after NA treatment cessation.
The following objectives and endpoints will be assessed overall and by study panel:
Objectives Endpoints
Primar
y
 To asse
ss changes in intrahepatic HBsAg 
between baseline and on-treatment liver  Changes in the proportion of HBsAg positive
hepatocytes between baseline and on-treatment
Week 40
a Note: O
ptional PegIFN α2a was introduced as ‘study intervention’ as of Protocol Amendment 4.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 8
Status: A
pproved,  Date: 25 November 2021Objectives Endpoints
biopsy 
in response to JNJ-3989-based
combination treatment
Secondar
y
 To asse
ss changes in intrahepatic immune 
response between baseline and 
on-treatment liver biopsy  Changes between baseline and on-treatment liver
biopsy in intrahepatic immune response (eg,
CD45+ T-cells, CD4+ T-cells, CD8+ T-cells,
Natural Killer cells, and dendritic cells)  in terms
of proportion of cells, cell types, and spatial
redistribution
 To asse
ss changes in intrahepatic viral 
nucleic acids and proteins between 
baseline and on-treatment liver biopsy  Changes from baseline in intrahepatic viral
parameters (such as cccDNA, pgRNA,
intrahepatic RNA, or HBsAg in terms of copy
number, or number of positive cells)
 Changes from baseline in intrahepatic cccDNA
levels and transcriptional activity
(pgRNA/cccDNA ratio)
 To eval
uate the efficacy of the study 
intervention as measured in blood  The proportion of participants during the study
intervention and follow-up phases with:
 HBsAg seroclearance at Week 72 (ie, 24
weeks after completion of all study
interventions at Week 48)  without restarting
NA treatment.
 (Sustained)  Reduction, suppression, and/or
seroclearance considering single and
multiple markers (such as HBsAg, HBeAg,
HBV DNA and ALT)
 HBsAg and HBeAg seroconversion
 Flares (virologic, biochemical, and clinical)
 Time to first HBsAg seroclearance
 To eval
uate the frequency of virologic 
breakthrough during study intervention  Proportion of participants with virologic
breakthrough
 To asse
ss HBV-specific T-cell responses  Changes from baseline in HBV-specific
peripheral blood T-cell responses during the
study intervention and follow-up phases
 To eval
uate the safety and tolerability of 
the study intervention  Proportion of participants with (S) AEs and
abnormalities in clinical laboratory tests
(including hematology, blood biochemistry,
blood coagulation, urinalysis, urine chemistry,
and renal biomarkers) , 12-lead ECGs, vital signs,
and physical examinations throughout the study
 To eval
uate the plasma PK of JNJ-3989 
(ie, JNJ-3976 and JNJ-3924) and  Plasma PK parameters of JNJ-3976, JNJ-3924,
and optionally of JNJ-6379, NA  and
PegIFN-α2a, as applicable
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 9
Status: 
Approved,  Date: 25 November 2021Objectives Endpoints
option
ally of JNJ-6379, NA and PegIFN-
α2a, as applicable
Explorat
ory
 To exp
lore the relationship of intrahepatic 
markers with blood markers (immune and 
viral) Association between levels and changes in
intrahepatic and blood markers
 To exp
lore the association of baseline 
characteristics and intrahepatic and/or 
blood (immune and viral)  biomarkers at 
baseline and on/off-treatment with selected 
on/off-treatment efficacy variables  Association of baseline characteristics and
baseline and on/off-treatment viral blood markers
(such as baseline NA treatment duration, age, and
baseline and on/off-treatment HBsAg levels)
with selected off-treatment efficacy variables
 Association of intrahepatic and blood biomarkers
(such as cccDNA levels, T-cell frequency)  with
selected on/off-treatment efficacy variables
 To exp
lore intrahepatic immune and viral 
changes at Week 72 and/or during off- 
treatment flares (only for participants with 
Week 72 biopsy available)  Changes from baseline and on-treatment liver
biopsy in intrahepatic immune and viral markers
at Week 72 and/or during off-treatment flares
(only for participants with Week 72 biopsy
available)
 To exp
lore changes in the severity of liver 
disease  Changes in fibrosis (according to Fibroscan liver
stiffness measurements)  at the end of study
intervention (EOSI)  and end of follow-up versus
screening/baseline*
 To exp
lore the efficacy in terms of changes 
in HBV RNA and hepatitis B core-related 
antigen (HBcrAg)  levels.  Changes from baseline in HBV RNA and
HBcrAg levels during study intervention and
follow-up phases. 
 To exp
lore the relationship between 
plasma PK parameters (JNJ-3989 [ie, 
JNJ-3976 and JNJ-3924] and/or JNJ-6379 
and/or NA  and/or PegIFN-α2a)  and 
selected pharmacodynamic (PD)  
parameters of efficacy and/or safety, as
applicable Relationship between various plasma PK
parameters (JNJ-3976 and JNJ-3924, and/or
JNJ-6379, and/or NA, and/or PegIFN-α2a)  and
selected efficacy and/or safety endpoints, as
applicable
 To exp
lore the HBV genome sequence  The emergence of intervention-associated
mutations during the study intervention and
follow-up phases
 To assess the impact of baseline HBV genome
polymorphisms on selected on/off-treatment
efficacy variables
* Only 
applicable to participants who are enrolled at a site with an on-site Fibroscan device.
Hypothesis
As this is an exploratory study, no hypothesis will be tested.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 10
Status: A
pproved,  Date: 25 November 2021OVERALL DESIGN
As of Protocol Amendment 5, this study is a Phase 2 single-arm, open-label, multicenter, study to assess
intrahepatic and peripheral changes of immunologic and virologic markers in response to a combination
regimen containing JNJ-3989 and NA in chronic HBV-infected participants.
With the implementation of an urgent safety measure, as described in Protocol Amendment 5, JNJ-6379
has been removed as study intervention and the study will continue as a single-arm study. Participants
randomized to Arm 1 had to stop JNJ‑6379 treatment immediately but continue JNJ-3989 + NA treatment.
In addition, participants who provide separate consent may receive optional treatment with PegIFN-α2a
starting after the Week 40 biopsy (or after the optional leukapheresis if applicable)  but before the Week 48
visit. The duration (either 12 or 24 weeks)  will be at the investigator’s discretion.
A target of 24 chronic HBV-infected male and female participants, 18-65 years (inclusive)  of age will be
enrolled in 2 panels, approximately 12 participants in each panel. Panel 1 will consist of participants who
are HBeAg positive and not currently treated and Panel 2 will consist of participants who are HBeAg
negative and virologically suppressed by entecavir (ETV) , tenofovir disoproxil, or tenofovir alafenamide
(TAF) treatment.
The study will be conducted in 3 phases for all participants: a screening phase (4 weeks) , an open-label
study intervention phase (48 weeks) , and a follow-up phase (48 weeks) . If necessary, eg, for operational
reasons, the screening phase may be extended up to a maximum of 6 weeks on a case-by-case basis and in
agreement with the sponsor. The duration of individual participation will be up to 102 weeks. Note that the
follow-up period will be extended for participants who are receiving optional treatment with PegIFN-α2a
and who meet NA treatment completion criteria at the end of treatment with NA and PegIFN-α2a to ensure
all participants have at least one year of follow-up after NA treatment cessation. For those participants, the
duration of individual participation may be extended up to 126 weeks.
Prior to Protocol Amendment 5, participants were randomized in a 1:1 ratio within each panel to receive
one of the following interventions (ie, treatments)for 48 weeks:
 Intervention arm 1, combination regimen JNJ-3989+JNJ-6379+NA (target of12 participants) :
 200 mg JNJ-3989 (SC injection once every 4 weeks [Q4W], with the last injection at Week 44) ,
AND
 250 mg JNJ-6379 (tablets once daily [qd]) , AND
 NA: ETV, tenofovir disoproxil, or TAF (tablets qd)
 Intervention arm 2, combination regimen JNJ-3989+NA (target of 12 participants) :
 200 mg JNJ-3989 (SC injection Q4W, with the last injection at Week 44) , AND
 NA: ETV, tenofovir disoproxil, or TAF (tablets qd)
As of Protocol Amendment 5:
 Participants who were randomized to study intervention with JNJ-6379 prior to Protocol Amendment
5, had to stop JNJ-6379 treatment immediately but will still receive the following interventions (ie,
treatments)  for 48 weeks:
 200 mg JNJ-3989 (SC injection Q4W, with the last injection at Week 44) , AND
 NA: ETV, tenofovir disoproxil, or TAF (tablets qd)
 New participants will enroll without randomization within each panel to receive the combination
regimen JNJ-3989 + NA as study intervention for 48 weeks:
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 11
Status: A
pproved,  Date: 25 November 2021 200 mg JNJ-3989 (SC injection Q4W, with the last injection at Week 44) , AND
 NA: ETV, tenofovir disoproxil, or TAF (tablets qd)
For participants who consented to receive optional PegIFN-α2a, the PegIFN-α2a treatment will be
completed after 12 or 24 weeks at the investigator’s discretion.
All participants will complete treatment with JNJ-3989 after a fixed duration of 48 weeks. If the NA
treatment completion criteria (see “Study Intervention Completion at Week 48”)  are met based on clinical
laboratory tests performed at Week 44, treatment with NA will also be completed at Week 48. In
participants not meeting these criteria, NA treatment will continue during the follow-up phase. Participants
who are receiving optional treatment with PegIFN-α2a and who have not met NA treatment completion
criteria at Week 48 may have NA treatment completion criteria assessed at the end of treatment with
PegIFN-α2a and stop NA if criteria are met.
All participants will have sparse PK sampling on Day 1 and at Weeks 4, 12, and 24 (and at early
withdrawal) . All participants who consent to participate in the intensive PK substudy (optional)  will
undergo intensive PK sampling at Week 4.
All participants will be monitored closely during the follow-up phase and, if applicable, should restart NA
treatment in accordance with the NA re-treatment criteria mentioned below.
Prior to Protocol Amendment 5, randomization within each panel was stratified by Fibroscan score (<7 kPa
vs ≥7 kPa) . Randomization and stratification are not applicable anymore per Protocol Amendment 5.
A participant will be considered to have completed the study if he or she has completed the assessments at
Follow-up Week 48. The follow-up phase will be extended by 24 weeks (ie, up to Follow-up Week 72)  for
participants who are receiving optional treatment with PegIFN-α2a and who meet NA treatment completion
criteria at the end of treatment with NA + PegIFN-α2a.
An Independent Flare Expert Panel (IFLEP)  will be appointed for this study.
Study Intervention Completion at Week 48
Participants will complete treatment with JNJ-3989 after a fixed duration of 48 weeks. If all of the below
criteria are met based on clinical laboratory tests performed at Week 44, treatment with NA will also be
completed at the next scheduled visit (ie, Week 48) :
 The participant has ALT <3x upper limit of normal (ULN) , AND
 The participant has HBV DNA < lower limit of quantification (LLOQ) , AND
 The participant is HBeAg negative, AND
 The participant has HBsAg <10 International Units Per Milliliter (IU/mL) .
Note: In case of ALT elevation ≥3x ULN at Week 44 the investigator must consider different potential
causes of increased ALT to ensure appropriate work up and management as needed. If the ALT elevation
is unrelated to HBV activity and/or <3x ULN by Week 48, NA completion may be considered at the
discretion of the investigator and in consultation with the sponsor.
Participants who do not meet the above criteria at Week 48 should continue NA treatment during the
48-week follow-up phase. Participants who are receiving optional treatment with PegIFN-α2a and who
have not met NA treatment completion criteria at Week 48 may have NA treatment completion criteria
assessed at the end of treatment with PegIFN-α2a and stop NA if criteria are met. The follow-up phase will
be extended up by 24 weeks (ie, up to Follow-up Week 72)  for participants who are receiving optional
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 12
Status: 
Approved,  Date: 25 November 2021treatment with PegIFN-α2a and who meet NA treatment completion criteria at the end of treatment with
NA + PegIFN-α2a.
NA Re-treatment Criteria and Monitoring After Stopping of NA
Participants who meet the NA treatment completion criteria (as described above)  will be monitored closely
during the follow-up phase.
After stopping NA treatment, participants should be monitored as follows:
 Regular monitoring visits will be every 4 weeks during the follow-up phase in accordance with the
schedule of activities.
 A post-treatment HBV DNA value of >20,000 IU/mL should trigger re-testing of ALT/AST, HBV
DNA, and total and direct bilirubin within a maximum of 7 days from receipt of the data and further
repeats as necessary (ie, weekly until HBV DNA returns to <20,000 IU/mL) .
 A post-treatment HBV DNA value of >2,000 IU/mL (but <20,000 IU/mL)  should trigger a re-test
within 14 days from receipt of the data and further repeats as necessary (ie, every other week until
HBV DNA returns to <2,000 IU/mL) .
 A post-treatment ALT value of >5x ULN should trigger re-testing of ALT, AST, ALP, total and direct
bilirubin, international normalized ratio (INR) , albumin, and HBV DNA on a weekly basis until ALT
and AST levels have returned to <5x ULN.
After stopping NA treatment, participants should re-start NA treatment:
 Immediately with signs of decreasing liver function based on laboratory findings (eg, INR, direct
bilirubin)  or clinical assessment (eg, ascites, hepatic encephalopathy) .
 Immediately with an HBV DNA value of >100,000 IU/mL (irrespective of confirmation and/or ALT
increase) .
 With confirmed post-treatment HBeAg seroreversion (HBeAg positive after it was negative at NA
completion)
 With confirmed* post-treatment increases in HBV DNA >2,000 IU/mL and ALT >5x ULN
 With confirmed* post-treatment increases in HBV DNA >20,000 IU/mL.
*At least 4 weeks apart –f requency of  visits as described above
Note:Additional re-testing and/or earlier restarting of NA treatment is at the investigator’s discretion, even
if the above cut-offs are not yet met.
To avoid delays in decision making, sites are encouraged to run local re-testing in parallel with central re-
testing in the situations described above that require more frequent re-testing. Local test results are to be
recorded in the CRF and/or source documents, including information on the HBV DNA assay used. In
addition, to avoid delays in NA re-treatment, it should be considered to dispense NA to participants who
potentially met the NA re-treatment criteria (eg, pending confirmation)  and who will not be available to
come to the study site immediately at the time the confirmatory test results will become available. This
should ensure that the participant can immediately restart NA treatment if indicated, upon direct
confirmation by the investigator.
In case NA treatment is re-started, participants will be followed until the end of the study or until clinical
stabilization, whichever comes later.
NA re-treatment criteria during follow-up are presented graphically in Section 10.12, Appendix 12: NA
Re-treatment During Follow-up.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 13
Status: 
Approved,  Date: 25 November 2021NUMBER OF PARTICIPANTS
A target of 24 chronic HBV-infected adult male and female participants will be randomized or enrolled.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 14
Status: 
Approved,  Date: 25 November 2021Description of Interventions
Intervention 
nameJNJ-3989 JNJ-6379****PegIFN-α2a Entecavir (ETV) 
monohydrate Tenofovir 
disoproxil Tenofovir
alafenamide (TAF)*
Type Drug
 Drug Drug Drug Drug Drug
Dosage 
f
ormulation Solution for 
injection Tablets Solution for 
injectionFilm-coated tablets Film-coated tablets Film-coated tablets
Unit d
ose 
strength(s)200 mg/vial 25 and 100 mg 180 µg/0.5 mL 0.5 mg 245 mg 25 mg
Dosage 
level 200 mg once every 
4 weeks (Q4W) 250 mg once daily 
(qd) 180 µg once weekly 
(QW)**Nucl eoside-naïve patients: 
0.5 mg qd
Lamivudine-refractory
patien
ts:
1 mg* qd (
but should
preferably be treated with
tenofovir disoproxil or
TAF instead)
Other indications:
1 mg* qd (
must be agreed
upon by the sponsor)245 mg qd 25 mg qd
Route 
of 
administration Subcutaneous 
injection preferably 
in the abdomen Oral Subcutaneous 
injection (in the
thigh or abdomen)Oral Oral Oral
Use Inv
estigational 
intervention Investigational 
intervention Investigational 
intervention Background intervention Background 
intervention Background
intervention
Sourcin
g Provided centrally 
by the sponsor Provided centrally 
by the sponsor Provided centrally 
by the sponsor*** Provided centrally by the 
sponsor Provided centrally 
by the sponsor Provided centrally
by the sponsor
Packag
ing and 
Labeling Each unit will be 
labeled with unique 
medication ID 
number Each unit will be 
labeled with unique 
medication ID 
number Commercial 
supplies will be 
sourced. Each unit 
will be labeled with 
unique medication 
ID number*** Commercial supplies will 
be sourced. Each unit will 
be labeled with unique 
medication ID number Commercial supplies 
will be sourced. 
Each unit will be 
labeled with unique 
medication ID 
number Commercial supplies
will be sourced.
Each unit will be
labeled with unique
medication ID
number
In chi
ld-resistant 
packaging In child-resistant 
packaging*** In child-resistant 
packaging In child-resistant 
packaging In child-resistant
packaging
Labels will contain inf ormation to meet the applicable regulatory requirements.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 15
Status: A
pproved,  Date: 25 November 2021Intervention
nameJNJ-3989 JNJ-6379****PegIFN-α2a Entecavir (ETV)
monohydrateTenofovir
disoproxilTenofovir
alafenamide (TAF)*
Food/Fast
ing
instructionsRegardless of food
intakeRegardless of food
intakePer the prescribing 
information Per prescribing
informationPer prescribing
informationPer prescribing
information
Q4W: onc
e every 4 weeks; qd: once daily; QW: once weekly
* In countries where TAF is available, it will be one of the NA treatment options.
** For PegIFN α2a, dose adjustment may be applicable for participants who develop laboratory abnormalities during PegIFN α2a treatment.
*** May vary based on local regulations.
**** Participants enrolled before Protocol Amendment 5 was in effect, may have received JNJ 6379 as part of their study intervention. As of Protocol Amendment 5: study
intervention includes JNJ 3989, NA and optionally PegIFN α2a.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 16
Status: 
Approved,  Date: 25 November 2021LIVER BIOPSYAND FINE NEEDLE ASPIRATION BIOPSY
Percutaneous core liver biopsies and fine needle aspiration biopsies (FNABs)will be performed at Week -1
and Week 40. If participants agree to undergo an additional optional liver biopsy, FNAB and/or core liver
biopsy samples may be taken at the selected location at Follow-up Week 24 or at the time points clinically
indicated.
Following local standard practice the biopsy location will be identified with ultrasound (which will also be
used to rule out contraindicating conditions for a biopsy)  and after application of local anesthesia the FNAB
samples and core liver biopsy samples will be collected.
The liver biopsy procedure should be preceded and followed by standard medical monitoring according to
local medical practice. This may include an overnight stay at the investigator’s discretion. The use of low-
dose aspirin is allowed with exception of 7 days prior to biopsies (see Section 6.5) .
The liver tissue will be used to assess HBsAg. Changes from baseline in the proportion of HBsAg positive
hepatocytes under therapy will be assessed.
In addition, the liver tissue may also be used to assess other HBV markers in the liver such as, but not
limited to, total intracellular HBV RNA and DNA, HBeAg, and HBc. Changes in the quantity and
potentially changes in the spatial distribution of these markers (including HBsAg) under therapy may be
assessed. Viral genome (RNA or DNA)  or transcript sequencing/analyses as well as assessment of HBV
integrants in the host genome may be performed.
Intrahepatic immune status at baseline and response to treatment will be assessed. Both innate and adaptive
immune compartment will be characterized, by measuring the relative number of specific cells and the
expression of functional markers in each cell population using various single cell approaches, such as single
cells transcriptomics in FNABs and Immunofluorescence staining, and transcriptomics and proteomics
profiling in core needle biopsies. Depending on the latest platform developments (spatial transcriptomics,
in situ sequencing approaches, etc.) , methods for immune cells characterization might be adjusted.
Hepatitis B virus-specific T-cells, although very rare in FNABs, may be characterized and counted by
multimers binding assays, staining and sorting for positive cells. Downstream profiling of collected
HBV-specific T-cells may be performed by T-cell receptor sequencing and RNA sequencing.
Infiltrating immune cells will be used for the evaluation of innate and adaptive immune responses, which
can be compared to responses in peripheral blood mononuclear cell (PBMCs) .
Hepatitis B virus cccDNA levels may be assessed using quantitative polymerase chain reaction (qPCR)
methods on a single cell level using laser capture microdissection or bulk analyses. The exact protocol of
cccDNA measurement will be determined based on the latest method available considering the performance
characteristics and the validation status of the assay. Southern Blot-based methods or novel methods for
cccDNA detection (eg, fluorescent in situ hybridization [FiSH])  might be used depending on the availability
of sample and established methodology. Quantification of intracellular pre-genomic HBV RNA can be used
to determine transcriptional activity of HBV cccDNA by assessing the ratio of pgRNA levels over cccDNA
levels.
Immune and virologic markers in the liver and/or changes thereof on-treatment will be used to assess
association with blood markers and/or treatment response and outcome.
Remaining samples may be used for determination of liver JNJ-3989 (ie, JNJ-3976 and JNJ-3924)  and/or
JNJ-6379 concentrations and/or research on viral and host biomarkers and immune markers at the viral
and/or host RNA/DNA, protein, and cell level.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 17
Status: 
Approved,  Date: 25 November 2021BLOOD EFFICACY  ASSESSMENTS
Qualitative and quantitative HBsAg and HBeAg, and quantitative HBcrAg as well as antibodies against
HBsAg and HBeAg will be determined using validated serologic assays in a central laboratory. Samples
for the determination of HBsAg and HBeAg will be processed in real-time. Samples for the determination
of HBcrAg can be analyzed in batch and at the sponsor’s discretion.
Hepatitis B virus DNA and HBV RNA will be quantified at central laboratories using validated assays for
the quantification of HBV DNA and HBV RNA. Samples for the determination of HBV DNA will be
processed in real-time. Samples for the determination of HBV RNA can be analyzed in batch and at the
sponsor’s discretion.
Hepatitis B virus DNA, HBsAg, HBeAg, anti-HBs, and anti-HBe antibody testing results will be provided
to the investigator and the sponsor from screening until the end of follow-up.
In participants enrolled at a site with an on-site Fibroscan device, Fibroscan assessments will be performed
to determine changes in fibrosis levels.
Samples may be used by the sponsor for additional exploratory assessments analyzing the serologic and
virologic characteristics of HBV infection and efficacy or safety of the study intervention.
Viral genome sequence analysis will be performed to identify pre-existing baseline polymorphisms and to
evaluate emergence of mutations associated with JNJ-3989, and/or JNJ-6379, and/or NA treatment.
BLOOD IMMUNE ASSESSMENTS
Peripheral Blood Mononuclear Cell Immune Analyses
Samples for PBMC immune analyses will be collected during the study intervention and follow-up phases
and will be analyzed centrally for HBV-specific responses by enzyme-linked immunospot (ELISpot)  and/or
intracellular cytokine staining (ICS)  after stimulation with HBV-specific antigens. ELISpot detects T-cells
that secrete gamma interferon (IFN-γ)  in response to a specific antigenic stimulation, whereas ICS
determines the frequency of CD4+ and CD8+ T-cells secreting cytokines such as IFN-γ, interleukin (IL) -2
and tumor necrosis factor (TNF) -α in response to a specific antigenic stimulation. Hepatitis B virus-specific
T-cells may be characterized in PBMCs by binding assays (multimer staining)  combined with downstream
TCR and transcriptome profiling.
Additional experiments may be performed to further phenotypically and functionally characterize PBMCs
using proliferation or cytotoxic assays or other methods such as cytometry by time of flight to evaluate
innate and adaptive immune responses. Leftover samples may be used at the sponsor’s discretion for
additional exploratory research related to HBV infection or study intervention (safety/efficacy) .
Additional PBMC samples may be taken in case of ALT flares, upon discussion with the sponsor, which
may require an unscheduled visit.
Leukapheresis (Optional With Separate Consent)
Leukapheresis allows to selectively collect higher quantities of PBMCs from participants without
withdrawing large volumes of blood.
Leukapheresis will only be performed for participants who consent separately to this component of the
study. Participants may withdraw such consent at any time without affecting their participation in other
aspects of the study.
Leukapheresis may be done at least 1 week (and up to 3 weeks)  after the liver biopsies (see Schedule of
Activities) . Prior to the procedure, the participant’s wellbeing will be checked and leukapheresis will only
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 18
Status: 
Approved,  Date: 25 November 2021be offered if there is no clinical reason against it. If a participant has had a recent febrile illness, the
leukapheresis should be postponed until body temperature is normal for at least 72 hours.
The leukapheresis procedure should mainly follow local standard procedures. Additional guidelines will be
provided via a separate manual in order to standardize this process across sites.
One leukapheresis session is expected to last between 1.5 - 5 hours.
During the procedure, the participant will receive intravenous saline infusions and citrate-based
anticoagulant. Use of heparin for anticoagulation is not allowed. A specialized leukapheresis trained
research nurse or physician will be in attendance and in charge of the participant’s immediate medical care
to monitor the leukapheresis.
After completion of the leukapheresis procedure, participants will stay at the site for at least 30 minutes to
monitor for any relevant safety events. Additional safety procedures may be performed at the discretion of
the site staff. Participants are advised to refrain from exercise and strenuous activities for 3 day after the
leukapheresis visit.
SAFETYEVALUATIONS
Safety and tolerability will be assessed throughout the study from the time that the informed consent form
is signed until completion of the last study-related activity, which may include contact for follow-up of
safety. The evaluations of safety and tolerability will include monitoring of (S) AEs, physical examinations
(including body weight) , vital signs measurements, triplicate 12-lead ECGs, and clinical laboratory tests
(including hematology, blood biochemistry, blood coagulation, urinalysis, urine chemistry, and renal
biomarkers) . Any clinically relevant changes occurring during the study must be recorded in the AE section
of the case report form.
Specific toxicity management plans in line with the known pharmacological profile of the study
intervention (and the drug classes)  evaluated in this study are implemented.
PHARMACOKINETIC EVALUATIONS
Venous blood samples will be collected for measurement of plasma concentrations of JNJ-3989 (ie,
JNJ-3976 and JNJ-3924) , NA (ETV, TAF, or tenofovir) and PegIFN-α2a, as applicable, at time points
specified in the Schedule of Activities. Bioanalysis of NA and PegIFN-α2a is optional at the discretion of
the sponsor. Bioanalysis of JNJ-6379 may also be done on samples collected from participants who received
JNJ-6379 up to Protocol Amendment 4.
All participants will have sparse PK sampling on Day 1 and at Weeks 4, 12, and 24 (and at early
withdrawal) . All participants who consent to participate in the intensive PK substudy (optional)  will
undergo intensive PK sampling at Week 4. If necessary (eg, for operational reasons) , this visit may be
scheduled at Week 8, 12, or 16.
Plasma concentration-time data for JNJ-3976, JNJ-3924, and optionally, JNJ-6379, NA and/or PegIFN-α2a
will be analyzed via noncompartmental methods for all participants who underwent intensive PK sampling.
The main PK parameter will be area under the plasma concentration-time curve over 24 hours (AUC 24h) ,
Cmax, tmax, plasma trough concentration (C 0h) , plasma concentration at the end of the dosing interval (τ)  (C τ) ,
and minimum plasma concentration (C min) . Additional exposure parameters may be calculated if applicable.
Data from this study may be combined with data from a selection of Phase 1 and 2 studies via population
PK modelling. Individual estimates of PK parameters may be generated from the population PK analysis
for potential use in exposure-response analysis.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 19
Status: 
Approved,  Date: 25 November 2021PHARMACOKINETIC/PHARMACODY NAMIC EVALUATIONS
Relationships of individual PK parameters for JNJ-3976, JNJ-3924, and optionally, JNJ-6379, NA and/or
PegIFN-α2a, with selected liver and blood biomarkers, and/or with selected safety endpoints may be
evaluated.
HOST GENETICS
A pharmacogenomic blood sample will be collected (preferably at baseline) to allow for the identification
of genetic factors that may influence the efficacy, safety, or PK of the study intervention, to identify genetic
factors associated with HBV infection, or to develop assays for the study intervention or HBV infection.
A blood sample will be taken for human leukocyte antigen (HLA) typing. In addition, host DNA blood
samples to allow for epigenetic analyses will be collected.
HOST BIOMARKERS
The study includes collection of blood samples for exploratory analysis of host blood biomarkers at the
host RNA, protein, and cell level.
Samples can only be used for research related to study intervention or HBV infection or may be used to
develop tests/assays related to study intervention or HBV infection.
Blood samples will be taken that can be used to explore immunogenicity of JNJ-3989. The emergence of
antibodies to JNJ-3989 (antidrug antibodies)  might be analyzed using assays such as an enzyme-linked
immunosorbent assay.
STATISTICAL METHODS
The primary analysis will be performed at the time when all participants have completed Week 48 or
discontinued earlier. The final analysis will be performed when all participants have completed the last
study visit (Follow-up Week 48)  or discontinued earlier.
Given the exploratory nature of the study and the limited sample size per intervention arm per panel, no
statistical testing will be performed. All data will be summarized descriptively including 90% confidence
intervals as appropriate.
Statistical Hypotheses
As this is an exploratory study, no hypothesis will be tested.
Sample Size Determination
This study aims to enroll 18 to 24 participants in total across Panels 1 and 2, ie, 8 to 12 participants per
study panel. Due to the exploratory nature of the study, the sample size was determined based on clinical
and feasibility considerations related to the liver biopsy procedures performed multiple times during the
study, rather than a formal statistical calculation.
Analyses of Efficacy and Antiviral Activity
To evaluate the efficacy and antiviral activity in blood and liver, the primary analysis set will be the intent-
to-treat (ITT)population.
All efficacy summaries will be presented with descriptive statistics, overall and by study panel.
If the endpoint is continuous, the descriptive statistics will include the number of participants, mean,
standard deviation (SD) , median, range, and interquartile range. If the endpoint is binary or categorical, the
frequency distribution with the number and percentage of participants in each category will be calculated.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 20
Status: 
Approved,  Date: 25 November 2021Graphic displays will also be used to summarize the data and to visualize trends by study panel.
Where applicable, additional specifics for analyses of primary, secondary, and exploratory endpoints are
detailed below.
Analysis of  the Primary Endpoint
The primary endpoint is the change between baseline and on-treatment liver biopsy (Week 40)  in terms of
the proportion of HBsAg-positive hepatocytes. The primary endpoint will be summarized descriptively and
modelled with an appropriate statistical model accounting for the number of hepatocytes sampled in each
liver biopsy. The change from baseline will be summarized for the overall study population and within each
panel, together with the between-panel difference in the change.
Analysis of  Secondary Endpoints
Changes in Intrahepatic Immune Response
Variation in proportion of major cell populations, such as but not limited to CD4+ T-cells, CD8+ T-cells,
CD45+ T-cells, Natural Killer cells, and dendritic cells, defined by single cell transcriptomics (in FNABs)
and immunofluorescence staining (in core needle biopsies) , will be assessed at Week 40 and compared to
baseline, overall and by study panel.
The functional characterization of major cell populations will be assessed by transcriptomics and/or
proteomics for major cell populations of interest at Week 40 and compared to baseline similarly.
Changes in Intrahepatic V iral Nucleic Acids and Proteins
Changes from baseline in cccDNA level and/or transcriptional activity will be assessed using the general
considerations outlined above.
Furthermore, the difference in the level of infected hepatocytes at baseline will be assessed by comparing
cccDNA level and/or transcriptional activity.
Analyses of other viral markers will be performed descriptively. Statistical analyses will depend on the
assay technology applied and the scope of the analyses.
Analysis of  Exploratory Endpoints
The association between intrahepatic markers and blood (immune and viral)  markers will be explored both
at baseline and on-treatment by study panel using graphical displays and relevant correlation coefficients.
Impact of baseline characteristics on selected efficacy variables and their association with intrahepatic and
blood markers will also be evaluated using similar methods.
Identification of markers (either intrahepatic or blood)  that could potentially be associated with selected
efficacy variables (such as decrease in blood HBsAg levels, intrahepatic cccDNA levels or any other
relevant variables)  will be conducted. Impact of treatment on different blood and hepatic markers will also
be evaluated.
Safety Analyses
The Safety Population will be used for all safety analyses and includes all participants who received at least
one dose of study intervention.
Safety will be evaluated by means of descriptive summaries of AEs including AEs of special interest to any
of the study interventions, clinical laboratory tests, ECGs, vital signs, and physical examinations. The safety
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 21
Status: 
Approved,  Date: 25 November 2021analysis will be done by study phase. Results will be presented in tabular format and/or graphically over
time, as appropriate.
Other Analyses
Pharmacokinetic Analyses
Descriptive statistics (number of participants, mean, SD, coefficient of variation, geometric mean, median,
minimum, and maximum)  will be calculated for the plasma concentrations of JNJ-3976, JNJ-3924, and
optionally, JNJ-6379, NA and/or PegIFN-α2a, as applicable, and for the derived plasma PK parameters
(noncompartmental analysis) .
Special attention will be paid to the plasma concentrations and PK parameters of those participants who
discontinued the study for an AE, or who experienced an AE ≥grade 3 or an SAE.
For each participant with intensive PK sampling, plasma concentration-time data of JNJ-3976, JNJ-3924,
and/or JNJ-6379, and/or NA and/or PegIFN-α2a will be graphically presented. Similarly, graphs of the
mean plasma concentration-time profiles and overlay graphs with combined individual plasma
concentration time profiles will be produced. Pharmacokinetic parameters will be subjected to an
exploratory graphical analysis, including various transformations, to get a general overview.
Population PK analysis of plasma concentration-time data JNJ-3976, JNJ-3924, and optionally, JNJ-6379,
NAand/or PegIFN-α2a maybe performedusing nonlinear mixed-effects modeling. Data may be combined
with those from Phase 1 and/or 2 studies to support a relevant structural model. Available baseline
characteristics (eg, demographics, laboratory variables, genotypes)  may be included in the model as
necessary. Details will be given in a population PK analysis plan and results of the population PK analysis,
if applied, will be presented in a separate report.
Individual estimates of PK parameters may be generated from the population PK analysis for potential use
in exposure-response analysis.
Pharmacokinetic/ Pharmacodynamic Analyses
Relationships of PK parameters for JNJ-3976, JNJ-3924, and optionally, JNJ-6379, NAand/orPegIFN-α2a
with selected efficacy and with selected safety endpoints may be evaluated and graphically displayed.
Modeling of key PD parameters (eg, HBsAg, HBV DNA)  may be performed using population PK/PD. If
PK/PD modeling of key efficacy endpoints is performed, treatment effect and possible covariates such as
disease progression may be investigated. Other biomarkers may be explored at the sponsor’s discretion.
Resistance Analysis
The results of HBV viral sequencing will be evaluated by the sponsor virologist. Relevant changes in amino
acid and/or nucleic acid variations (eg, substitutions)  in the HBV genome will be tabulated and described.
Additional exploratory characterization of the HBV viral sequence and phenotype may be performed and
reported separately.
Pharmacogenomic Analyses
The statistical approach for analyzing the exploratory host DNA research may depend on the objective of
the analyses (efficacy, safety, and PK)  and possibly relevant genes at the time of analysis. Analyses will be
conducted at the sponsor’s discretion, will always be under the sponsor’s supervision, and results will be
presented either in the clinical study report or a separate report.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 22
Status: 
Approved,  Date: 25 November 2021Host Exploratory Biomarker Analyses
Statistical approaches to explore associations between treatment response/clinical outcome and blood and
liver biomarkers vary and depend on the different data types of the applied technology platforms, as well
as on the extent of observed differences between participants. Analyses will be conducted at the sponsor’s
discretion, will always be under the sponsor’s supervision, and results will be presented either in the clinical
study report or a separate report.
Interim Analysis
Two interim analyses (IAs) may be performed: when all participants have completed Week 20 in the
intervention phase (or discontinued earlier)and when they have completed Week 72 in the follow-up phase
(ie, Follow-up Week 24)  (or discontinued earlier) . These IAs will be performed by the sponsor to support
interactions with health authorities, as well as to support internal decisions about additional studies and/or
investigation of other combination regimens.
Both primary and interim analyses will be based on all data available at the predefined cut-off time points
and may include data at later time points for those participants who have reached subsequent visits.
Independent Flare Expert Panel
An IFLEP will be appointed for this study. The IFLEP is composed of 3 independent medical experts with
experience and expertise in hepatitis B and its treatment. The IFLEP will monitor ALT flares and will make
recommendations regarding flare management based on an analysis of aggregate data.
In order to allow for an unbiased assessment, members of the IFLEP will not serve as study investigators.
Further details on the IFLEP process will be included in the IFLEP charter.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 23
Status: 
Approved,  Date: 25 November 20211.2. Schema
Figure 1: Schematic Overview of the Study –Prior to Protocol Amendment 5
ETV: entecavir; N: number of participants; LB: (planned)  liver biopsy; NA=nucleos(t) ide analog; Q4W: once every
4 weeks; qd: once daily; TAF: tenofovir alafenamide; TD: tenofovir disoproxil; QW: once weekly
* Participants who provide separate consent may receive optional treatment with PegIFN-α2a starting after the
Week 40 biopsy (or after the optional leukapheresis visit if applicable)  for a duration of either 12 or 24 weeks at the
investigator’s discretion.
** Treatment with JNJ-3989 (and JNJ-6379 if applicable)  will be stopped at Week 48. Optional treatment with
PegIFN-α2a will be stopped after 12 or 24 weeks (at the investigator’s discretion) . NA treatment may be stopped at
Week 48 (or later for participants on PegIFN-α2a treatment)  if NA treatment completion criteria are met.

JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 24
Status: 
Approved,  Date: 25 November 2021Figure 2: Schematic Overview of the Study –As of Protocol Amendment 5
ETV: entecavir; N: number of participants; LB: (planned)  liver biopsy; NA=nucleos(t) ide analog; Q4W: once every
4 weeks; qd: once daily; TAF: tenofovir alafenamide; TD: tenofovir disoproxil; QW: once weekly
* Participants who provide separate consent may receive optional treatment with PegIFN-α2a starting after the
Week 40 biopsy (or after the optional leukapheresis visit if applicable)  for a duration of either 12 or 24 weeks at the
investigator’s discretion.
** Treatment with JNJ-3989 will be stopped at Week 48. Optional treatment with PegIFN-α2a will be stopped after
12 or 24 weeks (at the investigator’s discretion) . NA treatment may be stopped at Week 48 (or later for participants
on PegIFN-α2a treatment)  if NA treatment completion criteria are met.
*** The follow-up phase will be extended for participants who are receiving optional treatment with PegIFN-α2a
and who meet NA treatment completion criteria at the end of treatment with NA and PegIFN-α2a to ensure all
participants have at least one year of follow-up after NA treatment cessation.
Note:Former Arm 1 participants will now be joining Arm 2, both in terms of treatment assignment as well as how
they w
ill be statistically analyzed.

JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 28
Status: 
Approved,  Date: 25 November 2021ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; CRF:
case report form; CT: computed tomography; D/d: day; DBP: diastolic blood pressure; DNA: deoxyribonucleic acid; ECG: electrocardiogram; eGFR: estimatedglomerular
filtration rate; FSH: follicle-stimulating hormone; HBc: hepatitis B core protein; HBe(Ag) : hepatitis B e (antigen) ; HBcrAg: hepatitis B core-related antigen; HBs(Ag) :
hepatitis B surface (antigen) ; HBV: hepatitis B virus; HCC hepatocellular carcinoma; HIV-1 (-2) : human immunodeficiency virus type 1 (type 2) ; HLA: human leukocyte
antigen; ICF: informed consent form; IgM: immunoglobulin M; MRI: magnetic resonance imaging; NA: nucleos(t) ide analog; PBMC: peripheral blood mononuclear cell;
PK: pharmacokinetic; RNA: ribonucleic acid; SBP: systolic blood pressure; ULN: upper limit of normal; W/w: week; WD: withdrawal.
a. All study visits are to be scheduled relative to the baseline (Day 1)  visit date.
b. If necessary (eg, for operational reasons) , the screening phase may be extended up to a maximum of 6 weeks in agreement with the sponsor.
c. Day 1 samples are to be collected before the first dose of study intervention.
d. End of study intervention. If NA treatment completion criteria are not met at Week 48 (see Section 6.6.1) , participants will continue NA treatment during the
follow-up phase. Participants who discontinue study intervention early will have an early WD visit and will enter follow-up (see the Schedule of
Activities - Follow-up Phase )  unless they withdraw consent. Participants who withdraw consent will be offered an optional safety follow-up visit to occur on the
day of consent withdrawal. For the optional safety follow-up visit, assessments are at the investigator’s discretion and could be similar to the early WD visit.
e. The ICF must be signed before the first study-related activity.
f. If participants agree to undergo an optional liver biopsy, they must sign a separate ICF at screening or at any time prior to the optional liver biopsy (which may
take place at Follow-up Week 24, or at any time during the study when clinically indicated) . Refusal to give consent for these optional liver biopsy samples does
not exclude a participant from participation in the study.
g. Minimum criteria for the availability of documentation supporting the eligibility criteria will be described in Section 10.3, Appendix 3, Regulatory, Ethical and
Study Oversight Considerations. Clinical status will be checked at screening and again before the first liver biopsies at Week -1 and before the first dose of study
intervention. If a participant’s clinical status changes (including any available laboratory results or receipt of additional medical records)  after the start of screening
but before the first liver biopsies at Week -1 or before the first dose of study intervention is given such that he or she no longer meets all eligibility criteria, then the
participant should be excluded from participation in the study. Retesting to assess eligibility will be allowed once, using an unscheduled visit during the screening
period.
h. Medical history also includes mode of HBV transmission, stage of liver fibrosis, and alcohol consumption. Historical HBV DNA data and available data on
previous HBV genotype assessments will be recorded in the CRF. Historical HBsAg, HBeAg, and ALT data, if available, will be recorded in the source document.
i. Liver disease staging assessments will be performed based on Fibroscan obtained within 6 months prior to screening or at the time of screening.
j. Only applicable to participants who are enrolled at a site with an on-site Fibroscan device.
k. Participants must have absence of signs of cirrhosis or portal hypertension (absence of nodules, smooth liver contour, normal portal vein, spleen size <12 cm) ,
absence of signs of HCC or clinically relevant renal abnormalities on an abdominal ultrasound performed within 6 months prior to screening or at the time of
screening. In case of suspicious findings on conventional ultrasound the participant may still be eligible if HCC or clinically relevant renal abnormalities have been
ruled out by a more specific imaging procedure (contrast enhanced ultrasound, CT or MRI) . Additional ultrasound assessments may be performed when clinically
indicated.
l. A liver ultrasound is recommended approximately every 24 weeks for HCC screening.
m. Following local standard practice the biopsy location will be identified with ultrasound (which will also be used to rule out contraindicating conditions for a
biopsy) and after application oflocal anesthesia the FNAB samples and core liver biopsy samples will be collected. Prior to any on-treatment biopsy, a recent
(≤ 1 week)  coagulation and hematology panel, and a platelet aggregation test are required (pre-biopsy visit) . Prior to the off-treatment biopsies, blood coagulation
and platelets will be assessed at a local laboratory according to local practice. On-treatment (pre) biopsy can either occur during a regularly scheduled visit or an
unscheduled visit.
n. In between study visits, participants will take oral study intervention at home. Participants will be requested to bring their study intervention with them to each
study visit. At study visits, the study intervention should be taken on site.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 29
Status: 
Approved,  Date: 25 November 2021o. Participants enrolled before Protocol Amendment 5 was in effect, may have received JNJ-6379 as part of their study intervention. Dispensation of JNJ-6379
stopped immediately with the removal of JNJ-6379 as study intervention through an urgent safety measure. Participants have to return JNJ-6379 tablets to the site
at the next scheduled visit.
p. NA will be dispensed at Week 48 for intake during the follow-up phase in case the participant cannot stop NA treatment at Week 48.
q. Complete physical examination, including height (only at screening) , body weight, skin examination, and other body systems (see Section 8.4.1) .
r. Vital signs include supine SBP, DBP, pulse rate, and body temperature.
s. All ECGs will be read centrally; ECGs should be completed before any tests, procedures or other consultation for that visit. 
t. Biochemistry samples must be taken after fasting for at least 10 hours for measurement of phosphate, calcium, creatinine, and lipids. Participants should bring their
oral study intervention with them to each visit and have that day’s intake at the site with breakfast.
u. Creatinine clearance (eGFR calculated by the CKD-EPI formula)  will be assessed.
v. Intervention-emergent ALT/AST elevations (ie, ALT and/or AST ≥3x ULN and ≥3x nadir [ie, lowest value during study participation]) , should trigger an
assessment of confounding factors (alcohol intake, change in concomitant medication, and comorbidities)and a confirmatory visit, to be scheduled preferably
within 7 days of the receipt of the initial ALT/AST results, to repeat laboratory testing of AFP, ALT, AST, ALP, bilirubin (total and direct) , INR, albumin, and
HBV DNA until ALT and AST levels have returned to <5x ULN and HBV DNA is <20,000 IU/mL. Additional tests should be considered based on clinical
judgement. For more details and further management guidance refer to Section 8.5.6.2 and Section 10.6.
w. Urinalysis by dipstick: specific gravity, pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase, and microscopic analysis if needed.
The dipstick reading should be done as soon as possible and in accordance with the manufacturer’s recommendation. In case of a positive dipstick result, a urine
sample will be set aside for additional examination of the positive parameter (eg, quantification as applicable) .
x. Urine chemistry sample (quantitative measurement) : creatinine, sodium, phosphate, glucose, protein, and albumin.
y. Urine sample for selected renal biomarkers including retinol binding protein and beta-2-microglobulin.
z. For postmenopausal women only: an FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal
contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to confirm a
woman is not of childbearing potential.
aa. HBV genotype will be determined at baseline using standard genotyping assay if HBV DNA levels are sufficiently high. For participants with low HBV DNA
levels, available historical data on previous HBV genotype assessment will be collected in the CRF. Exploratory genotyping assays might be performed.
bb. HBcrAg and HBV RNA samples may be batched and only selected samples may be tested at the sponsor’s request. Samples can be used for assessment of other
serologic/virologic markers of HBV.
cc. Samples may be sequenced based on the sponsor virologist’s request, considering the HBV DNA levels.
dd. Participants must first complete HBeAg testing and have results reviewed by the investigator to confirm if they qualify for study participation.
ee. Quantitative HBeAg assessment will only be performed in participants who are defined HBeAg positive at screening or who become HBeAg positive post-baseline
based on a qualitative HBeAg assay.
ff. Exploratory serology samples may be analyzed at the sponsor’s discretion. Samples may be used to assess virologic or serologic markers of HBV.
gg. All participants will have sparse PK sampling for JNJ-3976, JNJ-3924, and NA (ETV, TAF, or tenofovir) . Bioanalysis of NA and/or PegIFN-α2a is optional at the
discretion of the sponsor. Bioanalysis of JNJ-6379 may also be done on samples collected from participants who received JNJ-6379 up to Protocol Amendment 4
For all samples, the date and time of the preceding intake of oral study intervention (NA) , the date and time of the previous JNJ-3989 administration, and the date
and time of PK sampling should be recorded. Sparse PK sampling is not required if the participant is part of the intensive PK subgroup and has an extensive PK
sampling at the same visit.
hh. One sample at any time between 2 and 8 hours after JNJ-3989 dosing. Before leaving the study site, the participant’s wellbeing should be confirmed.
ii. Only in case of early withdrawal.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 30
Status: 
Approved,  Date: 25 November 2021jj. All participants who consent to participate in the intensive PK subgroup (optional)  will undergo intensive PK sampling at Week 4. If necessary (eg, for operational
reasons) , this visit may be scheduled at Week 8, 12, or 16. The study intervention should be taken on site and time of dosing should be recorded. Pharmacokinetic
samples will be taken predose and 15 minutes, 30 minutes, 1, 2, 3, 4, 6, 8,* 10,* and 24 hours postdose (*the 8 and 10 hours postdose samples are optional) . All
efforts will be made to obtain the PK samples at the exact nominal time relative to dosing. However, samples obtained within 20% of the nominal time from dosing
(eg, +/- 12 minutes of a 60-minute time point)  will not be captured as a protocol deviation if the exact time of the sample collection is noted on the source
document and CRF.
kk. Leukapheresis is optional and will only be performed for participants who provided separate consent for this procedure. Refusal to give consent for leukapheresis
does not exclude a participant from participation in the study. The leukapheresis procedure will be performed at least 1 week (and up to 3 weeks)after the liver
biopsies; this can either occur during a regularly scheduled visit or an unscheduled visit. Prior to the procedure, the participant’s wellbeing will be checked and
leukapheresis will only be offered if there is no clinical reason against it. If a participant has had a recent febrile illness, the leukapheresis should be postponed until
body temperature is normal for at least 72 hours. One leukapheresis session is expected to last between 1.5 - 5 hours. During the procedure, the participant will
receive intravenous saline infusions and citrate-based anticoagulant. Use of heparin for anticoagulation is not allowed. After completion of the leukapheresis
procedure, participants will stay at the site for at least 30 minutes to monitor for any relevant safety events. Participants are advised to refrain from exercise and
strenuous activities for 3 days after the leukapheresis visit.
ll. Additional PBMC samples may be taken in case of ALT flares, upon discussion with the sponsor, and may require an unscheduled visit.
mm. The pharmacogenomic (DNA)  sample should preferably be collected at baseline.
nn. Adverse events and concomitant medications will be monitored from the time a signed and dated ICF is obtained until completion of the participant’s last
study-related procedure.
oo. Includes close monitoring for neuropsychiatric adverse events during the optional PegIFN-α2a treatment period. Participants who develop a neuropsychiatric
adverse event during optional PegIFN-α2a treatment, will be monitored closely until the neuropsychiatric adverse event resolves, with frequent (at least weekly)
follow-up phone calls.
pp. As of Protocol Amendment 5, new participants will enroll without randomization within each panel to receive the combination regimen JNJ-3989 + NA as study
intervention for 48 weeks.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 34
Status: 
Approved,  Date: 25 November 2021j. Biochemistry samples must be taken after fasting for at least 10 hours for measurement of phosphate, calcium, creatinine, and lipids.
k. Creatinine clearance (eGFR calculated by the CKD-EPI formula)  will be assessed.
l. ALT/AST elevations (ie, ALT and/or AST ≥3x ULN and ≥3x nadir [ie, lowest value during study participation]) , should trigger an assessment of confounding
factors (alcohol intake, change in concomitant medication, and comorbidities) and a confirmatory visit, to be scheduled preferably within 7 days of the receipt of
the initial ALT/AST results, to repeat laboratory testing of AFP, ALT, AST, ALP, bilirubin (total and direct) , INR, albumin, and HBV DNA until ALT and AST
levels have returned to <5x ULN and HBV DNA is <20,000 IU/mL. Additional tests should be considered based on clinical judgement. For more details and
further management guidance refer to Section 8.5.6.2 and Section 10.6.
m. Liver function tests only.
n. Urinalysis by dipstick: specific gravity, pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase, and microscopic analysis if needed.
The dipstick reading should be done as soon as possible and in accordance with the manufacturer’s recommendation. In case of a positive dipstick result, a urine
sample will be set aside for additional examination of the positive parameter at the central laboratory (eg, quantification as applicable) .
o. Urine chemistry sample (quantitative measurement) : creatinine, sodium, phosphate, glucose, protein, and albumin.
p. A urinalysis and urine chemistry sample will be taken at Follow-up Week 4. In case of abnormalities, the tests should be repeated at the following visits.
q. Urine pregnancy tests for at-home use will be provided to the participants as necessary to ensure urine pregnancy tests are performed at least every 4 weeks.
Results will be reported at the next visit. If positive, the participant should contact the site immediately.
r. Only applicable to participants who are enrolled at a site with an on-site Fibroscan device.
s. HBcrAg and HBV RNA samples may be batched and only selected samples may be tested at the sponsor’s request. Samples can be used for assessment of other
serologic/virologic markers of HBV.
t. Samples may be sequenced based on the sponsor virologist’s request, considering the HBV DNA levels. A sample for viral genome sequencing will be taken at an
unscheduled visit for confirmation of virologic relapse.
u. Exploratory serology samples may be analyzed at the sponsor’s discretion. Samples may be used to assess virologic or serologic markers of HBV.
v. Leukapheresis is optional and will only be performed for participants who provided separate consent for this procedure. Refusal to give consent for these optional
procedures does not exclude a participant from participation in the study. The leukapheresis procedure will be performed at least 1 week (and up to 3 weeks) after
the liver biopsy; this can either occur during a regularly scheduled visit or an unscheduled visit. If no liver biopsy is being performed during follow-up,
leukapheresis should take place around the FU W24 time point. Prior to the procedure, the participant’s wellbeing will be checked and leukapheresis will only be
offered if there is no clinical reason against it. If a participant has had a recent febrile illness, the leukapheresis should be postponed until body temperature is
normal for at least 72 hours. One leukapheresis session is expected to last between 1.5 - 5 hours. During the procedure, the participant will receive intravenous
saline infusions and citrate-based anticoagulant. Use of heparin for anticoagulation is not allowed. After completion of the leukapheresis procedure, participants
will stay at the site for at least 30 minutes to monitor for any relevant safety events. Participants are advised to refrain from exercise and strenuous activities for 3
days after the leukapheresis visit.
w. Additional PBMC samples may be taken in case of ALT flare, upon discussion with the sponsor, and may require an unscheduled visit.
x. Adverse events and concomitant medications will be monitored from the time a signed and dated ICF is obtained until completion of the participant’s last study-
related procedure.
y. With implementation of Protocol Amendment 5, the follow-up phase of 48 weeks will be extended for participants who are receiving optional treatment with
PegIFN-α2a and who meet NA treatment completion criteria at the end of treatment with NA and PegIFN-α2a to ensure all study participants will be followed for
at least one year after NA treatment cessation. Visits will be scheduled at least every 4 weeks and assessments will be similar to assessments performed at the FU
W28 visit. At the respective EOS visit for these participants, assessments as described in the FU W48 EOS visit will be performed.
z. NA treatment should be re-started in accordance with the NA re-treatment criteria (refer to Section 6.6.2and Section 10.12Appendix 12 for guidance after
stopping NA treatment.)
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 35
Status: A
pproved,  Date: 25 November 2021aa. The investigator should consider to re start NA treatment per local standard of care at the EOS visit (Follow up Week 48 up to maximum Follow up Week 72)  for participants who
met the NA treatment completion criteria at Week 48 or for participants who met NA treatment completion criteria at the end of treatment with PegIFN α2a during the follow up
phase, who did not re start NA treatment during the follow up phase, and who did not achieve and maintain HBsAg seroclearance. NA will not be provided by the sponsor after the
final study visit .
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 38
Status: 
Approved,  Date: 25 November 20212. INTRODUCTION
Chronic Hepatitis B Infection
Hepatitis B virus (HBV)  is a small deoxyribonucleic acid (DNA)  virus that specifically infects the
human liver. It consists of a nucleocapsid in which the viral DNA is packed with hepatitis B core
protein (HBc)  and a membraneous envelope containing hepatitis B surface antigen (HBsAg) . The
acute phase of the infection (less than 6 months)  is either followed by an immune controlled state
(spontaneous cure from the infection)  or progresses to chronic hepatitis B (more than 6 months) .
Chronic HBV infection may lead to serious illnesses such as liver cirrhosis and decompensation,
and hepatocellular carcinoma (HCC) , often with fatal outcome.33
The worldwide estimated prevalence of chronic HBV infection is 4.9% with about 292 million
people affected.28 Despite the availability of an efficacious prophylactic vaccine, yearly rates of
new infections remain high. Approximately 680,000 people per year worldwide die from cirrhosis
and HCC due to chronic HBV infection.31
The natural course of chronic HBV infection is the consequence of a complex interaction between
the virus and the host which in the chronic setting might evolve over a duration of decades. This
is associated with different disease phases or stages. The European Association for the Study of
the Liver (EASL)  guidelines differentiate between chronic infection and chronic hepatitis
(Table 1 ) .
Table 1: Various Stages of HBV Infection –Terminology and Characteristics (EASL 2017)5
HBeAg positive HBeAg negative
Chroni
c 
infectionChronic hepatitis Chronic infection Chronic hepatitis
HBsAg Hi
gh High/intermediate Low  Intermediate
HBeAg P
ositive Positive Negative Negative
HBV DNA
 >107 IU/mL 104-107 IU/mL <2,000 IU/mL°° >2,000 IU/mL
ALT No
rmal Elevated Normal Elevated*
Liver 
disease None/minimal Moderate/severe None Moderate/severe
Old 
termin
ology Immune
 tolerant Immune  reactive HBeAg 
positi
ve Inacti
ve carrier HBeAg ne gative chronic
hepati
tis
ALT: al
anine aminotransferase; DNA: deoxyribonucleic acid; EASL: European Association for the Study of the Liver;
HBeAg: h
epatitis B e antigen; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; IU/mL: International Units Per
Millil
iter
* Persis
tently or intermittently. °°HBV deoxyribonucleic acid (DNA)  levels can be between 2,000 and 20,000 IU/mL in
some p
atients without signs of chronic hepatitis.
Note t
hat different definitions and naming of HBV disease phases may be used across different countries/regions.
Accord
ing to the EASL treatment guidelines, the primary treatment goal for patients with chronic
HBVinfectionis to improve survival and quality of life by preventing progression of liver disease,
particularly to cirrhosis, liver failure, and HCC.
Irrespective of the hepatitis B e antigen (HBeAg)  status, antiviral therapy is recommended for all
patients with signs of active chronic hepatitis.2,5,30,33 Approved therapies for chronic HBVinfection
are pegylated interferon alpha (PEG-IFN-α) and nucleos(t) ide analog (NA) inhibitors (ie, NA
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 39
Status: 
Approved,  Date: 25 November 2021treatment)  of the HBV polymerase/reverse transcriptase, the enzyme synthesizing HBV DNA from
pre-genomic ribonucleic acid (pgRNA) .
Oral treatment with NAs is effective at suppressing viral DNA formation and lowering virus
concentration in the blood to levels below the lower limit of quantification (LLOQ)  of the HBV
DNA assays commonly used. This is associated with normalization of liver enzymes and reduced
or halted progression of liver disease to cirrhosis and/or decompensation and even with regression
of cirrhotic transformation.4,18,22,25,36 While the risk of HCC development is reduced as well, it is
not eliminated.18,22,25
Hepatitis B surface antigen seroclearance 24 weeks after end of treatment is currently considered
to be associated with the most thorough suppression of HBV replication and has been termed
“functional cure”.21 Unfortunately, with currently available NA treatment strategies the rate of
HBsAg seroclearance remains very low (around 3%)  even under long-term treatment.
Pegylated IFN is associated with a slightly higher rate of HBsAg seroclearance compared to NAs
and is recommended for a fixed treatment duration of 48 weeks, but is administered
subcutaneously (SC)and is associated with higher toxicity than NAs.27
With the low rate of functional cure with current treatments, and persistently high global
prevalence of HBV-associated mortality,5,33 there is a medical need for more effective finite
treatment options that lead to sustained seroclearance of HBsAg and HBV DNA off treatment
("functional cure") . In order to achieve an effective finite treatment, combination of therapies with
different mechanisms of action, as is standard of care for other chronic viral infections like hepatitis
C virus (HCV)and human immunodeficiency virus (HIV) , is deemed required.
A challenge for the clinical development of novel HBV agents is that while blood markers are used
to assess their efficacy and immune response induced by these agents, their target organ is the
liver. Although some of the efficacy blood markers are very well established from a clinical
perspective, questions remain on how good these markers correlate with intrahepatic events, such
as HBV covalently closed circular DNA (cccDNA) level and transcriptional activity. In addition,
the immune response measured in the periphery is known to insufficiently reflect the situation in
the liver. For example, the frequency of HBV-specific T-cells as well as liver resident immune
cells cannot be adequately assessed by measuring immune response in the periphery. Multiple
studies have shown the value of full needle core biopsies as well as fine needle aspirates to assess
intrahepatic virologic and immunologic events of HBV. A wide range of methods are currently
available, such as polymerase chain reaction (PCR) based methods, single cell analyses and high
multiplex fluorescence-based methods.
JNJ-73763989 (JNJ-3989)  is a liver-targeted antiviral therapeutic for SC injection designed to treat
chronic HBV infection via a ribonucleic acid interference (RNAi)  mechanism. JNJ-3989 consists
of two RNAi triggers, one targeting the HBsAg open reading frame (JNJ-73763976 [JNJ-3976]) ,
and one targeting the HBV X protein open reading frame (JNJ-73763924 [JNJ-3924]) . Hence,
engagement of the cellular RNAi machinery by JNJ-3989 results in specific cleavage of HBV
ribonucleic acid (RNA)  transcripts, thereby reducing the levels of HBV proteins and the pgRNA,
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 40
Status: 
Approved,  Date: 25 November 2021the precursor of viral relaxed circular DNA. The RNAi triggers in JNJ-3989 injection are designed
to target all HBV RNA transcripts derived from cccDNA, as well as transcripts derived from
integrated viral DNA. The latter has been suggested to be a significant source of HBsAg in HBeAg
negative patients or patients on long term treatment with NAs, the current standard of care.35
JNJ-56136379 (JNJ-6379)  is an orally administered capsid assembly modulator (CAM)  that is
being developed for the treatment of chronic HBV infection. JNJ-6379 binds to HBc and interferes
with the viral capsid assembly process, thereby preventing the polymerase-bound pgRNA
encapsidation. This results in the formation of HBV capsids, devoid of HBV DNA or RNA (non-
functional capsids) , and ultimately in the inhibition of HBV replication. In addition, JNJ-6379 also
acts at an early stage of the viral life cycle by inhibiting the de-novo formation of cccDNA
potentially by interfering with the capsid disassembly process. JNJ-6379 was initially part of the
study intervention but has been removed as study intervention with the implementation of an
urgent safety measure, as described in Protocol Amendment 5.
Prior to Protocol Amendment 5, the term “study intervention” throughout the protocol, refers to
JNJ-3989, JNJ-6379, NA, and optional PegIFN-α2aa.
As of Protocol Amendment 5, the term “study intervention” throughout the protocol, refers to
JNJ-3989, NA, and optional PegIFN-α2a.
The term "sponsor" used throughout this document refers to the entities listed in the Contact
Information page(s) , which will be provided as a separate document.
The term "participant" throughout the protocol refers to the common term "subject".
2.1. Study Rationale
This liver biopsy study is primarily performed to assess changes in intrahepatic viral and host
immune markers in response to JNJ-3989-based combination treatment. This analysis can be used
to characterize mode of action (MoA)  of the treatment. Furthermore, this study aims to explore
association of hepatic and peripheral viral and/or host markers with selected efficacy variables,
identify subpopulations that show a defined response, and identify cellular and molecular
determinants of response. Hepatic and peripheral viral and immune markers and their correlations
will be assessed. In addition, changes in liver histology may be assessed. The totality of results
may be used to inform on the optimal use of therapeutics in current or future combinations. This
study aims to assess intrahepatic events in the context of a full (48-week)  treatment regimen as
used in 2 ongoing Phase 2b studies in a similar HBV population to facilitate comparison of the
results across studies.
The efficacy and safety of finite treatmentduration will be assessed with a fixed 48-week treatment
duration for JNJ-3989, in combination with NA treatment. Participants meeting pre-defined
response criteria (outlined in Section 6.6.1)  will also complete NA treatment after 48 weeks. The
a Note: Op
tional PegIFN α2a was introduced as ‘study intervention’ as of Protocol Amendment 4.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDENT
IAL –FOIA Exemptions Apply in U.S. 41
Status: A p
proved,  Date: 25 November 2021participants may also receive optional treatment with PegIFN-α2a for either 12 or 24 weeks at the
investigator’s discretion, to investigate whether addition of PegIFN-α2a towards the end of the
existing treatment regimen further decreases HBsAg.
2.2. Background
For the most comprehensive nonclinical and clinical information regarding JNJ-3989 and
JNJ-6379, refer to the latest version of the Investigator's Brochure (IB)  and addenda.14 16,39
Note: JNJ-6379 was initially part of the study intervention but has been removed as study
intervention with the implementation of an urgent safety measure, as described in Protocol
Amendment 5. For completeness, background information on JNJ-6379 is still included in this
section.
2.2.1. Nonclinical Studies
2.2.1.1. JNJ-3989 and JNJ-6379
Nonclinical assessments to support clinical development have been performed for the single agents
JNJ-3989 and JNJ-6379, and also for their combination (up to 3 months studies) .
JNJ-3989
Little potential for off-target inhibition of human gene expression in participants is expected, based
on in silico human genome database screening.
The nonclinical safety profile of JNJ-3989 has been evaluated through a series of in vitro and in
vivo studies. Repeat-dose SC toxicity studies of 2 weeks up to 24 or 37 weeks were conducted in
rat and monkey, respectively. In the 2-week studies, JNJ-3989 was administered once weekly via
SC injection at up to mg/kg. In the 24- or 37-week studies, JNJ-3989 was administered
once weekly for the first month, followed by once monthly thereafter at up to  mg/kg. JNJ-
3989 was well tolerated in these studies.
In the 2-week and the 24-week studies in rat, JNJ-3989-related target organs were the liver, the
kidney, and the injection site. The mandibular and mesenteric lymph nodes were identified as
target organ in the 24-week study only. In the liver, hepatocyte alteration and hepatocyte mitosis,
accompanied by an increase in hepatocellular vacuoles, oval cell hyperplasia, Kupffer cell
vacuolation and/or increased liver weights were observed. The hepatocyte findings correlated to
increased alkaline phosphatase (ALP)  activity levels seen in the 24-week study. Kidney findings
were characterized by cytoplasmic alteration of the cortical tubule epithelium. At the injection site,
mononuclear cell or vacuolated macrophage infiltrates, epidermal exudate, hemorrhages and/or
interstitial granules were observed. Macrophage vacuolation was observed in the sinus spaces of
the mandibular and mesenteric lymph nodes.
Liver findings persisted throughout the recovery period. Partial recovery was observed in the
kidney. No findings were present anymore at the injection sites and the lymph nodes at the end of
the recovery period.
CCI
CCI
CCI
CCI
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 42
Status: A
pproved,  Date: 25 November 2021All these changes likely represented the distribution, accumulation, and clearance of JNJ-3989 and
were considered not to be adverse due to the nature of the findings and the low severity. These are
commonly described findings for N-acetylgalactosamine-conjugated RNAi.17 The no observed
adverse effect level (NOAEL)  was therefore considered to be the highest dose tested, ie, mg/kg
in the 24-week study.
In the 2-week study in monkey, apart from a minimally increased ALP activity which was
considered not adverse, no JNJ-3989-related effects were observed. In the 37-week study,
JNJ-3989-related target organs were the liver, mandibular and/or mesenteric lymph nodes, and the
SC injection site. Findings included Kupffer cell basophilia/hypertrophy in the liver, vacuolated
macrophages in the lymph nodes, and macrophage infiltrates in the injection site. Partial
reversibility was observed for these findings. This likely represented the distribution,
accumulation, and clearance of JNJ-3989 and was considered not to be adverse due to the low
severity and/or nature of the findings. These are commonly described findings for
N-acetylgalactosamine-conjugated RNAi.17 A non-adverse minimally increased ALP activity was
observed at mg/kg without a microscopic correlate. The NOAEL in the monkey was
considered to be the highest dose tested, ie, mg/kg in the 37-week study.
In the embryofetal development (EFD)  studies, JNJ-3989 was not teratogenic in rats and rabbits.
The fertility study showed no effects on parental and reproductive parameters in male and female
rats given JNJ-3989 up to a dose of mg/kg/week.
JNJ-3989 was shown to be non-genotoxic when tested in the bacterial reverse mutation assay, and
in vitro and in vivo micronucleus test.
Results of the non-Good Laboratory Practice (GLP)  in vitro studies demonstrated there is no
potential for induction of the innate immune system (cytokine and complement activation) ,
mitochondrial toxicity/cytotoxicity, or platelet aggregation associated with JNJ-3989 exposure at
concentrations up to µg/mL.
The animal-to-human exposure ratios were calculated using rat and monkey exposures at NOAEL
from the 24-week and 37-week studies, respectively, and human exposures after a single SC
injection of 200 mg JNJ-3989 in human volunteers (Study AROHBV1001)  ( Table 2 ) .
Table 2: Animal/Human Exposure Ratios at NOAEL for JNJ-3989
Sex NOAEL  
(mg/kg) C max 
(ng/ mL) AUC  b
(ng. h/mL) Ratio To
tal Concentration
Cmax 
A/H 
Ratio AUCb
A/H R atio
JNJ-3976
H
uman exposurea 1,315 20,136 - -
24-week 
ratc M 41,100 437,000 31.3 21.7
F 43,100 270,000 32.8 13.4
37-we
ek 
monkeyd M 73,200 1,230,000 55.7 61.1
F 65,800 988,000 50.0 49
.1
CCI
CCI
CCI
CCI
CCI
CCI
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDENT
IAL –FOIA Exemptions Apply in U.S. 43
Status: A p
proved,  Date: 25 November 2021Table 2: Animal/Human Exposure Ratios at NOAEL for JNJ-3989
Sex NOAEL  
(mg/kg) C max 
(ng/m L) AUCb 
(ng.h/ mL) Ratio Tot
al Concentration
Cmax 
A/H R
atio AUCb
A/H Ra tio
JNJ-3924
Human ex
posurea 363 4,605
24-week 
ratc M 25,200 271,000 69.4 58.8
F 26,200 163,000 72.2 35.4
37-w
eek 
monkeyd M 21,600 383,000 59.5 83.2
F 23,000 392,000 63.4 85.
1
AUC: area
 under the plasma concentration time curve; AUC 0-24h: area under the plasma concentration time curve from
administration to 24 h; AUC 0-last: area under the plasma concentration time curve from administration to last quantifiable sampling
point; A/H: animal/human ratio; C max: maximum plasma concentration; F: female; M: male; NOAEL: no observed adverse effect
level; PK: pharmacokinetics; SC: subcutaneous
a Single dose of 200 mg JNJ 3989 in healthy volunteers via SC injection (Study AROHBV1001; based on recent clean dataset
with data cut off 29 October 2019. Clinical PK update will be included in next revision of the IB) .
bAUC 0-last for human exposure; AUC 0-24h for animal exposures
cOnce weekly dosing for 4 weeks, followed by once monthly dosing, up to a total of 24 weeks
dOnce weekly dosing for 5 weeks followed by once monthly dosing, up to a total of 37 weeks
JNJ-6379
Following 6 months of treatment in rats, the kidney and female reproductive tract (irregular estrous
cycle)  were identified as target organs. However, after further assessment of the kidney findings
and their clinical relevance, it is deemed unlikely that the retrograde nephropathy seen in 1 out of
20 male rats following 6 months of dosing with JNJ-6379 at 100 mg eq./kg/day are relevant for
the clinical studies. The retrograde nephropathy was partially recovered after a 9-week recovery
period. In the 6-month rat study, female rats (at 200 mg eq./kg/day)  showed an irregular estrous
cycle, from which they recovered at the end of the 9-week treatment-free period. These irregular
estrous cycles were also apparent in the female fertility studies (main and mechanistic) . These
changes were related to lowered hormone levels (luteinizing hormone, progesterone, estradiol) .
JNJ-6379, however, did not affect female fertility. The fetal loss seen during the early stages of
pregnancy was considered to result from low hormone levels. In the dog study, no changes were
observed in the reproductive tract at higher exposures in dogs.
In the 9-month dog study, the target organs identified were the adrenal glands and bone marrow.
The adrenal glands did not show degenerative changes or loss of function and were therefore
considered as non-adverse target organs. One female dog out of 4 dosed at 25 mg eq./kg/day (the
highest dose)  was sacrificed on Day 61, after showing poor health condition. A JNJ-6379 plasma
level of 42,000 ng/mL was observed for this animal on Day 61, at approximately 24 hours after
last dosing. Pronounced clinical pathologic changes, including pancytopenia, were noted. Marked
increase in plasma cell-like cells was seen in the bone marrow during histopathologic examination,
resulting in a marked reduction of hematopoietic tissue and extramedullary hematopoiesis in liver
and spleen. The cause of the deteriorating condition was likely related to changes in the bone
marrow. A second dog in the same dose group with pancytopenia recovered after a drug holiday
and was re-exposed uneventfully.
In the EFD studies, JNJ-6379 was not teratogenic in rats and rabbits.
CCI
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDENT
IAL –FOIA Exemptions Apply in U.S. 44
Status: A p
proved,  Date: 25 November 2021JNJ-6379 was not genotoxic in the in vitro micronucleus and Ames tests, and in the in vivo
micronucleus tests in rats.
Animal/human ratios at the NOAEL in rat and dog for human exposure at 250 mg JNJ-6379 once
daily (qd)  for 28 days are displayed in Table 3 .
Table 3: Animal/Human Ratios at the NOAEL in Rat and Dog (Human Exposure at 250 mg JNJ-6379
Once Daily for 28 Days [Study 56136379HPB1001])
Sex NOAEL  
(mg eq./kg/day) Cmax 
(ng/mL) AUC 0-24h 
(ng.h/mL) Ratio Total
ConcentrationRatio
Concentration
Corrected for
Plasma Protein
Bindingb
Cmax 
A/H 
Ra
tio AUC 0-24h 
A/H 
Ratio Cmax 
A/H 
Ratio AUC 0-24h
A/H
Ratio
Human ex
posurea 13,798 267,180 - -
6M rat M 7,540 93,10
0 0.6 0.3 0.9 0.6
M 13,600d 180,000d 1.0 
0.7 1.7 1.1
F 19,900 233,000 1.4 0.9 2.4 1.5
9M dog M 30,000 606,000 2.2 2.3 3.3 3.4
F 22,500 383,000 1.
6 1.4 2.5 2.2
AUC: area under the plasma concentration time curve; AUC 0-24h: area under the plasma concentration time curve from
administration to 24 h; A/H: animal/human ratio; C max: maximum plasma concentration; F: female; M: male; NOAEL: no
observed adverse effect level; qd: once daily.
a 250 mg JNJ 6379 qd for 28 days (Study 56136379HPB1001) .
b Ratio of the total C maxor AUC corrected for species difference in plasma unbound fraction. Calculation: [animal C maxor
AUC 0-24hx mal free fraction] / [human C maxor AUC 0-24hx human free fraction].
c A dose of mg eq./kg/day in male rats is considered to be above the NOAEL due to kidney findings in male rats, which
are likely elevant for human.
d The plasma C maxof 13,600 ng/mL and AUC 0-24hof 180,000 ng.h/mL in male rats at 100 mg eq./kg/day corresponds to an
unbound C maxof 1,754 ng/mL and AUC 0-24hof 23,220 ng.h/mL (fraction unbound rat plasma 12.9%) . This unbound plasma
exposure will be achieved in humans at a total plasma C maxof 22,784 ng/ml and AUC 0-24hof 301,558 ng.h/mL (fraction
unbound in human plasma 7.7%) .
Combinati
on of  JNJ-3989 and JNJ-6379
A 1-month repeat-dose combination toxicity study of JNJ-6379 and JNJ-3989 was conducted in
male and female Sprague-Dawley rats. JNJ-6379 (in PEG400 + 10% PVP-VA)  was administered
daily via oral gavage at mg/kg, alone or in combination with JNJ-3989 (in phosphate-buffered
saline)  which was administered weekly via SC injections a and mg/kg. In addition,
mg/kg JNJ-3989 (SC, weekly)  was dosed as well in a monotherapy group. Control animals
received both vehicles via the respective routes.
The data showed that weekly SC injections with JNJ-3989 a o mg/kg in combination with
daily administration of JNJ-6379 at mg/kg (oral)  for one month were well tolerated with no
clinical signs or treatment-related mortality. Changes in clinical pathology and histopathology
were mostly similar to the findings for the monotherapy groups dosed with JNJ-6379 at mg/kg
(oral)  alone or with JNJ-3989 at mg/kg (SC)  alone. The only synergistic changes included a
slight decrease in body weight (gain)  at ≥ mg/kg, in food consumption at  mg/kg,
and a further decrease in lymphoid cellularity in the thymus of females at  mg/kg. These
alterations were minor and non-adverse in nature. Based on these results, the NOAEL was
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDENT
IAL –FOIA Exemptions Apply in U.S. 45
Status: A p
proved,  Date: 25 November 2021considered to be  mg/kg. Maximum plasma concentration (C max) and AUC 0 24h values for
JNJ-6379 in males were 13,200 ng/mL and 181,000 ng∙h/mL, and for females 15,500 ng/mL and
206,000 ng∙h/mL, respectively, after 1 month of treatment. The mean C max and AUC 0 24h values
for analyte JNJ-3924 in males were 20,900 ng/mL and 160,000 ng∙h/mL, and for females
21,300 ng/mL and 125,000 ng∙h/mL, respectively. For analyte JNJ-3976, the mean C max and
AUC 0 24hvalues in males were 35,200 ng/mL and 258,000 ng∙h/mL, and for females 35,300 ng/mL
and 201,000 ng∙h/mL, respectively.
A 3-month combination toxicity study of JNJ-3989 and JNJ-6379 is ongoing, preliminary data is
available. In this study, JNJ-3989 was initially administered weekly (ie, a total of 6 doses)  and
monthly thereafter, via SC injections at dose levels o and mg/kg when given in
combination with JNJ-6379, and at 180 mg/kg for the monotherapy group. JNJ-6379 was
administered daily via oral gavage at a dose level of mg/kg in the monotherapy and
combination groups. Control animals received both vehicles via the respective routes.
No test article-related mortalities were noted among animals dosed with JNJ-6379 alone, JNJ-3989
alone, or with JNJ-6379 + JNJ-3989 at mg/kg. One male receiving JNJ-3989 alone at
mg/kg died on Day 45, after a rapid change in its clinical condition. The death ofthis animal was
considered to reflect an acute stress response without a relationship to the test article. One
accidental death due to a possible gavage error was noted among the toxicokinetic animals in the
mg/kg combination group. No bone marrow abnormalities were seen in these 2 animals.
One male rat dosed at mg/kg JNJ-6379/JNJ-3989 was euthanized on Day 24 after showing
severe clinical signs in the morning (decreased activity, erected fur, pallor, and cold to touch) . No
clinical signs were noted for this animal until Day 23, and body weight and weight gain were
unaffected during the first 3 weeks of the study. The cause of moribundity was considered to be a
markedly decreased hematopoietic cellularity of the bone marrow with pancytopenia, including
markedly reduced platelet counts and consequent hemorrhages and blood loss. A relation to the
treatment with JNJ-6379 and/or JNJ-3989 cannot be excluded.
Clinical pathology analysis in this rat revealed a marked decrease in white blood cells (WBCs)
(neutrophil, lymphocyte, and monocyte counts) , marked decreases in red blood cell (RBC) mass
parameters (hemoglobin, hematocrit, and RBC count)  including reticulocyte count, and platelet
count. There was a mildly increased fibrinogen concentration and mildly prolonged prothrombin
time. Other clinical pathology findings were observed for this animal, but they are not related to
the bad condition and euthanasia.
At necropsy, the rat showed dark red discoloration/dark red foci in a wide variety of organs and
tissues, and dark red material in the abdominal cavity adhered to the spleen (freshly clotted blood) .
This correlated to minimal to marked hemorrhages in multiple tissues, including brain.
At microscopic examination, the bone marrow of this animal showed markedly decreased
cellularity of hematopoietic tissue. Based on the morphology of the remaining hematopoietictissue
and the absence of necrosis, this bone marrow finding was considered not acute but rathersubacute
or subchronic in nature. In absence of pre-values or earlier time points for hematology, it was not
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDENT
IAL –FOIA Exemptions Apply in U.S. 46
Status: A p
proved,  Date: 25 November 2021possible to define the onset of the initiating event. Minimal to marked acute hemorrhages were
noted in a wide range of tissues. Some other microscopic findings unrelated to the event were
identified.
Altogether, the decreased cellularity of hematopoietic tissue in the bone marrow and the
hematology/coagulation data indicate that reduced hematopoiesis resulted in decreases in WBC,
reticulocyte, and platelet counts. The hemorrhages were interpreted to be the result of a deficit in
primary hemostasis, consistent with the markedly reduced platelet counts. None of the remaining
animals of this study showed decreased cellularity of the bone marrow.
In addition to the changes described above, decreased platelet counts were seen in females at
and mg/kg JNJ-6379/JNJ-3989. However, the decrease in platelet counts for these
groups was mild, similar across animals within the groups and to those seen in a previous 1-month
combination toxicity study with JNJ-6379/JNJ-3989, and not accompanied by other cytopenia nor
bone marrow abnormalities. The decrease in platelet counts for these groups are likely caused by
a different mechanism than for the male rat that was euthanized on Day 24, as described above.
No relevant changes on urinary biomarkers were detected in male and female rats given JN-6379
at mg/kg/day (clusterin, albumin, ß2-microglobulin, Kidney Injury Molecule-1 [KIM-1],
Neutrophil Gelatinase Associated Lipocalin [NGAL] and cystatin-C) .
Based on the observation of pancytopenia in 1 rat and a mild platelet decrease in the combination
groups in the 3-month combination toxicity study, the sponsor is implementing additional
monitoring of significant on-treatment hematologic changes in clinical studies with dosing longer
than 4 weeks (see Section 8.5.6.5 ) . However, no significant abnormalities of hematologic
parameters have been observed in clinical studies to date.
For further information, refer to the IBs and addenda.14 16,39
2.2.1.2. Combination of JNJ-3989 or JNJ-6379 with Entecavir, Tenofovir
Disoproxil, or Tenofovir Alafenamide
There is no common target organ between JNJ-6379 or JNJ-3989 and entecavir (ETV) .23 The
single common toxicity target organ between JNJ-6379, JNJ-3989, and tenofovir disoproxil or
tenofovir alafenamide (TAF)is the kidney.
In the chronic rat studies with JNJ-3989, slight alteration of the renal tubular epithelium was
characterized by basophilic stippling and/or microvacuolation of the cytoplasm of renal tubules in
the outer cortex in rats. These findings were not considered toxicologically meaningful since they
were related to compound accumulation, there was no evidence of cellular damage
(degeneration/necrosis)  and there were no correlated clinical pathology indicators of changes in
renal function.12,17 These kidney findings have been observed in both the 2-week and 6-month
studies and did not worsen over time. No kidney findings were observed in monkeys.
In the chronic rat study (6 months)  with JNJ-6379, retrograde nephropathy, secondary to papillary
or pelvic calculi/precipitates, was noted in male rats but not in dogs or female rats. This finding is
CCI
CCI
CCI
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 47
Status: 
Approved,  Date: 25 November 2021mainly due to precipitation or calculi formation in distal parts of the kidney/lower urinary tract and
is of limited relevance to man, due to differences in urinary composition and functional anatomy
between (male)  rats and humans. In general, compounds or metabolites of low solubility and high
renal clearance may cause concretions in the kidneys/ urinary tract, especially at high doses, as the
urine concentrates in the distal nephron and supersaturation of the compound can occur. Urinary
pH, proteins and osmolality can also influence the formation of urinary concretions. Male rat urine
normally has a high concentration of protein and high osmolality. In addition, rats may be
predisposed to retrograde nephropathy because they are known to experience spontaneous urine
reflux during micturition or urinary bladder contraction, and this reflux phenomenon can be
increased or exacerbated by treatment induced obstructions. The retrograde nephropathy in male
rats correlated with increased urea and creatinine in plasma and with urinary changes (red/brown
discolored urine, increased volume, decreased pH, presence of blood and white and RBCs in
sediment) .3,32 No kidney findings were observed in dogs.
Although both compounds (JNJ-3989 and JNJ-6379)  showed histological kidney findings in the
rat, the primary anatomical location, mechanism and severity are different. For JNJ-3989 the renal
findings are without anticipated clinical or clinicopathological consequences and located in the
proximal part of the nephron (outer cortex)  and intracellular (not in the tubular lumen) . For JNJ-
6379, the main findings are restricted to male rats and initiate in distal parts of the kidney (renal
pelvis/ papilla)  and/or in the lumen of the lower urinary tract with secondary more proximal
changes due to reflux.
For tenofovir disoproxil, renal tubular epithelial karyomegaly was observed in rats, dogs, and
monkeys.24In dogs, the species most sensitive to tenofovir disoproxil-related effects onthe kidney,
additional microscopic alterations following chronic administration of tenofovir disoproxil
(10 mg/kg/day for 42 weeks)  included individual tubular cell necrosis, tubular dilatation, tubular
degeneration/regeneration, pigment accumulation, and interstitial nephritis. This was associated
with biochemical changes such as slight elevation in serum creatinine, glucosuria, proteinuria, and
increased urine volume. The incidence and severity of nephrotoxicity was dose-related. Effects
were reversible following cessation of treatment. In Rhesus monkeys, biochemical and/or
histopathologic evidence of nephrotoxicity was observed at high doses. In rats, slight elevations in
serum creatinine were observed without any histopathology correlation.
For TAF, minimal renal cortical tubular karyomegaly and/or basophilia was seen in rats and dogs.
In addition, minimal renal cortical tubular degeneration/regeneration were reported in dogs. No
renal findings were reported in monkeys.6
Based on the available toxicology data, there are no specific concerns about additive or synergistic
toxicities in the kidney when JNJ-6379 or JNJ-3989 are combined with ETV, tenofovir disoproxil
or TAF.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 48
Status: A
pproved,  Date: 25 November 20212.2.1.3. Combination of JNJ-3989 with PegIFN-α2a
A 3-month combination toxicity study of JNJ-3989 and PegIFN-α2a (Pegasys®)  was conducted
in male and female Cynomolgus monkeys (Study TOX14273) . JNJ-3989 was administered at
or mg/kg (SC, monthly)  in combination with PegIFN-α2a at 0.015 mg/kg (SC, twice weekly) .
In addition, mg/kg JNJ-3989 (SC, monthly)  or PegIFN-α2a (0.015 mg/kg; SC, twice weekly)
were dosed in monotherapy groups. The study was conducted in monkeys as the toxicity profile
of both PegIFN-α2a and JNJ-3989 were known in monkeys (rat studies were not performed with
PegIFN-α2a) .
There were no test item-related mortalities. JNJ-3989 (alone or combined with PegIFN-α2a) was
well tolerated and did not induce effects on clinical signs, body weight, food consumption,
ophthalmoscopic examination, electrocardiology evaluation, coagulation, clinical chemistry or
urinalysis parameters, as well as organ weight and macroscopic examination.
Transient local reactions (edema and erythema)  were observed at the administration site a
and/or mg/kg JNJ-3989. These reactions were also observed with PegIFN-α2a alone and
incidentally in control females (erythema only) . They were not correlated with microscopic
findings.
Administration of JNJ-3989 alone or combined with PegIFN-α2a elicited minimal to mild,
transient (on Day 30 only) , non-dose-related increases in neutrophils and total WBCs. Similar
findings were observed in the group administered 0.015 mg/kg PegIFN-α2a alone.
The combination of JNJ-3989 with PegIFN-α2a did not induce any further effects on biomarkers
(interferon gamma inducible protein 10 and interferon alpha)  than the increases observed with
PegIFN-α2a treatment alone on Day 1.
JNJ-3989-related microscopic findings were observed in the lymph nodes (minimal to mild
vacuolation of macrophages)  at ≥60 mg/kg and in the liver (minimal hypertrophy of Kupffer cells)
at mg/kg in single agent and combination groups. The microscopic changes were comparable
between the animals administered with JNJ-3989 alone or combined with PegIFN-α2a indicating
an absence of synergistic effect.
Systemic exposure to JNJ-3924 and JNJ-3976 in plasma was similar after single and repeated
dosing following administration of JNJ-73763989 alone or combined with reference item PegIFN-
α2a.
In conclusion, the intermittent SC administration of JNJ-3989 up to mg/kg given alone or
combined with PegIFN-α2a for 3 months was well tolerated in Cynomolgus monkeys at up to
mg/kg. Treatment only induced transient local reactions at the injection site, transient
hematological changes and microscopic findings in liver and lymph nodes, all considered as non-
adverse. In addition, the administration of PegIFN-α2a in combination with test item did not
amplify any toxicological effect. Based on these results, there were no additive or synergistic
effects on the toxicity profile and no drug-drug interactions when JNJ-3989 is combined with
PegIFN-α2a.
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 49
Status: 
Approved,  Date: 25 November 2021For further information, refer to the latest version of the IB and IB addendum for JNJ-398915,16.
2.2.1.4 . Combination of JNJ-6379 with PegIFN-α2a
As there is no appropriate species for studying the combination of JNJ-6379 with PegIFN-α2a, an
in vitro study on human bone marrow derived erythroid and myeloid progenitors using colony
forming assays was done. JNJ-6379 (5-100 μM)  and PegIFN-α2a (Pegasys®, 0.00005-0.1 μM)
were tested in combination in order to evaluate their potential additive or synergistic effects (study
TOX14629) .
The IC 50 values of the combination treatment were markedly lower compared to JNJ-6379 alone
for all tested concentrations but similar to the values with PegIFN-α2a alone. When the higher
concentrations of PegIFN-α2a were tested in combination with JNJ-6379, the reduction in colonies
was mainly due to the strong toxicity of PegIFN-α2a at these concentrations.
Comparing the predicted (adding the percent of reduction of JNJ-6379 and PegIFN-α2a alone)  and
the actual percent reduction in colonies relative to the solvent control, it became clear that there
were only minimal differences, pointing more to an additive effect and not a synergistic effect
when JNJ-6379 and PegIFN-α2a were combined.
2.2.2. Clinical Studies
2.2.2.1. JNJ-3989 and JNJ-6379
JNJ-3989
Clinical data on pharmacokinetics (PK) , efficacy, and safety of JNJ-3989 are available from the
ongoing Phase 1/2a AROHBV1001 study with a data cut-off date of 29 October 2019. All dosing
with JNJ-3989 has been completed and ongoing participants are in the follow-up. Twenty adult
healthy participants have received single SC injections of JNJ-3989 (35, 100, 200, 300, and 400
mg)  and 84 adult chronic HBV-infected participants have received multiple doses of JNJ-3989
(25, 50, 100, 200, 300, and 400 mg) , administered as 3 SC injections separated by either 7-day,
14-day, or 28-day intervals. All participants either continued or started ETV or tenofovir disoproxil
on Day 1.
JNJ-3989 was generally safe and well tolerated with no deaths, serious adverse events (SAEs)
considered at least possibly related to the study intervention, or adverse events (AEs)  leading to
study intervention discontinuation. All AEs were mild to moderate, with exception of 1 severe
blood creatine phosphokinase increased in 1 chronic HBV-infected participant. All reported
injection site reactions (ISRs)  were mild. Adverse events and laboratory abnormalities were
distributed across all dose levels and also occurred on placebo treatment, except for mild ISRs,
which were only reported in participants on JNJ-3989 treatment. Most reported laboratory
abnormalities were isolated incidents and resolved while on study intervention.
Antiviral-activity data were available for 56 chronic HBV-infected participants who received 3 SC
injections of 25 to 400 mg JNJ-3989 every 4 weeks (Q4W) .8,37 In general, mean HBsAg declines
reached nadir at Day 113 (ie, 8 weeks after last JNJ-3989) . Mean HBsAg levels remained
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 50
Status: A
pproved,  Date: 25 November 2021suppressed (below baseline levels)  at least until Day 392 (ie, 9 months after last dose)  in a
substantial proportion of patients.
JNJ-6379
At the time of protocol writing, 126 adult healthy and 41 chronic HBV-infected participants have
been dosed with JNJ-6379 in 5 completed Phase 1 studies (56136379HPB1001,
56136379HPB1002, 56136379HPB1003, 56136379HPB1004, and 56136379HPB1005) . In
addition, data are available from 148 adult chronic HBV-infected participants in the ongoing Phase
2a study, 56136379HPB2001, also referred to as JADE.
Human Pharmacokinetics and Product Metabolism
Single Dose Studies in Healthy Participants
In Study 56136379HPB1001, single ascending doses (25, 50, 150, 300 and 600 mg)  of JNJ-6379
(or placebo)  were administered under fasting conditions to healthy participants. No major
differences were observed in the shape of the mean JNJ-6379 plasma concentration-time curves
for the different dose levels. Mean and individual PK profiles showed minimal lag-time. A single
rather flat concentration peak was observed in the PK profiles of most participants. Plasma
concentrations in the terminal phase declined generally in parallel for all dose levels. The C maxand
AUC from administration to 24 hours (AUC 0 24h) increased proportionally with dose after
single-dose administration of JNJ-6379 doses of 25 mg to 300 mg and less than dose
proportionally at the dose of 600 mg. The AUC from administration to last quantifiable sampling
point (AUC 0 last)  and the AUC to last sampling point from time zero extrapolated to infinity
(AUC ∞)  increased proportionally between the JNJ-6379 25-mg and 600-mg dose levels. Mean
values for terminal half-life (t 1/2term)  were comparable for the 25-mg to 300-mg dose levels, and
averaged between 93.3 hours and 110.5 hours. For the 600-mg dose group, the average t 1/2termwas
141.3 hours. Mean values for the total apparent oral clearance (CL/F)  were comparable for the
25-mg, 50-mg and 150-mg dose level, and appeared to decrease at higher dose levels. Mean values
of the apparent volume of distribution were generally comparable for the different dose groups.
In Study 56136379HPB1002, study intervention exposure levels using a novel tablet formulation,
containing hydroxypropylmethylcellulose E5 based spray-dried powder, were similar to exposure
levels observed in study 56136379HPB1001 using the original formulation, both in fed conditions.
The relative bioavailability of new 25-mg oral tablets of JNJ-6379 administered as a 150-mg dose
under fasting and fed conditions, and of new 100-mg oral tablets of JNJ-6379 administered as a
300-mg dose under fasting conditions, was assessed in healthy adult participants. Assuming
proportionality, based on the geometric mean ratios between the 3x 100-mg dose, fasting (test)
and the 6x 25-mg dose, fasting (reference)  of the dose-normalized PK parameters, C max was
21.56% lower for the 100-mg tablet strength compared to the 25-mg tablet strength, and AUC 0 last
and AUC ∞were similar. The median time to reach C max(tmax)  was around 1.75 hours when 150 mg
JNJ-6379 was dosed as 6x 25-mg oral tablets, and around 3.00 hours when 300 mg JNJ-6379 was
dosed as 3x 100-mg oral tablets.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 51
Status: A
pproved,  Date: 25 November 2021In Study 56136379HPB1005, the oral bioavailability of a single 300-mg dose of JNJ-6379
administered as a 100-mg tablet containing hydroxypropylmethylcellulose-acetate succinate based
spray-dried powder (test tablet)  was assessed. All 14 healthy adult participants received a
300-mg dose of JNJ-6379 under fasted conditions. Preliminary PK analysis was performed and
mean C max was 3,105 ng/mL, mean AUC 0 72h was 111,286 ng.h/mL and mean AUC ∞ was
280,926 ng.h/mL. The median t maxwas around 3.00 hours. These preliminary PK parameter values
are comparable to the PK parameters obtained after administration of JNJ-6379 formulated as
hydroxypropylmethylcellulose E5 based spray-dried powder tablet.
Multiple Dose Studies in Healthy Participants
In Session 7 of Study 56136379HPB1001, participants received 150 mg JNJ-6379 twice daily
under fed conditions for the first 2 days of treatment, followed by 100 mg JNJ-6379 qd until
Day 12. JNJ-6379 plasma concentrations accumulated during the study (accumulation ratio of
approximately 6) . The CL/F at steady-state and the t 1/2term were similar to values observed after
single-dose administration, suggesting time-linear PK.
In Study 56136379HPB1004, participants received 250 mg of JNJ-6379 twice daily on Days 6 and
7 (fed conditions) , followed by 170 mg qd on Day 8 to 25 in fed conditions (with exception of
Day 21) . On Day 21, a single dose of JNJ-6379 170 mg and a single dose of
drospirenone/ethinylestradiol 3 mg/0.02 mg and a single dose of midazolam 2 mg were
administered under fasted conditions. Mean JNJ-6379 C max and area under the plasma analyte
concentration-time curve over the dose interval (AUC τ)  increased between Day 6 (first dose of
JNJ-6379)  and Day 20 as JNJ-6379 plasma concentrations accumulated due to the multiple-dose
regimen administered in this study. Steady-state was reached before Day 20. Plasma
concentration-time profiles of JNJ-6379 were similar to those observed in
Study56136379HPB1001.
Multiple Dose Studies in chronic HBV -inf ected Participants
In Sessions 8, 9, 10, 11, and A of Study 56136379HPB1001, treatment-naïve chronic
HBV-infected-infected participants were administered multiple-dose regimens (25, 75, 150, and
250 mg)  of JNJ-6379 for 28 days. Pharmacokinetics of JNJ-6379 were not markedly different
between healthy participants and chronic HBV-infected participants. Mean JNJ-6379 exposures in
chronic HBV-infected participants could be predicted from data in healthy participants. The PK
data show that exposure of JNJ-6379 in chronic HBV-infected participants is dose proportional
and CL/F is constant over time.
Food Interaction
Although Study 56136379HPB1001 suggested slightly higher exposure of JNJ-6379 in fed
conditions, data from Study 56136379HBP1002 with a higher number of participants showed that
there is no food effect on JNJ-6379 exposure, and a preliminary PK analysis from
Study56136379HBP1005 suggests the same.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 52
Status: 
Approved,  Date: 25 November 2021Drug-drug Interaction
Oral contraceptives:  When administered simultaneously with 3 mg drospirenone/0.02 mg
ethinylestradiol in Study 56136379HPB1004, JNJ-6379 increases the extent of exposure and
decreases the CL/F of ethinylestradiol while the peak plasma concentration decreased. In contrast,
JNJ-6379 has no clear effect on the extent of exposure and CL/F of drospirenone, a cytochrome
P450 (CYP) 3A4 sensitive progestin: peak plasma concentration decreased while no change in
exposure and apparent clearance was observed. Consequently, oral contraceptives are still
considered to be effective when administered simultaneously with JNJ-6379. However, as a
precaution to avoid high exposure to ethinylestradiol, ethinylestradiol-containing contraceptives
are only allowed if the ethinylestradiol content is ≤20 µg.
Midazolam: In Study 56136379HPB1004, coadministration of 170 mg JNJ-6379 qd with oral
midazolam as a CYP3A4 probe substrate showed a reduction of 41.7% in C maxand 53.9% in AUC
of midazolam, implying that JNJ-6379 may induce the metabolism of CYP3A4 sensitive
substrates.
Ef f icacy Studies
Antiviral activity data are available from Part II of Study 56136379HPB1001 (final analysis,
57 treatment-naïve participants treated with multiple-dose regimens of 25 to 250 mg JNJ-6379 qd
for 28 days, unblinded) . Available antiviral activity data for 4 weeks of treatment with JNJ-6379
in this study showed potent HBV DNA and RNA reductions but no changes in HBsAg, indicating
that longer treatments are needed.
Interim efficacy data are available from the Phase 2a JADE study. Interim analysis (IA)2 (cut-off
date: 8 February 2019)  includes Week 12 data from 64 chronic HBV-infected participants not
treated at screening of whom 26 received 75 mg qd JNJ-6379 monotherapy (open-label)  and 38
received 75 mg qd JNJ-6379 or placebo in addition to an NA (blinded) . Interim analysis 2 also
includes unblinded Week 24 data from 44 virologically suppressed chronic HBV-infected
participants of whom 33 received 75 mg qd JNJ-6379 and 11 received placebo in addition to an
NA. Interim analysis 3 (cut-off date: 7 March 2019)  includes blinded Week 12 data from 40
virologically suppressed chronic HBV-infected participants who received 250 mg qd JNJ-6379 or
placebo in addition to an NA.
The 12-week interim efficacy data in currently not treated participants on 75 mg JNJ-6379
monotherapy showed a mean reduction from baseline of HBV DNA of >3.5 log 10 International
Units Per Milliliter (IU/mL) at Week 12. This decline was similar to the mean decline in
participants treated with JNJ-6379 or placebo in combination with an NA (data still blinded) .
The 24-week interim efficacy data in virologically suppressed participants on 75 mg JNJ-6379
showed that most participants had HBV DNA levels below the limit of quantification at baseline.
At 24 weeks of treatment, 5 (23.8%)  of 21 participants on JNJ-6379 experienced a mean reduction
from baseline in HBV RNA of >2 log 10 IU/mL versus 1 (14.3%)  of 7 participants on placebo.
Hepatitis B virus RNA levels at Week 24 were undetectable for 21 (100.0%)  of 21 participants on
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 53
Status: A
pproved,  Date: 25 November 2021JNJ-6379 and 4 (57.1%)  of 7 participants on placebo. No relevant mean changes from baseline in
HBsAg and HBeAg were noted so far.
In the monotherapy arm with 75 mg JNJ-6379, 5 of 28 participants (status after IA cut-off date)
experienced a virologic breakthrough defined as confirmed on-treatment HBV DNA increase by
>1 log 10 from nadir level or confirmed on-treatment HBV DNA level >200 IU/mL in participants
who had HBV DNA level below the LLOQ of the HBV DNA assay. All 5 participants with
virologic breakthrough hadan emerging core amino acid mutation T33N, which is known to confer
reduced JNJ-6379 activity in vitro. All 5 participants discontinued JNJ-6379 and started NA
treatment. An urgent safety measure was implemented to discontinue JNJ-6379 treatment in all
participants in this arm and offer NA treatment. No cases of virologic breakthrough were observed
in any of the arms combining JNJ-6379/placebo with NA treatment. A futility rule was
implemented in the 250 mg JNJ-6379 monotherapy arm (if ≥1 participant in the 250 mg
monotherapy arm experiences virologic breakthrough during the first 24 weeks of treatment, NA
treatment will be added to JNJ-6379 treatment as soon as possible for all remaining participants) .
In the monotherapy arm with 250 mg JNJ-6379, 1 participant experienced virologic breakthrough
(status after IA cut-off date) . The participant discontinued JNJ-6379 treatment and started NA
treatment at the withdrawal visit, due to meeting non-response criteria. Nucleos(t) ide analog
treatment will be added for all remaining participants in the JNJ-6379 250 mg monotherapy arm
in accordance with the futility rule mentioned above.
Saf ety Studies
Data from 5 completed Phase 1 studies (56136379HPB1001, 56136379HPB1002,
56136379HPB1003, 56136379HPB1004, and 56136379HPB1005)  in healthy and chronic
HBV-infected participants (N 126 and 41, respectively) , indicate that orally administered
JNJ-6379 as single doses up to 600 mg or as multiple doses (250 mg twice daily for 2 days followed
by 170 mg qd for 18 days or 150 mg twice daily for 2 days followed by 100 mg qd for 10 days)  in
healthy participants and as multiple doses up to 250 mg for 28 days in chronic HBV-infected
participants was safe and well tolerated. No SAEs considered at least possibly related to the
study intervention were reported. Most AEs were mild and not considered treatment-related, with
no dose-related trends.
Safety data are also available from IAs 2 and 3 conducted for the Phase 2a JADE study, which
were mentioned above. There were no deaths, SAEs considered at least possibly related to the
study intervention, or AEs leading to discontinuation. Most AEs were grade 1 or 2 in severity. The
majority of reported AEs were considered unrelated to JNJ-6379 by the investigator. Grade 2 to 4
AEs considered at least possibly related to JNJ-6379 by the investigator were grade 2 asthenia
(3 participants) , grade 4 alanine aminotransferase (ALT) increased, grade 2 headache, grade 2
vertigo, grade 3 anemia (corrected to grade 2 by the investigator after the IA cut-off date) , grade 2
hypertension, and grade 2 fatigue (all observed in 1 participant each) .
Increased cholesterol is considered a laboratory abnormality of interest for JNJ-6379, based on
safety review from nonclinical and clinical trials. Cholesterol increased was reported as an AE in
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 54
Status: 
Approved,  Date: 25 November 20214 (4.1%)participants on JNJ-6379 for the pooled Phase 1 studies, in 1 (2.4%)  participant on
JNJ-6379 for the Phase 1 study 56136379HPB1005, and in none of the participants in the Phase 2a
JADE study.
Combination of  JNJ-3989 and JNJ-6379
Clinical data of triple combination treatment of JNJ-3989, JNJ-6379, and NA are available from
the ongoing Phase 1/2a AROHBV1001 study (Cohort 12) . Twelve adult chronic HBV
mono-infected participants have received 3 SC injections of JNJ-3989 (200 mg Q4W)  in
combination with oral JNJ-6379 (250 mg qd)  and oral NA treatment (ETV or tenofovir disoproxil) .
Up to the interim analysis (IA)  cut-off date of 29 October 2019, no deaths, SAEs, or
treatment-emergent adverse events (TEAEs)  leading to study intervention discontinuation were
reported. Two (16.7%)  participants reported at least 1 TEAE during the treatment phase. The
TEAEs (upper respiratory tract infection and hypertension)  were of mild severity and considered
not related to the study intervention by the investigator.
The triple combination treatment of JNJ-3989, JNJ-6379, and NA is currently being investigated
in chronic HBV mono-infected participants in the ongoing Phase 2 clinical studies
73763989HPB2001 (REEF-1, 90 participants in triple combination Arm 1) and
73763989PAHPB2002 (REEF-2, 80 participants in triple combination Arm 1) . Up to 48-week
hematology data from the ongoing Phase 2 clinical study REEF-1 are available and overall around
5% of the participants experienced AEs or laboratory abnormalities related to hematology, the
majority of mild to moderate severity. The hematologic abnormalities resolved on continued JNJ-
3989+JNJ-6379+NA treatment.16
Since the initial protocol writing, interim results of the REEF-1 and REEF-2 studies had become
available. In the primary REEF-1 analysis (Week 48, end of treatment)  the mean reduction of
HBsAg levels in the triple arm (JNJ-6379+JNJ-3989 100mg+NA)  appeared to be less than in the
dual arm (JNJ-3989 100mg+NA) . More recent interim results of the REEF-2 study (Week 48, end
of treatment)  confirmed this observation when the effect of JNJ-6379+JNJ-3989 200mg+NA on
mean HBsAg level reduction in REEF-2 study is compared to JNJ-3989 200mg+NA in the
REEF-1 study. To match with the REEF-2 population, this cross-study comparison focused on the
REEF-1 subpopulation of HBeAg negative, virologically suppressed participants with chronic
hepatitis B. PK-PD modelling analyses accounting for variability in baseline characteristics further
support this observation. Therefore, a negative effect of JNJ-6379 on the HBsAg lowering effect
of JNJ-3989+NA is suspected.
2.2.2.2. Combination of JNJ-3989 and JNJ-6379 with Entecavir, Tenofovir
Disoproxil, or Tenofovir Alafenamide
Entecavir monohydrate is an HBV NA reverse transcriptase inhibitor indicated for the treatment
of chronic HBVinfectionin adults and children at least 2 years of age with evidence of active viral
replication and either evidence of persistent elevations in serum aminotransferases (ALT or
aspartate aminotransferase [AST])  or histologically active disease. The most common adverse
reactions (≥3% of participants)  are headache, fatigue, dizziness, and nausea.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 55
Status: 
Approved,  Date: 25 November 2021There is no common target organ between JNJ-6379 or JNJ-3989 and ETV.23
Tenofovir disoproxil (available in several salt forms including tenofovir disoproxil fumarate and
tenofovir disoproxil maleate)  is a first-generation oral prodrug of the NA tenofovir that is indicated
for the treatment of chronic HBV infection in adult and pediatric patients at least 12 years of age.
In addition, tenofovir disoproxil in combination with other antiretrovirals is indicated for the
treatment of HIV type 1 (HIV-1)  infection in adult and pediatric patients at least 2 years of age.
The most common adverse reactions (≥10% of participants)  are abdominal pain, nausea, insomnia,
pruritus, vomiting, dizziness, and pyrexia.
TAF is an ester prodrug of the NA tenofovir that is indicated for the treatment of chronic HBV-
infected in adults and that is characterized by a better safety profile than tenofovir disoproxil. The
most common adverse reaction (≥10% of participants)  is headache.
The single common toxicity target organ between JNJ-6379, JNJ-3989, and tenofovir disoproxil
or TAF is the kidney (see Section 2.2.1.2 ) .
Clinical data on dual combination treatment of JNJ-6379 and NA are available from the ongoing
Phase 2a 56136379HPB2001 study (JADE) .14 In participants treated with tenofovir disoproxil,
Ctrough concentrations of tenofovir at Week 12 were higher in participants receiving tenofovir
disoproxil in combination with JNJ-6379 than in participants receiving tenofovir disoproxil as
monotherapy (94.2 [30.0] and 115 [66.0] ng/mL for 75- and 250-mg JNJ-6379, respectively in
combination with tenofovir disoproxil, vs 66.8 [37.0] ng/mL as tenofovir disoproxil monotherapy) .
Clinical data of triple combination treatment of JNJ-3989, JNJ-6379, and NA are available from
the ongoing Phase 1/2a AROHBV1001 study (see Section 2.2.2.1 ) . Dosing JNJ-6379 or JNJ-3989
with NA for 12 weeks, did not show any clinically relevant changes in kidney
parameters/glomerular function.
For further information regarding ETV, tenofovir disoproxil, and TAF, refer to the respective
currently approved prescribing information.
Overall Assessment of  the Combination Therapy
Based on the points listed below, no clinically relevant drug-drug interactions (DDIs)  and no
specific concerns about additive or synergistic toxicities in the kidney are expectedwhenJNJ-6379
or JNJ-3989 are combined with ETV, or tenofovir disoproxil, or TAF:
 Available toxicology data, described in Section 2.2.2.1
 In vitro drug transporters
 Metabolic interaction data
 Absence of relevant DDIs in the combination toxicity studies up to 3 months with JNJ-6379
and JNJ-3989
 Absence of synergistic or additive histology findings in the kidney observed in the
combination toxicity studies up to 3 months with JNJ-6379 and JNJ-3989
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 56
Status: A
pproved,  Date: 25 November 2021 Available clinical data with JNJ-6379 (JADE study [56136379HPB2001])  up to 48 weeks
treatment on the absence of changes in kidney parameters/glomerular function
 Available clinical data of triple combination treatment of JNJ-3989, JNJ-6379, and NA
described in Section 2.2.2.1 .
In addition, pancytopenia in 1 rat and a mild platelet decrease were seen in the combination groups
in the 3-month combination toxicity study (preliminary data, Section 2.2.1) . No significant
abnormalities of hematologic parameters have been observed in clinical studies to date. The
sponsor is implementing additional monitoring of significant on-treatment hematologic changes
in clinical studies with dosing longer than 4 weeks (see Section 8.5.6.5 ) . For further information,
refer to the IBs and addenda.14 16,39
2.2.2.3. Combination of JNJ-3989 and JNJ-6379 with PegIFN-α2a
PegIFN-α2a is a covalent conjugate of recombinant alfa-2a interferon that is indicated for the
treatment of chronic hepatitis B in adult and pediatric patients at least 3 years of age. In addition,
PegIFN-α2ain combination with other medicinal products is indicated for the treatment of chronic
hepatitis C virus (HCV) -infection in adult and pediatric patients at least 5 years of age and not
treated before. The most common adverse reactions (≥10% of participants)  are anorexia, anxiety,
headache, concentration impairment, dyspnea, cough, alopecia, dermatitis, pruritis, dry skin,
myalgia, arthralgia, asthenia, pyrexia, and fatigue. For further information regarding PegIFN-α2a,
refer to the currently approved prescribing information.
Treatment with PegIFN-α2ahas been associated with decreases in platelet count (common adverse
reaction) . In the ongoing Phase 1/2a AROHBV1001 study (see Section 2.2.2.1 ) , no effect on
platelet count has been observed in the triple combination treatment cohort 12 (JNJ-3989,
JNJ-6379, and NA) . Of the 84 adult chronic HBV-infected participants that received
3 subcutaneous injections of JNJ-3989, 6 participants developed grade 1 plateletreduction with no
general trend towards a continuous decline. For JNJ-6379, no effect on platelet count has been
observed in the ongoing Phase 2a study 56136379HPB2001 (JADE)  for the 189 adult chronic
HBV-infected participants that were dosed with JNJ-6379.
Based on preclinical data, a potential common toxicity target organ between JNJ-6379, JNJ-3989,
and PegIFN-α2a is the bone marrow (see Section 2.2.1.1 ) . Bone marrow suppression is a known
side effect of PegIFN-α2a (rare) .
No pharmacokinetic (PK)interaction is expected between JNJ-3989 and PegIFN-α2a based on the
known pharmacologic profile of JNJ-398915,16,41.
At the time of protocol amendment 4 writing, no clinical data on the combination of JNJ-3989 and
JNJ-6379 with PegIFN-α2a are available. Nonclinical studies to investigate the effect on platelet
count decreases and on bone marrow in non-human primates (JNJ-3989)  and bone marrow stem
cells (JNJ-6379)  were completed, and results are summarized in Section 2.2.1.1 .
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 57
Status: A
pproved,  Date: 25 November 20212.3. Benefit-Risk Assessment
More detailed information about the known and expected benefits and risks of JNJ-3989 and JNJ-
6379 may be found in the respective IBs and addenda.14 16,39
For the benefit-risk evaluation of ETV, tenofovir disoproxil, TAF, and PegIFN-α2a refer to the
respective prescribing information.
JNJ-6379 was initially part of the study intervention but has been removed as study intervention
with the implementation of an urgent safety measure, as described in Protocol Amendment 5.
Emerging data from the REEF-1 and REEF-2 studies resulted in an unfavorable benefit-risk
balance of JNJ-6379 in combination with JNJ-3989+NA, compared to JNJ-3989+NA alone.
Therefore, the Sponsor decided to discontinue treatment with JNJ-6379 in all ongoing clinical
studies effective immediately. Participants who were on treatment with JNJ-6379 were contacted
and requested to stop taking JNJ-6379, while continuing treatment with NA, JNJ-3989 and
PegIFN-α2a. For newly enrolled participants, JNJ-6379 was taken out of the treatment regimen.
For completeness, the benefit-risk assessment for JNJ-6379 is still included in this section.
2.3.1. Benefits for Study Participation
2.3.1.1. Known Benefits
The clinical benefit of JNJ-3989 and JNJ-6379 remains to be established.
2.3.1.2. Potential Benefits
Results from clinical studies with JNJ-3989, JNJ-6379, NAs, and optional PegIFN-α2a may be
useful for the development of a novel therapeutic approach for chronic HBV infection.
The combination of JNJ-6379 and JNJ-3989 on a background of NAs would target different stages
of the viral life cycle. While NA treatment reduces HBV DNA to levels close to or below the
LLOQ of the HBV DNA assay, HBV replication is not completely inhibited, resulting in
replenishment of the cccDNA pool. The addition of JNJ-6379, which targets the HBV capsid
assembly (“primary” MoA)  and the de novo cccDNA formation (“secondary” MoA) , is expected
to block HBV replication more profoundly by inhibiting formation of HBV RNA and DNA
containing particles, and to inhibit de novo cccDNA formation, ultimately leading to reduction in
cccDNA levels/transcriptional activity and HBsAg seroclearance (“intensified viral suppression”) .
The addition of JNJ-3989 to an NA, or to JNJ-6379 in combination with an NA, is expected to
intensify viral suppression (further)  by downregulating levels of the HBV DNA precursor pgRNA.
In addition, JNJ-3989 reduces levels of all viral proteins including HBsAg, which is known to
interfere with the host immune responses.7,20,34By acting on both viral replication and by reducing
barriers to the host immune-responses, higher functional cure rates may be achieved.
The addition of short-term PegIFN-α2a (for 12 or 24 weeks)  to the regimen at a time when HBsAg
is already significantly reduced or eliminated, may lead to further improvement of the immune
response (such as reactivation of NK-cells and further activation of endogenous HBV-specific T-
cells)  and ultimately could lead to immune control of HBV (ie, functional cure) . In addition,
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 58
Status: A
pproved,  Date: 25 November 2021PegIFN-α2a has shown to have direct antiviral effects on HBV which could also contribute to the
efficacy of the regimen. By adding short-term PegIFN-α2a to the regimen, higher efficacy may be
achieved.
2.3.2. Risks for Study Participation
2.3.2.1. Known Risks
No known risks associated with JNJ-3989 or JNJ-6379 have been identified from clinical
observations so far in the Phase 1 and 2 studies. Injection site reactions were identified as adverse
drug reactions for JNJ-3989.
The side effect profile of PegIFN-α2a is well established and includes, but is not limited to,
neuropsychiatric, autoimmune, ischemic, ophthalmologic, hematological, and infectious
disorders. Exacerbations of hepatitis during hepatitis B therapy are common and characterized by
transient and potentially severe increases in serum ALT. Marked increases in ALT were sometimes
accompanied by bilirubin elevation and other liver test abnormalities. In many, but not all cases,
these disorders resolve after stopping PegIFN-α2a therapy. For a full list of known risks for
PegIFN-α2a, refer to the respective prescribing information.
2.3.2.2. Potential Risks
All therapies have the potential to cause adverse experiences. In addition, the discontinuation of
NA treatment bares a risk of hepatitis B flares.
Patients with positive HBV DNA and positive HBsAg can always experience increases in liver
transaminases which may indicate immune activation and may result in the reduction of viral
parameters such as HBV DNA and/or HBsAg. Whether this occurs at higher frequency during or
after treatment with JNJ-6379 and JNJ-3989 is not known.
Please refer to Section 2.2for details on the safety results in the studies conducted to date.
2.3.2.2.1. Potential Risks for JNJ-3989
ALT Elevations
ALT elevations are considered an important potential risk for JNJ-3989. Two distinct patterns of
ALT elevations have been observed in participants receiving JNJ-3989: a rapidly rising and
resolving ALT elevation or a more sustained pattern of ALT elevation. The latter has been
observed in HBV/HDV co-infected participants in study 73763989HPB2004 during double-blind
treatment phase. A causal association of ALT elevations with JNJ-3989 has not been confirmed
and the underlying mechanism for ALT elevations being more frequent in the context of
HBV/HDV co-infection is not yet understood.16
Reproductive Risks and Pregnancy
In the EFD studies, JNJ-3989 was not teratogenic in rats and rabbits. The fertility in male and
female rats is not impacted with JNJ-3989 up to a dose of mg/kg/week.
CCI
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDENT
IAL –FOIA Exemptions Apply in U.S. 59
Status: A p
proved,  Date: 25 November 2021Based on the difference in metabolic pathways and in vitro data indicating absence of impact of
JNJ-3989 on CYP enzymes and transporters, no clinically relevant interactions are anticipated
between JNJ-3989 and oral contraceptives.
Potential Genotoxicity
JNJ-3989 is considered to be devoid of genotoxic activity. Nonclinical carcinogenicity studies
have not been conducted.
Other Potential Toxicity/Events of Special Interest
JNJ-3989 is considered non-cytotoxic, did not activate human platelet aggregation, did not activate
the innate immune system to a significant degree in vitro, and did not activate complement in vitro.
Hematologic abnormalities are an event of special interest for JNJ-3989 and JNJ-6379 based on
animal studies (refer to Section 2.3.2.2.2 for further information) .
Viral Resistance
Treatment with JNJ-3989 may lead to viral resistance, but resistance to JNJ-3989 is not anticipated
to impact treatment with other small interfering RNAs (siRNAs) . Using these agents in
combination, especially in combination with ETV or tenofovir is expected to minimize the risk of
emerging resistant viral variants.
2.3.2.2.2. Potential Risks for JNJ-6379
Since the initial protocol writing, interim results of the REEF-1 and REEF-2 studies had become
available. The data suggested that JNJ-6379 has a negative impact on the HBsAg lowering effect
of JNJ-3989+NA (see Section 2.2.2.1 ) . In addition, there were new insights in the adverse renal
profile of JNJ-6379 (see below) . Taken together, it was concluded that JNJ-6379 had an
unfavorable benefit-risk balance in combination with JNJ-3989+NA, compared to JNJ-3989+NA
alone. Therefore, the Sponsor decided to discontinue treatment with JNJ-6379 in all ongoing
clinical studies effective immediately. For completeness, the potential risks for JNJ-6379 are still
described in this section.
Reproductive Risks and Pregnancy
In the fertility study in females, early embryonic development was affected: an increase in pre- and
post-implantation loss, reduction in implantation and live fetuses at mg eq./kg/day. The fetal
loss seen during the early stages of pregnancy was considered the result of low hormone levels
(decreased luteinizing hormone, progesterone, estradiol)  induced by treatment with JNJ-6379.
In the EFD studies, JNJ-6379 was not teratogenic in rats and rabbits.
In the EFD study in rats, fetal weights at mg eq./kg/day were lowered, and there was retarded
ossification from mg eq./kg/day onwards. The NOAEL for EFD was considered to be mg
eq./kg/day. At this dose, the AUC 0 24h was 84,000 ng.h/mL and the C maxwas 5,190 ng/mL.
CCI
CCI
CCI
CCI
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDENT
IAL –FOIA Exemptions Apply in U.S. 60
Status: A p
proved,  Date: 25 November 2021In the EFD study in rabbits, the NOAEL for EFD was considered to be the highest dose tested, ie,
mg eq./kg/day. At this dose, the AUC 0 24hwas 99,200 ng.h/mL and the C maxwas 6,880 ng/mL.
Potential Genotoxicity
JNJ-6379 was not genotoxic in the in vitro and in vivo tests.
JNJ-6379 did not affect male or female fertility. Carcinogenicity studies are not yet conducted.
Other Potential Toxicity/Events of Special Interest
Based on nonclinical findings in rats and dogs and based on clinical findings, increased cholesterol
was identified as a laboratory abnormality of interest.
Renal complications are considered an event of special interest for JNJ-6379. Immediate
treatment-emergent decrease in mean eGFR, which was initially observed in the JADE study, has
also been observed in both JNJ-6379 treatment arms in the ongoing REEF-1 study. The eGFRcr
values remained reduced during treatment, with a fast rebound after end oftreatment. The eGFR
decrease (calculated from serum creatinine)  may be an anomaly due to JNJ-6379 possibly
interfering with tubular excretion of creatinine via inhibition of MATE-1 transporter.39 This
hypothesis was supported by the absence of a pattern of increased biomarkers of proximal tubulo-
toxicity (the beta-2microglobulin/creatinine and the retinol binding protein/creatinine ratios) ,
suggesting that the eGFRcr reduction was due to transporter inhibition at the level of creatinine
excretion from the proximal tubule rather than renal toxicity.
Emerging data from the REEF-2 study became available, confirming the transient pattern of
eGFRcr declines but, in addition, showing an increase of the beta-2microglobulin/creatinine and
the retinol binding protein/creatinine ratios in some participants when TDF was continued and
combined with JNJ-6379+JNJ-3989. These new data are suggesting that JNJ-6379 in combination
with TDF may contribute to renal tubulo-toxicity.
Hematologic abnormalities are considered an event of special interest for JNJ-3989 and JNJ-6369.
Mild thrombocytopenia was observed in recently conducted non-clinical toxicology studies with
the combination of JNJ-3989 and JNJ-6379. In addition, in a 3-month combination study with
80 rats, 1 rat developed pancytopenia related to bone marrow depletion after 23 days of dosing.
Previously, in a 9-month dog study in 24 dogs treated with JNJ-6379 alone, pancytopenia which
correlated with a marked increase in plasma cell-like cells in the bone marrow was observed in
1 dog after 60 days of dosing. Refer to Section 8.5.6.5 . A minor additive effect was observed in
vitro in human bone marrow derived erythroid and myeloid progenitors when combining JNJ-6379
and Peg-IFN-α2a.14
Viral Resistance
Treatment with JNJ-6379 may lead to emergence of viral variants with reduced susceptibility or
resistance to JNJ-6379. Based on nonclinical data, these variants remain susceptible to tenofovir
and ETV but might affect treatment options with CAMs in the future. All 5 participants with
virologic breakthrough in the JADE study who received 75 mg JNJ-6379 monotherapy, had an
CCI
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 61
Status: A
pproved,  Date: 25 November 2021emerging core amino acid mutation T33N, which is known to confer reduced JNJ-6379 activity in
vitro (see Section 2.2.2.1 for the results of the IAs) .
Drug-drug Interactions
Based on results from DDI study 56136379HPB1004 investigating the potential effect of
coadministration of JNJ-6379 with oral contraceptives, it is not anticipated that the efficacy of oral
contraceptives will be impacted during coadministration with JNJ-6379 since the exposure of a
progestin sensitive to CYP3A4 induction was not significantly affected by coadministration of
JNJ-6379. In contrast, it is anticipated that coadministration with ethinylestradiol-containing
contraceptives will result in an increased exposure to ethinylestradiol. Therefore, specific
requirements on the use of ethinylestradiol-containing contraceptives are included in Section 6.5.
2.3.2.2.3. Potential Risks for Tenofovir Disoproxil and PegIFN-α2a
For the general potential risks of tenofovir disoproxil and PegIFN-α2a refer to the respective
prescribing information.
Risks specific for this study design are listed below:
 PegIFN-α2a might increase the immunogenicity of JNJ-3989.
 Combination of PegIFN-α2a with JNJ-3989 and JNJ-6379 might increase the risk of
hematologic abnormalities and/or of bone marrow suppression.
 JNJ-6379 might increase tenofovir plasma concentrations.
2.3.2.3. Risks Due to Study Procedures
2.3.2.3.1. Potential Risks and Inconvenience Associated with the Liver Biopsy
Procedures
Percutaneous core liver biopsies and fine needle aspiration biopsies (FNAB)  will be performed
during this study for research purposes.
The risks and complications related to these procedures will be described in the informed consent
form (ICF)and may include:
 Pain and discomfort located at or near the puncture site and radiating upwards toward the right
shoulder region, which may last for up to a few hours or rarely days after the procedure.
 Bleeding at the biopsy site.
 Infection and internal bleeding and/or puncture of other internal organs (gall bladder, lung,
intestine or kidney)  which can lead to serious complications (uncommon 1 in 1000 to 1 in
100)  including the need for emergency surgery, blood transfusion, or removal of organs.
Deaths directly related to liver biopsy occur rarely (approximately 1 in every 10,000 biopsies) .
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 62
Status: 
Approved,  Date: 25 November 20212.3.2.3.2. Potential Risks and Inconvenience Associated with the Optional
Leukapheresis Procedure
Participants who provide separate consent may undergo leukapheresis. The risks and
complications related to this procedure will be described in the ICF and may include:
 Frequent side effects (~5% of participants) : chills, reactions to the citratebased anticoagulant
(eg, prolonged bleeding for up to 20 minutes after the procedure) , numbness or tingling of the
lips, face, or on the fingertips, muscle cramps, abnormal heart rhythm, or metallic taste in the
mouth
 Occasional side effects (<5% of participants) : bruising or discomfort at the injection sites,
pain/numbness in the arm (usually of short duration) , tiredness the day following the
procedure, weakness, nausea/vomiting, fainting due to decreased blood pressure, pink or red
coloration of urine, hemolysis
 Rare side effects (≤1% of participants) : superficial inflammation of the vein in the arm that is
being used for the procedure which may result in pain, heat, and redness, pulmonary
embolism, rapid breathing, chest pain, or cough
2.3.3. Benefit-risk Assessment for Study Participation
Based on the available data and proposed safety measures, the overall risk/benefit assessment for
JNJ-3989 and JNJ-6379 clinical studies is deemed acceptable for the following reasons:
 At the time of protocol writing, JNJ-3989 was generally safe and well tolerated during the
ongoing Phase 1/2a Study AROHBV1001 (see Section 2.2.2) . All but one AE were mild or
moderate in severity. All ISRs, identified as adverse drug reactions for JNJ-3989, were mild
in intensity.
 No clinically significant safety concerns had been raised for JNJ-6379 at the time of initial
protocol writing, based on the safety information from studies in healthy adult participants
and adult participants with chronic HBV infection. Most observed AEs at that time were mild
in severity and considered not related to JNJ-6379 by the investigator (see Section 2.2.2) . At
the time of Protocol Amendment 5 writing, it was concluded that JNJ-6379 has an unfavorable
benefit-risk balance in combination with JNJ-3989+NA, compared to JNJ-3989+NA alone
(see Section 2.3.2.2.2 ) . Therefore, the Sponsor decided to discontinue treatment with JNJ-
6379 in all ongoing clinical studies effective immediately, as a measure to minimize risk to
participants of this and other studies.
 Events of Special Interest are significant AEs that are judged to be of special interest because
of clinical importance, known class effects or based on nonclinical signals. Events of Special
Interest that will be carefully monitored during the study include ISRs, ALT/AST elevations,
renal complications, hematological abnormalities, and events related to cholesterol increase
(Section 8.5.6and Section 8.4.4) . In addition, the following toxicities will also be carefully
monitored: rash and acute systemic allergic reactions (Section 8.5.7) .
 Continued careful assessment of the safety, efficacy, and PK during treatment is included in
this study.
 To minimize potential risk and stress to participants, the following measures are in place:
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 63
Status: A
pproved,  Date: 25 November 2021 Utilization of selection criteria which exclude participants who may potentially be at
higher risk of an AE (see Section 5) .
 Utilization of withdrawal criteria (see Section 7) . If a participant drops out due to
withdrawal of consent, he/she retains the option to participate in the safety follow-up
procedures.
 Following local standard practice the biopsy location will be identified with ultrasound
(which will also be used to rule out contraindicating conditions for a biopsy) . At the
off-treatment biopsy, blood coagulation and platelets will be assessed according to local
practice. Prior to the on-treatment biopsy, a recent (≤ 1 week)  coagulation and
hematology panel and a platelet aggregation test are required, to ensure normal count and
function of platelets and normal coagulation parameters. Site selection will be based on
their experience in the performance of core liver biopsies and FNABs.
 Participants will be monitored closely during the optional leukapheresis. In case of
serious complications, the leukapheresis procedure will be stopped immediately.
Participants will stay on site for at least 30 minutes after leukapheresis to monitor for
potential side effects. Additional safety-related assessments may be performed at the
discretion of the investigator and may include additional laboratory tests after the
procedure to measure hematologic parameters.
 At regular time points throughout the study (see Schedule of Activities ) , blood samples
for biochemistry, blood coagulation, and hematology and urine samples for urinalysis,
urine chemistry, and renal biomarkers will be collected. Vital signs (systolic and diastolic
blood pressure [SBP and DBP]) , pulse rate, and body temperature) , height (only at
screening) , body weight, and electrocardiograms (ECGs)  will be recorded throughout the
study. Physical examinations will be performed and AEs will be assessed (see
Section 8.3, Safety Assessments) . Events of Special Interest will be closely monitored
(Section 8.5.6, Adverse Events of Special Interest) .
 Based on pre-clinical and clinical data available today, the combination of JNJ-3989, JNJ-
6379, tenofovir disoproxil, and short-term PegIFN-α2a is considered safe. Data from
nonclinical combination toxicity studies showed a minimal additive effect on myeloid
and erythroid cells in vitro when combining JNJ-6379 and PegIFN-α2a (Section 2.2.1.4 )
and confirmed that combination of PegIFN-α2a with JNJ-3989 did not induce any
synergistic or additive effect in monkeys up to 3 months of treatment (Section 2.2.1.3 ) .
Review of 48-week hematology data from the ongoing Phase 2 clinical study REEF-1
(Section 2.2.2.1 )  did not identify any safety concerns.
 The impact of PegIFN-α2a addition to JNJ-3989 on ALT elevations is not known in the
context of HBV monoinfection. Strict rules for management of ALT elevation are in place
(refer to Section 8.5.6.2 , Intervention-emergent ALT/AST Elevations) .
 An Independent Flare Expert Panel (IFLEP)  will be appointed to characterize and
adjudicate each ALT flare (see Section 9.6) .
 After stopping treatment with NA, JNJ-3989, JNJ-6379 (if applicable) , and PegIFN-α2a
(if applicable) , participants will be monitored closely during the follow-up phase, with
frequent follow-up visits and pre-defined NA re-treatment criteria in case of flares
(Section 6.6.2) .
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 64
Status: A
pproved,  Date: 25 November 2021 The post-treatment monitoring and NA re-treatment criteria (Section 6.6.2)  were further
updated based on findings from a case of post-treatment HBV reactivation with subacute
hepatic failure and assessment of additional REEF-2 study data.
 JNJ-3989 will be administered using a proper SC technique to decrease the risk of ISRs.
Injection site reactions will be managed as outlined in Section 8.5.6.1 .
 Any clinically significant abnormalities persisting at the end of the study/early
discontinuation will be followed up by the investigator until resolution (return to baseline)
or until stabilization (to be agreed upon with the sponsor) .
3. OBJECTIVES AND ENDPOINTS
The following objectives and endpoints will be assessed overall and by study panel:
Objectives Endpoints
Primary
 To asses
s changes in intrahepatic HBsAg
between baseline and on-treatment liver
biopsy in response to JNJ-3989-based
combination treatment Changes in the proportion of HBsAg positive
hepatocytes between baseline and on-treatment
Week 40
Secondar
y
 To asse
ss changes in intrahepatic immune
response between baseline and
on-treatment liver biopsy Changes between baseline and on-treatment liver
biopsy in intrahepatic immune response (eg,
CD45+ T-cells, CD4+ T-cells, CD8+ T-cells,
Natural Killer cells, and dendritic cells) in terms
of proportion of cells, cell types, and spatial
redistribution
 To asse
ss changes in intrahepatic viral
nucleic acids and proteins between
baseline and on-treatment liver biopsy Changes from baseline in intrahepatic viral
parameters (such as cccDNA, pgRNA,
intrahepatic RNA, or HBsAg in terms of copy
number, or number of positive cells)
 Changes from baseline in intrahepatic cccDNA
levels and transcriptional activity
(pgRNA/cccDNA ratio)
 To eval
uate the efficacy of the study
intervention as measured in blood The proportion of participants during the study
intervention and follow-up phases with:
 HBsAg seroclearance at Week 72 (ie, 24
weeks after completion of all study
interventions at Week 48)  without restarting
NA treatment.
 (Sustained)  Reduction, suppression, and/or
seroclearance considering single and
multiple markers (such as HBsAg, HBeAg,
HBV DNA and ALT)
 HBsAg and HBeAg seroconversion
 Flares (virologic, biochemical, and clinical)
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 65
Status: 
Approved,  Date: 25 November 2021Objectives Endpoints
 Time t
o first HBsAg seroclearance
 To eva
luate the frequency of virologic 
breakthrough during study intervention  Proportion of participants with virologic
breakthrough
 To ass
ess HBV-specific T-cell responses  Changes from baseline in HBV-specific
peripheral blood T-cell responses during the
study intervention and follow-up phases
 To eva
luate the safety and tolerability of 
the study intervention  Proportion of participants with (S) AEs and
abnormalities in clinical laboratory tests
(including hematology, blood biochemistry,
blood coagulation, urinalysis, urine chemistry,
and renal biomarkers) , 12-lead ECGs, vital signs,
and physical examinations throughout the study
 To eva
luate the plasma PK of JNJ-3989 
(ie, JNJ-3976 and JNJ-3924) and 
optionally of JNJ-6379, NA  and/or 
PegIFN-α2a, as applicable Plasma PK parameters of JNJ-3976, JNJ-3924,
and optionally of JNJ-6379, NA  and/or
PegIFN-α2a, as applicable
Explorat
ory
 To exp
lore the relationship of intrahepatic 
markers with blood markers (immune and 
viral) Association between levels and changes in
intrahepatic and blood markers
 To exp
lore the association of baseline 
characteristics and intrahepatic and/or 
blood (immune and viral)  biomarkers at 
baseline and on/off-treatment with selected 
on/off-treatment efficacy variables  Association of baseline characteristics and
baselineand on/off-treatment viral blood markers
(such as baseline NA treatment duration, age, and
baseline and on/off-treatment HBsAg levels)
with selected off-treatment efficacy variables
 Association of intrahepatic and blood biomarkers
(such as cccDNA levels, T-cell frequency)  with
selected on/off-treatment efficacy variables
 To exp
lore intrahepatic immune and viral 
changes at Week 72 and/or during off- 
treatment flares (only for participants with 
Week 72 biopsy available)  Changes from  baseline and on-treatment liver
biopsy in intrahepatic immune and viral markers
at Week 72 and/or during off-treatment flares
(only for participants with Week 72 biopsy
available)
 To exp
lore changes in the severity of liver 
disease  Changes in fibrosis (according to Fibroscan liver
stiffness measurements)  at the end of study
intervention (EOSI) and end of follow-up versus
screening/baseline*
 To exp
lore the efficacy in terms of changes 
in HBV RNA and hepatitis B core-related 
antigen (HBcrAg) levels.  Changes from baseline in HBV RNA and
HBcrAg levels during study intervention and
follow-up phases. 
 To exp
lore the relationship between 
plasma PK parameters (JNJ-3989 [ie, 
JNJ-3976 and JNJ-3924] and/or JNJ-6379 
and/or NA  and/or PegIFN-α2a)  and
selected pharmacodynamic (PD) Relationship between various plasma PK
parameters (JNJ-3976 and JNJ-3924, and/or
JNJ-6379, and/or NA, and/or PegIFN-α2a)  and
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 66
Status: 
Approved,  Date: 25 November 2021Objectives Endpoints
parame
ters of efficacy and/or safety, as 
applicable selected efficacy and/or safety endpoints, as
applicable
 To exp
lore the HBV genome sequence  The emergence of intervention-associated
mutations during the study intervention and
follow-up phases
 To assess the impact of baseline HBV genome
polymorphisms on selected on/off-treatment
efficacy variables
* Only 
applicable to participants who are enrolled at a site with an on-site Fibroscan device.
Refer to Section 8for evaluations related to endpoints.
HY POTHESIS
As this is an exploratory study, no hypothesis will be tested.
4 . STUDY DESIGN
4 .1. Overall Design
As of 
Protocol Amendment 5, the study is a Phase 2 single-arm, open-label, multicenter, study to
assess intrahepatic and peripheral changes of immunologic and virologic markers in response to a
combination regimen containing JNJ-3989 and NA in chronic HBV-infected participants.
With the implementation of an urgent safety measure, as described in Protocol Amendment 5,
JNJ-6379 has been removed as study intervention and the study will continue as a single-arm study.
Participants randomized to Arm 1 had to stop JNJ‑6379 treatment immediately but continue JNJ-
3989 + NAtreatment.
In addition, participants who provide separate consent may receive optional treatment with
PegIFN-α2a starting after the Week 40 biopsy (or after the optional leukapheresis if applicable)
but before the Week 48 visit. The duration (either 12 or 24 weeks)  will be at the investigator’s
discretion.
A target of 24 chronic HBV-infected male and female participants, 18-65 years (inclusive)  of age
will be enrolled in 2 panels, approximately 12 participants in each panel. Panel 1 will consist of
participants who are HBeAg positive and not currently treated and Panel 2 will consist of
participants who are HBeAg negative and virologically suppressed by ETV, tenofovir disoproxil,
or TAF treatment.
The study will be conducted in 3 phases for all participants: a screening phase (4 weeks) , an open-
label study intervention phase (48 weeks) , and a follow-up phase (48 weeks) . If necessary, eg, for
operational reasons, the screening phase may be extended up to a maximum of 6 weeks on a case-
by-case basis and in agreement with the sponsor. The duration of individual participation will be
up to 102 weeks. Note that the follow-up period will be extended for participants who are receiving
optional treatment with PegIFN-α2a and who meet NA treatment completion criteria at the end of
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 67
Status: A
pproved,  Date: 25 November 2021treatment with NA and PegIFN-α2a to ensure all participants have at least one year of follow-up
after NA treatment cessation. For those participants, the duration of individual participation may
be extended up to 126 weeks.
Prior to Protocol Amendment 5, participants were randomized in a 1:1 ratio within each panel to
receive one of the following interventions (ie, treatments)for 48 weeks:
 Interventionarm 1, combination regimen JNJ-3989+JNJ-6379+NA(target of 12 participants) :
 200 mg JNJ-3989 (SC injection Q4W, with the last injection at Week 44) , AND
 250 mg JNJ-6379 (tablets qd) , AND
 NA: ETV, tenofovir disoproxil, or TAF (tablets qd)
 Intervention arm 2, combination regimen JNJ-3989+NA (target of 12 participants) :
 200 mg JNJ-3989 (SC injection Q4W, with the last injection at Week 44) , AND
 NA: ETV, tenofovir disoproxil, or TAF (tablets qd)
As of Protocol Amendment 5:
 Participants who were randomized to study intervention with JNJ-6379 prior to Protocol
Amendment 5, had to stop JNJ-6379 treatment immediately but will still receive the following
interventions (ie, treatments)  for 48 weeks:
 200 mg JNJ-3989 (SC injection Q4W, with the last injection at Week 44) , AND
 NA: ETV, tenofovir disoproxil, or TAF (tablets qd)
 New participants will enroll without randomization within each panel to receive the
combination regimen JNJ-3989 + NA as study intervention for 48 weeks:
 200 mg JNJ-3989 (SC injection Q4W, with the last injection at Week 44) , AND
 NA: ETV, tenofovir disoproxil, or TAF (tablets qd)
In addition, participants who provide separate consent may receive optional treatment with
PegIFN-α2a starting after the Week 40 biopsy (or after the optional leukapheresis if applicable) .
The duration (either 12 or 24 weeks)  will be at the investigator’s discretion. This will allow to
investigate whether addition of PegIFN-α2a for 12 or 24 weeks may increase the participant’s
chance to achieve HBsAg loss.
All participants will complete treatment with JNJ-3989 after a fixed duration of 48 weeks. If the
NA treatment completion criteria (outlined in Section 6.6.1)  are met based on clinical laboratory
tests performed at Week 44, treatment with NA will also be completed at Week 48. In participants
not meeting these criteria, NA treatment will continue during the follow-up phase. Participants
who are receiving optional treatment with PegIFN-α2a and who have not met NA treatment
completion criteria at Week 48 may have NA treatment completion criteria assessed at the end of
treatment with PegIFN-α2a and stop NA if criteria are met.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 68
Status: 
Approved,  Date: 25 November 2021All participants will be monitored closely during the follow-up phase and, if applicable, should
restart NA treatment in accordance with the NA re-treatment criteria (see Section 6.6.2for more
details) .
Prior to Protocol Amendment 5, randomization within each panel was stratified by Fibroscan score
(<7 kPa vs ≥7 kPa) . Randomization and stratification are not applicable anymore per Protocol
Amendment 5.Safety and tolerability, including (S) AEs, laboratory assessments, ECGs, vital
signs, and physical examination, will be assessed throughout the study from the time of signing
the ICF until completion of the last study-related activity (see Section 8.4and Section 8.5) .
At Week-1 and Week 40, FNAB samples and core liver biopsy samples will be taken. Additional
optional FNAB and/or core liver biopsy samples may be taken (eg, at follow-up Week 24)  from
participants who provide separate consent (see Section 8.1) .
Efficacy will be evaluated using different parameters including HBsAg and HBeAg (see
Section 8.2) .
Samples for HBV genome sequencing will be taken at the time points indicated in the Schedule of
Activities (see Section 8.2.1) . Sequencing of samples obtained may be triggered by the sponsor’s
virologist based on changes in HBV DNA levels observed in each individual participant and the
limits of the sequencing assay.
Peripheral blood mononuclear cell (PBMC) samples for immune analyses will be collected at the
time points indicated in the Schedule of Activities (see Section 8.3) .
The study includes collection of blood samples for exploratory analysis of viral markers (see
Section 8.1)  and host blood biomarkers at the host RNA, protein, and cell level (see Section 8.10) .
All participants will have sparse PK sampling on Day 1 and at Weeks 4, 12, and 24 (and at early
withdrawal) . All participants who consent to participate in the intensive PK substudy (optional)
will undergo intensive PK sampling at Week 4.
A population PK analysis may be performed based on the available data for JNJ-6379, JNJ-3989,
and optionally, NA and/or PegIFN-α2a, potentially in combination with data from a selection of
Phase 1 and/or 2 studies. PK parameters in participants undergoing intensive PK sampling will be
calculated via noncompartmental methods.
Pharmacokinetic/pharmacodynamic relations may be explored (see Section 8.8) .
Host DNA samples will be collected to allow for the identification of genetic factors (see
Section 8.9) . In addition, host DNA blood samples to allow for epigenetic analyses will be
collected.
Human leukocyte antigen (HLA)  typing will be performed as indicated in the Schedule of
Activities .
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 69
Status: 
Approved,  Date: 25 November 2021In case of premature discontinuation of investigational intervention (before Week 48) , follow-up
assessments should be obtained until 48 weeks after EOSI unless the participant withdraws
consent.
If a participant withdraws before completing the study intervention, the reason for withdrawal (if
known)  is to be documented in the case report form (CRF)  and in the source document. Participants
who withdraw consent will be offered an optional safety follow-up visit.
An IFLEP will be appointed for this study (see Section 9.6) .
A diagram of the study design is provided in Section 1.2.
4 .2. Scientific Rationale for Study Design
Study Population
Patients with chronic HBV infection will be eligible if (1)  they are HBeAg positive and not
currently being treated or (2)  if they are HBeAg negative and virologically suppressed by NA
treatment.
Patients with advanced liver fibrosis or liver cirrhosis are excluded, as the goal of the study is to
assess the potential of a finite treatment to achieve functional cure, and discontinuation of
treatment in patients with cirrhosis is not current practice due to concerns about poor tolerability
of liver flares associated with increased viral replication. The safety of the combination regimens
evaluated in this study will first be established in patients without liver cirrhosis prior to initiating
studies in patients with more advanced liver disease.
Study Design Change –Protocol Amendment 5
Based on emerging data from the REEF-1 (73763989HPB2001)  and REEF-2
(73763989PAHPB2002)  studies, the study design has been adapted in Protocol Amendment 5.
In summary, the data from the REEF-1 and REEF-2 studies suggested that JNJ-6379 has a negative
impact on the HBsAg lowering effect of JNJ-3989+NA (see details in Section 2.2.2.1 )  and that
JNJ-6379 in combination with TDF may further contribute to renal tubulo-toxicity (see details in
Section 2.3.2.2.2 ) . Together, this led to a conclusion of an unfavorable benefit-risk balance of JNJ-
6379 in combination with JNJ-3989+NA, compared to JNJ-3989+NA alone. Therefore, the
Sponsor decided to discontinue treatment with JNJ-6379 in all ongoing clinical studies effective
immediately. Participants currently on treatment with JNJ-6379 were contacted and requested to
stop taking JNJ-6379, while continuing treatment with NA, JNJ-3989, and PegIFN-α2a. For newly
enrolled participants, JNJ-6379 was taken out of the treatment regimen. 
Furthermore, the sponsor decided to make additional changes to the study design because of a
severe clinical ALT flare that was reported following discontinuation of NA treatment in a
participant who was randomized to the control arm (placebo + placebo + NA)  in the REEF-2 study.
Discontinuation of NA treatment was following the protocol-defined criteria and in line with recent
EASL treatment guidelines5. Flares following NA discontinuation are not unexpected, but the
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 70
Status: 
Approved,  Date: 25 November 2021rapid evolution and clinical deterioration seen in this participant who had no history or evidence
of liver cirrhosis was unforeseeable. Therefore, to protect the safety of participants, the protocol
was amended: more frequent monitoring of participants who discontinued NA treatment during
follow-up was included and the NA re-treatment criteria for all participants who discontinued NA
treatment were revised.
In addition, the follow-up phase in this study has been extended to ensure that all participants have
at least one year of follow-up after NA treatment cessation.
Randomization, Stratification Factors and Blinding
Note that randomization and stratification are not applicable anymore per Protocol Amendment 5.
Prior to Protocol Amendment 5, randomization and stratification were performed as described
below.
Within each of the two study panels (ie, HBeAg positive patients who are not currently being
treated and HBeAg negative patients being virologically suppressed by NA treatment) ,
randomization was used to minimize bias in the assignment of participants to intervention arms,
to increase the likelihood that known and unknown participant attributes (eg, demographic and
baseline characteristics)  were evenly balanced across intervention groups, and to enhance the
validity of statistical comparisons across intervention arms.
Randomization within each panel was stratified by Fibroscan score (<7 kPa vs ≥7 kPa) .
As this is an exploratory study, participants will be treated in an open-label fashion. In addition,
most relevant assessments will be based on objective markers (biopsy and peripheral immunology)
and are not subject to bias from the participants or observers.
Criteria for Completion of NA Treatment
To explore the possibility of finite treatment, all participants who completed the 48-week study
intervention will stop all study interventions including NAs at Week 48 if they meet NA treatment
completion criteria (described in Section 6.6.1) . The treatment completion criteria which take
ALT, HBV DNA, HBeAg and HBsAg levels into consideration, have been selected to ensure that
only participants with a chance of sustained off-treatment response are allowed to complete all
study intervention. Across a range of studies, HBsAg levels below 100 IU/mL are consistently
associated with favorable off treatment response.19,26 The stringent HBsAg cutoff of 10 IU/mL for
NA treatment completion was chosen to account for the direct effect of JNJ-3989 on HBsAg levels.
Participants who are receiving optional treatment with PegIFN-α2a and who have not met NA
treatment completion criteria at Week 48 may have NA treatment completion criteria assessed at
the end of treatment with PegIFN-α2a and stop NA if criteria are met.
After stopping all study interventions, participants will be monitored closely during the 48-week
follow-up phase and should restart NA treatment in accordance with the NA re treatment criteria
(see Section 6.6.2, for more details) .
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 71
Status: 
Approved,  Date: 25 November 2021Follow-up Procedures and Criteria for Re-initiation of NA Treatment
The follow-up period will be extended for participants who are receiving optional treatment with
PegIFN-α2a and who meet NA treatment completion criteria at the end of treatment with NA and
PegIFN-α2a to ensure all participants have at least one year of follow-up after NA treatment
cessation.
To ensure safety of patients during the follow-up phase, an ALT flare management plan is in place,
including a high visit frequency for patients after completion of NA treatment (at Week 48) , and
weekly visits for patients with ALT/AST ≥3x upper limit of normal (ULN)  and ≥3x nadir until
stabilization.
Increases in ALT and HBV DNA are frequently seen in patients after discontinuation of NA
treatment. These ALT elevations can be reflecting an activation of the host cellular immune
response and can as such lead to functional cure. Cases of fulminant HBV reactivation with fatal
outcome were described after cessation of NA treatment, but the vast majority of such cases were
described in patients with decompensated liver disease at the time of NA discontinuation. These
patients are not eligible to participate in the study. Still, a vigilant follow-up of patients during this
phase of the study is critical to ensure patient safety. Increases in ALT that are accompanied by
signs of decreased liver function, or an HBV DNA value of >100,000 IU/mL (irrespective of
confirmation and/or ALT increase) , will trigger immediate re-initiation of NA treatment based on
protocol-defined NA re-treatment criteria (see Section 6.6.2) .
Re-initiation of NA treatment is also required in case of confirmed HBeAg seroconversion
(HBeAg positive after it was negative at NA completion) , in case of confirmed* ALT increase
(>5x ULN)  in combination with increased HBV DNA replication (>2,000 IU/mL) , and in case of
confirmed* increased HBV DNA replication at higher levels (>20,000 IU/mL) .
* At least 4 weeks apart
A post-treatment HBV DNA value of >20,000 IU/mL should trigger re-testing of ALT/AST, HBV
DNA, and total and direct bilirubin within a maximum of 7 days from receipt of the data and
further repeats as necessary (ie, weekly until HBV DNA returns to <20,000 IU/mL) . A post-
treatment HBV DNA value of >2,000 IU/mL (but <20,000 IU/mL)  should trigger a re-test within
14 days from receipt of the data and further repeats as necessary (ie, every other week until HBV
DNA returns to <2,000 IU/mL) . A post-treatment ALT value of >5x ULN should trigger re-testing
of ALT, AST, ALP, total and direct bilirubin, INR, albumin, and HBV DNA on a weekly basis
until ALT and AST levels have returned to <5x ULN. Additional re-testing and/or earlier restarting
of NA treatment is at the investigator’s discretion, even if the above cut-offs are not yet met.
To avoid delays in decision making, sites are encouraged to run local re-testing in parallel with
central re-testing in the situations described above that require more frequent re-testing. Local test
results are to be recorded in the CRF and/or source documents, including information on the HBV
DNA assay used. In addition, to avoid delays in NA re-treatment, it should be considered to
dispense NA to participants who potentially met the NA re-treatment criteria (eg, pending
confirmation)  and who will not be available to come to the study site immediately at the time the
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 72
Status: 
Approved,  Date: 25 November 2021confirmatory test results will become available. This should ensure that the participant can
immediately restart NA treatment if indicated, upon direct confirmation by the investigator.
The decision to re-start NA treatment should take into consideration the dynamics of HBV DNA
and/or ALT values and should be discussed with the sponsor. Refer to Section 6.6.2.
NA re-treatment criteria during follow-up are presented graphically in Section 10.12, Appendix
12: NA Re-treatment During Follow-up.
Liver Biopsy
HBV is a hepatropic virus, with the liver being the site of its replication which requires a
modulation of intrahepatic immune response to allow the establishment of a chronic persistent
infection. Although some of the viral blood markers are well established from a clinical
perspective, questions remain on the relationship of these markers with intrahepatic events, such
as expression of viral proteins (eg, HBsAg) , HBV pgRNA, DNA and cccDNA level and
transcriptional activity in the liver, ie, the target organ of HBV infection. Similarly, while
assessment of peripheral immune response can provide insights into the HBV related immune
response, it is well accepted that a large proportion of the relevant immune responses are enriched
and/or restricted to the liver environment.10,11,29 For example, many HBV specific CD8+ T-cells
have a tissue-resident phenotype and innate-like populations such as mucosal associated invariant
T (MAIT)  cells and Natural Killer cells are enriched with the latter having also a specialized liver-
resident component.11,29
Collecting liver biopsy samples will allow to perform critical assessments of intrahepatic virologic
and immune events occurring in response to treatment with JNJ-3989, JNJ-6379 and NA, and to
correlate the findings in the liver with treatment response and to viral and immune blood markers.
In addition, these analyses are expected to improve the understanding of the molecular
mechanisms of the treatment interventions and to provide important insight into the HBV
pathology.
Both core liver biopsies and fine needle aspirates will be collected for high dimensional profiling
of the liver tissue. The cryopreserved core biopsies will allow characterization of the infected
hepatocytes compartment and phenotyping of the major immune cell populations (proportion of
cells and spatial distribution) . The liver tissue will be used to assess changes from baseline in the
proportion of HBsAg positive hepatocytes under therapy. In addition, the liver tissue will also be
used to assess other HBV markers in the liver such as, but not limited to, pgRNA, total intracellular
HBV RNA and DNA, and HBc. Changes in the quantity and potentially changes in the spatial
distribution of these markers (including HBsAg)  under JNJ-3989 and JNJ-6379 (if applicable)
containing therapy or NA treatment will be assessed. Viral genome (RNA or DNA)  sequencing of
the samples as well as assessment of HBV viral transcripts and HBV DNA integrants in the host
genome may be performed. This will also allow to compare viral parameters assessed in the liver
with viral parameters in the blood compartment.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 73
Status: 
Approved,  Date: 25 November 2021From an immune perspective, both, the innate and adaptive intrahepatic immune compartment will
be characterized. These analyses will include cells such as CD4+ T-cells, CD8+ T-cells, CD45+
cells, dendritic cells, and Natural Killer cells. Characterization of infiltrating immune cells will be
used for the evaluation of innate and adaptive immune responses, which can be compared to
responses in the PBMCs collected during the study.
Fine needle aspirates biopsies will be profiled by single cell transcriptomics approaches to better
understand the innate and adaptive immune cells composition and functional status9 (very few
hepatocytes are expected to be collected with fine needle aspirates) . Hepatitis B virus-specific
T-cells will be one of the main targeted cell populations, detected and sorted by multimers binding
assays. Downstream transcriptomic profiling of collected HBV specific T-cells may be performed
by T-cell receptor sequencing and RNA sequencing. Similar multimer binding assays approaches
might be applied to leukapheresis collected PBMCs, as HBV specific T-cells are present in very
low frequency in patients with chronic HBV infection.9
Remaining samples may be used for determination of liver JNJ-3989 (ie, JNJ-3976 and JNJ-3924)
and/or JNJ-6379 concentrations and/or research on viral and host biomarkers and immune markers
at the viral and/or host RNA/DNA, protein, and cell level.
Host DNA and Biomarker Collection
It is recognized that genetic variation can be an important contributory factor to interindividual
differences in intervention distribution and response and can also serve as a marker for disease
susceptibility and prognosis. Pharmacogenomic research may help to explain interindividual
variability in clinical outcomes and may help to identify population subgroups that respond
differently to an intervention. The goal of the pharmacogenomic component is to collect DNA to
allow the identification of genetic factors that may influence the efficacy, safety, or PK of
JNJ-3989 and JNJ-6379, to identify genetic and epigenetic factors associated with HBV infection,
or to develop assays for the study intervention or HBV infection.
Biomarker samples will be collected to evaluate the MoA  of JNJ-3989 and JNJ-6379 (if
applicable)  in combination with NA, help to explain interindividual variability in clinical
outcomes, or may help to identify population subgroups that respond differently to an intervention.
The biomarker research can be used to address questions related to the safety, PK, and efficacy of
the study intervention and HBV infection or to develop assays for the study intervention or HBV
infection.
Host DNA (pharmacogenomic)  and biomarker samples may be used to help address emerging
issues and to enable the development of safer, more effective, and ultimately individualized
therapies.
4 .2.1. Study-Specific Ethical Design Considerations
Potential participants will be fully informed of the risks and requirements of the study and, during
the study, participants will be given any new information that may affect their decision to continue
participation. They will be told that their consent to participate in the study is voluntary and may be
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 74
Status: 
Approved,  Date: 25 November 2021withdrawn at any time with no reason given and without penalty or loss of benefits to which they
would otherwise be entitled. Only participants who are fully able to understand the risks, benefits,
and potential AEs of the study, and provide their consent voluntarily will be enrolled.
Percutaneous core liver biopsies and FNABs will be performed during this study for research
purposes. The risks and complications related to these procedures are described in Section 2.3.2.3 .
These risks and complications will be described in the ICF and will be clearly explained to
potential participants prior to enrollment.
While all participants will receive the study intervention in combination with an approved therapy
for HBV infection, some ethical consideration should be given to the fact that participants will not
have access to potentially alternative or new effective therapies for the duration of the study
(intervention and follow-up phase)  since they may not begin any other approved or investigational
therapies for treatment of HBV infection during this time. Participants with worsening HBV
infection can discontinue the investigational intervention at any time, and the investigational
intervention should be discontinued if a participant requires additional therapy for HBV infection.
The total blood volume to be collected is considered to be an acceptable amount of blood to be
collected over this time period from the population in this study based upon the standard of the
American Red Cross standard blood donation.1
4 .3. Justification for Dose
The proposed dose and treatment duration are selected to maximize the chance for patients to
achieve functional cure and are supported by scientific understanding of available data. For both
compounds, doses are selected that are currently being tested in ongoing Phase 2b studies
REEF-1(73763989HPB2001)  and REEF-2 (73763989PAHPB2002)  (ie, 200 mg for JNJ-3989 and
250 mg for JNJ-6379) .
Note: JNJ-6379 was initially part of the study intervention but has been removed as study
intervention with the implementation of an urgent safety measure, as described in Protocol
Amendment 5.
4 .3.1. JNJ-3989
Clinical data on PK, efficacy, and safety of JNJ-3989 are available from the ongoing Phase 1/2a
AROHBV1001 study with a data cut-off date of 29 October 2019. All dosing with JNJ-3989 has
been completed and ongoing participants are in the follow-up phase. Twenty adult healthy
participants have received single SC injections of JNJ-3989 (35, 100, 200, 300, and 400 mg)  and
84 adult chronic HBV-infectedparticipants have received multiple doses of JNJ-3989 (25, 50, 100,
200, 300, and 400 mg) , administered as 3 SC injections separated by either 7 day, 14-day, or 28-
day intervals. All participants either continued or started on ETV or tenofovir disoproxil on Day 1.
JNJ-3989 was generally safe and well tolerated at all doses. No clinically relevant safety signal
was identified.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 75
Status: 
Approved,  Date: 25 November 2021Antiviral activity data were available for 56 chronic HBV-infected participants who received 3 SC
injections of 25 to 400 mg JNJ-3989 Q4W. In general, mean HBsAg declines reached nadir at Day
113 (ie, 8 weeks after last JNJ-3989) . Mean HBsAg levels remained suppressed (below baseline
levels)  at least until Day 392 (ie, 9 months after last dose)  in a substantial proportion of patients.8,37
A dose of 200 mg JNJ-3989 Q4W is chosen based on the observed decline in HBsAg in study
AROHBV1001 at this dose over 3 injections, and the lack of a substantial incremental efficacy
response at higher doses.
The Phase 2b study REEF-1 is designed to establish the optimal dose of JNJ-3989. Based on data
from the Phase 1/2a study AROHBV1001 with limited treatment duration, 200 mg was selected
as the highest dose of JNJ-3989 tested in REEF-1. Until lower doses are proven equivalently
effective in REEF-1, additional combination studies with JNJ-3989 and JNJ-6379 are conducted
with 200 mg of JNJ-3989.
4 .3.2. JNJ-6379
Note: JNJ-6379 was initially part of the study intervention but has been removed as study
intervention with the implementation of an urgent safety measure, as described in Protocol
Amendment 5.
At the time of initial protocol writing, a dose of 250 mg JNJ-6379 qd was chosen for this study.
A dose of 250 mg of JNJ-6379 was being considered to ensure maximal viral inhibition via
“primary” MoA (ie, interfering with the capsid assembly process) . In addition, it ensured sufficient
high exposures to engage the “secondary” MoA (ie, inhibition of de novo cccDNA formation) .
This dose selection was supported by translational PK/PD analyses and viral kinetic modeling.
Analyses of the HBV DNA data from the 4-week 56136379HPB1001 study showed a profound
but slightly less substantial reduction of plasma HBV DNA, as a measure of the “primary” MoA,
in the 25 mg dose group compared to the 75 mg and higher dose groups, suggesting that for JNJ-
6379 maximum effect (E max)  in terms of HBV DNA inhibition via primary MoA was approached
starting from a dose of 75 mg onwards. Since it was not possible to derive the engagement of the
“secondary” MoA from the available short term data, the in vitro primary human hepatocyte 90%
effective concentration values in the presence of serum proteins obtained for both MoAs were used
to translate from the “primary” to the “secondary” MoA.
Participants were to be treated with JNJ-6379 for 48 weeks. Based on the MoA of JNJ-6379, it
was expected that continued complete suppression of virus production and de novo cccDNA
formation over many months was required to achieve reduction of the transcriptional active
cccDNA pool, which was considered a prerequisite for HBsAg reduction and/or seroclearance.
Interim analysis data were at that time available from the ongoing Phase 2a JADE study in which
the 250-mg dose was being tested for 48 weeks. Blinded Week 12 data from 40 virologically
suppressed chronic HBV-infected participants who received 250 mg qd JNJ-6379 or placebo in
addition to an NA showed that there were no deaths, grade 4 AEs, or AEs leading to
discontinuation. Most AEs were mild or moderate in severity.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 76
Status: 
Approved,  Date: 25 November 20214 .4 . End of Study Definition
End of Study Definition
The end of study (EOS)is considered as the last visit (Follow-up Week 48 or early discontinuation)
for the last participant in the study. With implementation of Protocol Amendment 5, the last visit
for the last participant in the study may be up to Follow-up Week 72 (see Study Completion
Definition below for rationale) . The final data from the study site will be sent to the sponsor (or
designee)  after completion of the final participant visitat that study site, in the time frame specified
in the Clinical Trial Agreement.
Study Completion Definition
A participant will be considered to have completed the study if he or she has completed the
assessments at Follow-up Week 48. With implementation of Protocol Amendment 5, the follow-
up phase of 48 weeks will be extended with a maximum of 24 weeks (ie, Follow-up Week 72)  for
participants who are receiving optional treatment with PegIFN-α2a and who meet NA treatment
completion criteria at the end of treatment with NA and PegIFN-α2a to ensure all participants have
at least one year of follow-up after NA treatment cessation.
5. STUDY POPULATION
Screening for eligible participants will be performed within 4 weeks before administration of the
study intervention. If necessary, eg, for operational reasons, the screening phase may be extended
up to a maximum of 6 weeks on a case-by-case basis and in agreement with the sponsor.
The inclusion and exclusion criteria for enrolling participants in this study are described below. If
there is a question about these criteria, the investigator must consult with the appropriate sponsor
representative and resolve any issues before enrolling a participant in the study. Waivers are not
allowed.
Retesting to assess eligibility will be allowed once, using an unscheduled visit during the screening
period.
For a discussion of the statistical considerations of participant selection, refer to Section 9.2.
5.1. Inclusion Criteria
Each potential participant must satisfy all of the following criteria to be enrolled in the study:
1. Adult participants ≥18 years of age (or the legal age of consent in the jurisdiction in which
the study is taking place)  to ≤65 years of age.
2. Participants must be medically stable on the basis of physical examination, medical
history, vital signs, and triplicate 12-lead ECG performed at screening. Anyabnormalities
must be consistent with the underlying illness in the study population and this
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 77
Status: 
Approved,  Date: 25 November 2021determination must be recorded in the participant's source documents and initialed by the
investigator.
3. Participants must have HBV infection documented by serum HBsAg positivity at
screening. In addition, chronicity must be documented by any of the following at least
6 months prior to screening: serum HBsAg positivity, HBeAg positivity or HBV DNA
positivity, ALT elevation above ULN without another cause than HBV infection,
documented transmission event, liver biopsy with changes consistent with chronic HBV.
If none of the above are available, the following ways of documenting chronicity are
acceptable at the time of screening: absence of marker for acute infection such as
immunoglobulin M (IgM) anti-HBs and anti-HBc antibodies, which can be tested at
screening.
4. Participants who are not currently treated (defined as not having been on HBV treatment,
including NAs and IFNproducts within 6months prior to screening) , including treatment-
naïve participants (defined as never having received HBV treatment, including NAs and
IFN products)  should:
a. be HBeAg positive, AND
b. have serum HBV DNA at screening ≥20,000 IU /mL, AND
c. have ALT levels at screening <10x ULN, AND
d. have indication for NA treatment according to local standard practice.
5. Virologically suppressed participants should:
a. be HBeAg negative, AND
b. be on stable HBV treatment, defined as currently receiving NA treatment (ETV,
tenofovir disoproxil, or TAF)  for at least 6 months prior to screening and have been
on the same NA treatment regimen (at the same dose)  for at least 3 months at the
time of screening, AND
c. have serum HBV DNA <60 IU/mL on 2 measurements at least 3 months apart (one
of which is at screening) , AND
d. have documented ALT values <2.0x ULN on 2 measurements at least 3 months apart
(one of which is at screening) .
6. Participants must have HBsAg >100 IU/mL at screening.
7. Participants must have a body mass index (weight in kg divided by the square of height
in meters)  between 18.0 and 35.0 kg/m2, extremes included.
8. Participants must have fibroscan liver stiffness measurement ≤9.0 kPa within 6 months
prior to screening or at the time of screening.
Note: Other radiologic liver staging modalities (eg, acoustic radiation force impulse)
might be used if standard practice at the site or if otherwise validated and agreed with the
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 78
Status: 
Approved,  Date: 25 November 2021sponsor. Results should be equivalent to Metavir F0-F2 with absence of signs of portal
hypertension.
Note: Conventional imaging procedures (eg, conventional liver ultrasound, computed
tomography [CT] or magnetic resonance imaging [MRI])  and serum marker panels are
not allowed to rule out severe fibrosis or cirrhosis.
9. Female participants of childbearing potential must have a negative highly sensitive serum
pregnancy test ( -human chorionic gonadotropin [ -hCG])  at screening and a negative
urine pregnancy test on Day 1 before the first dose of study intervention.
10. Criterion modified per Amendment 5
10.1 A woman must be(as defined in Section 10.8, Appendix 8, Contraceptive and Barrier
Guidance and Collection of Pregnancy Information) :
a. not of childbearing potential
b. of childbearing potential and practicing a highly effective, preferably user-
independent method of contraception (failure rate of <1% per year when used
consistently and correctly)  for at least 30 days prior to screeningand agrees to remain
on a highly effective method while receiving study intervention and until 90 days
after last dose of study intervention.
Examples of highly effective methods of contraception are located in Section 10.8,
Appendix 8, Contraceptive and Barrier Guidance and Collection of Pregnancy
Information.
Note: Typical use failure rates may differ from those when used consistently and
correctly. Use should be consistent with local regulations regarding the use of
contraceptive methods for participants in clinical studies.
Note (no longer applicable as of  Protocol Amendment 5, because of  the removal of
JNJ-6379 as study intervention): Female participants of childbearing potential who
are on a stable treatment regimen with hormonal contraceptives (ie, same dose and
not starting or stopping hormonal contraceptive use for at least 30 days prior to
screening)  should continue the same dose regimen until 90 days after the last dose of
study intervention. Ethinylestradiol-containing contraceptives are only allowed if the
ethinylestradiol content is ≤20 µg. Female participants stable on an ethinylestradiol-
containing regimen with a dose >20 µg who switch to an ethinylestradiol-containing
regimen with a dose ≤20 µg, should be on that new regimen for at least 1 week before
the first dose of study intervention. For female participants of childbearing potential
who will start a hormonal contraceptive treatment during the study, ethinylestradiol-
containing contraceptives are not allowed.
11. Male participants must agree to wear a condom when engaging in any activity that allows
for passage of ejaculate to another person during the study intervention period and until
90 days after last dose of study intervention.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 79
Status: 
Approved,  Date: 25 November 202112. Female participants must agree not to donate eggs (ova, oocytes)  for the purposes of
assisted reproduction during the study intervention period and until 90 days after last dose
of study intervention.
13. Male participants must agree not to donate sperm for the purpose of reproduction during
the study intervention phase and until 90 days after last dose of study intervention.
14. Participants must sign an ICF indicating that he or she understands the purpose of, and
procedures required for, the study and is willing to participate in the study.
15. Participants must separately consent if he or she agrees to undergo optional study
procedures (ie, leukapheresis, intensive PK, and/or optional biopsy) . Refusal to give
consent to one or all of these optional study procedures does not exclude from
participation in the study.
16. In the investigator’s opinion, the participant is able to understand and comply with
protocol requirements, instructions, and study restrictions and is likely to complete the
procedures as planned for this this study.
5.2. Exclusion Criteria
Any potential participant who meets any of the following criteria will be excluded from
participating in the study:
1. Criterion modified per Amendment 4
1.1 Criterion modified per Amendment 5
1.2 Participants with evidence of hepatitis A virus infection (hepatitis A antibody IgM) ,
HCV infection (HCV antibody) , hepatitis D virus (HDV)infection (HDV antibody) , or
hepatitis E virus (HEV) infection (HEV antibody IgM) , or HIV-1 or HIV-2 infection
(laboratory confirmed)  at screening.
Note: Participants with a positive HCV antibody test can be enrolled if they have
negative HCV RNA at screening and documented negative HCV RNA at least 6 months
prior to screening.
Note: Participants with a positive HDV antibody test may be enrolled after discussion
with the sponsor if an active HDV co-infection can be ruled out by documentation of
negative HDV RNA.
Note: Participants with a positive IgM antibody test for HEV infection may be enrolled
after discussion with the sponsor if an active HEV infection can be ruled out by
documentation of negative anti-HEV IgG.a
a Negati
ve HEV RNA may also be acceptable to rule out active HEV infection depending on local standard
practices.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 80
Status: 
Approved,  Date: 25 November 2021Note: Participants with a positive HIV-1 or HIV-2 antibody/antigen test at screening
should have a confirmatory HIV RNA test, to rule out false positive results. They can
be enrolled if they have a negative HIV RNA test at screening. Participants with
evidence of HIV-1 or HIV-2 infection who are on antiretroviral treatment are excluded.
2. Participants with any of the following laboratory abnormalities within 12 months prior
to screening or at the time of screening:
a. Total bilirubin >1.5x ULNa, OR
b. Direct bilirubin >1.2x ULNa, OR
c. Serum albumin <3.2 g/dLa,
3. History or evidence of clinical signs/symptoms of hepatic decompensation including
but not limited to: portal hypertension, ascites, hepatic encephalopathy, esophageal
varices.
4. Participants with evidence of liver disease of non-HBV etiology. This includes but is
not limited to hepatitis virus infections mentioned in exclusion criterion 1, drug- or
alcohol related liver disease, autoimmune hepatitis, hemochromatosis, Wilson’s
disease, α-1 antitrypsin deficiency, primary biliary cholangitis, primary sclerosing
cholangitis, Gilbert’s syndrome (mild cases are allowed, see exclusion criterion 2 a) , or
any other non-HBV liver disease considered clinically significant by the investigator.
5. Participants with history or signs of cirrhosis or portal hypertension (nodules, no smooth
liver contour, no normal portal vein, spleen size ≥12 cm) , signs of HCC or clinically
relevant renal abnormalities on an abdominal ultrasound performed within 6 months
prior to screening or at the time of screening.
Note:In case of suspicious findings on conventional ultrasound the participant may still
be eligible if HCC or clinically relevant renal abnormalities have been ruled out by a
more specific imaging procedure (contrast enhanced ultrasound, CT or MRI) .
6. Participants with one or more of the following laboratory abnormalities at screening as
defined by the Division of Acquired Immunodeficiency Syndrome (DAIDS)  Toxicity
Grading Scale:
a. Estimated glomerular filtration rate (eGFR cr)  ≥grade 3 (<60 mL/min/1.73m²) ,
calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
formula;
b. Pancreatic lipase elevation ≥grade 3;
c. Pancreatic amylase elevation ≥grade 3
d. Hemoglobin ≤10.9 g/dL (males) , ≤10.4 g/dL (females) ;
a Unless
 explained by a clinical setting that is not hepatic decompensation.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 81
Status: 
Approved,  Date: 25 November 2021e. Platelet count ≤lower limit of normal (LLN) ;
f. Alpha-fetoprotein (AFP) >100 ng/mL;
Note: Participants with AFP >ULN but ≤100 ng/mL may be eligible if HCC can
be ruled out based on a sensitive imaging study (eg, contrast enhanced ultrasound,
CT, or MRI)  during screening.
g. Any other laboratory abnormality considered to be clinically significant by the
investigator.
7. Participants with presence of coagulopathy or bleeding disorder as indicated by:
a. International normalized ratio (INR)  ≥1.1 x ULN;
b. Partial thromboplastin time > 1.1 x ULN;
c. Any signs of prolonged bleeding (>10 minutes) .
8. Participants with presence of hemoglobinopathy (including sickle cell disease,
thalassemia) .
9. Participants who had a liver biopsy performed prior to screening that led to
complications and that in the opinion of the investigator would prohibit another liver
biopsy.
10. Participants with history of amyloidosis.
11. Participant refusal to accept blood transfusions.
12. Participants with hemoglobin A1c >8% at screening.
13. Participants with a history of malignancy within 5 years prior to screening (exceptions
are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix,
or malignancy, which are considered cured with minimal risk of recurrence) .
14. Participants with abnormal sinus rhythm (heart rate <45 or >100 beats per minute
[bpm]) ; QT interval corrected for heart rate according to Fridericia’s formula (QTcF)
>450 ms for males and >470 ms for females; QRS interval ≥120 ms; PR interval
>220 ms ; abnormal conduction; or any other clinically significant abnormalities on a
12-lead ECG at screening.
15. Participants with a history of or current cardiac arrhythmias (eg, extrasystole,
tachycardia at rest) , history of risk factors for Torsade de Pointes syndrome (eg,
hypokalemia, family history of long QT Syndrome)  or history or other clinical evidence
of significant or unstable cardiac disease (eg, angina, congestive heart failure,
myocardial infarction, diastolic dysfunction, significant arrhythmia and/or coronary
heart disease) , moderate to severe valvular disease, or uncontrolled hypertension at
screening.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 82
Status: 
Approved,  Date: 25 November 202116. Participants with any current or previous illness for which, in the opinion of the
investigator and/or sponsor, participation would not be in the best interest of the
participant (eg, compromise the well-being)  or that could prevent, limit, or confound
the protocol specified assessments. This may include but is not limited to significant
vascular, pulmonary (eg, chronic obstructive pulmonary disease) , gastrointestinal (eg,
significant diarrhea, gastric stasis, or constipation that in the investigator’s opinion
could influence drug absorption or bioavailability) , endocrine (eg, thyroid disease) ,
neurologic, hematologic, rheumatologic, psychiatric, neoplastic, or metabolic
disturbances. Any condition possibly affecting drug absorption (eg, gastrectomy or
other significant gastrointestinal tract surgery, such as gastroenterostomy, small bowel
resection, or active enterostomy)  will also lead to exclusion.
17. Participants who have received an organ transplant (except for skin, hair, or cornea
transplants) .
18. Participants with any history of or current clinically significant skin disease requiring
regular or periodic treatment.
19. Participants with clinically relevant drug or alcohol abuse within 12 months before
screening.
20. Participants with history of clinically relevant drug rash.
21. Participants who have taken any disallowed therapies as noted in Section 6.5before the
planned first dose of study intervention.
22. Participants having used any invasive investigational medical device within 3 months,
or having received an investigational intervention or a biological product,
immunoglobulin or other blood product not intended for the treatment of HBV within
6 months or 5 half-lives (whichever is longer) , before the planned first dose of study
intervention, or is currently enrolled in an interventional clinical study with an
investigational product.
23. Female participants who are pregnant, or breast-feeding, or planning to become
pregnant while enrolled in this study or within 90 days after the last dose of study
intervention.
24. Male participants who plan to father a child while enrolled in this study or within
90 days after the last dose of study intervention.
25. Participants who had major surgery (eg, requiring general anesthesia) , excluding
diagnostic surgery, within 12 weeks before screening; or who have not fully recovered
from surgery; or have surgery planned during the time of expected participation in the
study.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 83
Status: A
pproved,  Date: 25 November 2021Note: Participants with planned surgical procedures to be conducted under local
anesthesia may participate.
26. Participant is an employee of the investigator or study site, with direct involvement in
the proposed study or other studies under the direction of that investigator or study site,
as well as family members of the employees or the investigator.
27. Vulnerable participants (eg, incarcerated individuals, individuals under a legal
protection measure) .
28. Criterion modified per Amendment 5
28.1 Participants with known allergies, hypersensitivity, or intolerance to JNJ-3989 or
its excipients (refer to the IBs and addendum) .14 16
29. Participants with contraindications to the use of ETV, tenofovir disoproxil, or TAF per
local prescribing information.
30. For participants undergoing optional leukapheresis: contraindications to the use of
citrate
-based anticoagulation per local prescribing information.
Additional exclusion criteria for optional PegIFN-α2a treatment:
31. Criterion added per Amendment 4
Criterion modified per Amendment 5
31.1 The following needs to be checked after the participant has signed the separate
consent to receive the optional PegIFN-α2a treatment.
a. Patients with signs or symptoms compatible with autoimmune disorders.
b. Participants with bone marrow suppression.
c. Patients with hypoglycemia, hyperglycemia, and/or diabetes mellitus, who cannot
be effectively controlled by medication.
d. Participants with pre-existing ophthalmologic disorders.
e. Participants with one or more of the following laboratory abnormalities:
 ANC <1,500 cells/mm3 (<1,000 cells/mm³ for black or African American
participants) .
 Serum creatinine >1.5xULN.
 Inadequately controlled thyroid function (TSH and T4) .
f. Participants with a history of a severe psychiatric disorder, including severe
depression, suicidal ideation and attempted suicide, or a current depression or other
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 84
Status: 
Approved,  Date: 25 November 2021psychiatric disorders that is not adequately controlled on a stable medication
regimen.
NOTE: Investigators should ensure that all study enrollment criteria have been met at screening.
If a participant's clinical status changes (including any available laboratory results or receipt of
additional medical records)  after screening but before the Week -1 liver biopsy or before the first
dose of study intervention is given such that he or she no longer meets all eligibility criteria, then
the participant should be excluded from participation in the study. The required source
documentation to support meeting the enrollment criteria are noted in Section 10.3, Appendix 3,
Regulatory, Ethical, and Study Oversight Considerations.
5.3. Lifestyle Considerations
Potential participants must be willing and able to adhere to the following lifestyle restrictions
during the course of the study to be eligible for participation:
1. Agree to follow all requirements as outlined in Section 6.5(details regarding prohibited
and restricted therapy during the study) .
2. Agree to follow all requirements that must be met during the study as noted in the
Inclusion and Exclusion Criteria (eg, contraceptive requirements) .
5.4 . Screen Failures
NOTE:  Retesting of abnormal laboratory values that may lead to exclusion will be allowed once.
Retesting will take place during an unscheduled visit in the screening phase.
Participant Identification, Enrollment, and Screening Logs
The investigator agrees to complete a participant identification and enrollment log to permit easy
identification of each participant during and after the study. This document will be reviewed by
the sponsor study-site contact for completeness.
The participant identification and enrollment log will be treated as confidential and will be filed
by the investigator in the study file. To ensure participant confidentiality, no copy will be made.
All reports and communications relating to the study will identify participants by participant
identification and age at initial informed consent. In cases where the participant is not randomized
into the study, the date seen and age at initial informed consent will be used.
Individuals who do not meet the criteria for participation in this study (screen failure) may not be
rescreened without the sponsor’s agreement.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDENT
IAL –FOIA Exemptions Apply in U.S. 85
Status: A p
proved,  Date: 25 November 20216. STUDY INTERVENTION
6.1. Study Intervention(s) Administered
Physical Description of Study Interventions
The JNJ-3989 supplied for this study will be provided as an aqueous clear, colorless to light yellow
solution with 200 mg/mL of JNJ-3989(containing the two RNAi triggers, JNJ-3976 and JNJ-3924)
for SC injection, containing
( ) .
Note that as of Protocol Amendment 5, JNJ-6379 is no longer included as part of the study
intervention in this study.
Prior to implementation of Protocol Amendment 5, the JNJ-6379 supplied for this study was
formulated as oral tablets containin mg ( )  and mg ( )JNJ-56136379-AAA. The
JNJ-6379 tablets had to be swallowed as a whole.
JNJ-3989 and JNJ-6379 will be/was to be provided under the responsibility of the sponsor. Refer
to the IBs and addenda for a list of excipients.14 16,39
The NAs ETV, tenofovir disoproxil, and TAF formulated as oral film-coated tablets of 0.5-mg,
245-mg, and 25-mg strength, respectively, will be provided by the sponsor.
PegIFN-α2a formulated as solution for subcutaneous injection in a prefilled syringe with
180 µg/0.5 mL of PegIFN-α2a, will be provided by the sponsor. Refer to the prescribing
information for a list of excipients.
Packaging and Labeling
All study interventions will be packaged with each unit labeled with a unique medication ID
number. Packaging and labeling of JNJ-3989, JNJ-6379, PegIFN-α2a, and the NAs will be/was to
be done in an open label way. Commercial supplies of NAs and PegIFN-α2a will be sourced and
a clinical study label will be applied. Study intervention labels will contain information to meet
the applicable regulatory requirements.
JNJ-6379 was to be dispensed in child-resistant packaging. Nucleos(t) ide analog and PegIFN-α2a
treatment may also be repackaged into child-resistant packaging if this is not already the case.
No study interventions can be repacked or relabeled without prior approval from the sponsor.
Study Intervention Administration
Study intervention administration must be captured in the source documents and the CRF.
JNJ-3989 injections will be administered SC (preferably in the abdomen)at the study site.
In between study visits, participants will take their oral study intervention (NA treatment)  at home
and they will bring their oral study intervention with them to each study visit. At study visits, the
CCI
CCI
CCI
CCI
CCI
CCI
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 86
Status: 
Approved,  Date: 25 November 2021oral study intervention should be taken on site to allow biochemistry and renal biomarker samples
to be taken in fasted conditions.
During the study, virologically suppressed participants will continue the same NA treatment they
were receiving at time of screening (and during at least 3 months prior to screening) . In case
participants experienced toxicity to ETV, tenofovir disoproxil, or TAF prior to screening, they
should be treated with one of the other two NAs during this study.
Participants who are not receiving any HBV treatment at screening will receive tenofovir
disoproxil at start of intervention.
If clinically indicated, switching from one NA treatment (ETV, tenofovir disoproxil, or TAF)  to
another NA treatment (ETV, tenofovir disoproxil, or TAF)  during the study is allowed for all
participants after consultation with the sponsor.
For PegIFN-α2a, administration should be done SC in the thigh or abdomen, preferably in the
evening by self-injection. Used PegIFN-a2a syringes should be separated from the needle via the
sharps container and then placed into their original box and returned to the site, if allowed per local
guidelines and regulations. The used needles in the sharps container will be returned to the study
site after completion of treatment with PegIFN- α2a or disposed of following local standard
procedures. If desired, participants can also choose to have the weekly administration of
PegIFN-α2a performed at the study site irrespective of the time of day.
If JNJ-3989 and PegIFN-α2a are both injected in the abdomen, they should be injected into
different areas of the abdomen and approximate location should be recorded.
For a definition of study intervention overdose, refer to Section 8.5.7.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 87
Status: A
pproved,  Date: 25 November 2021Description of Interventions
Intervention name JNJ-3989 JNJ-6379**** PegIFN-α2a Entecavir (ETV) 
monohydrate Tenofovir 
disoproxil Tenofovir
alafenamide (TAF)*
Type Drug D
rug Drug Drug Drug Drug
Dosage f
ormulation Solution for injection Tablets Solution for 
injectionFilm coated tablets Film coated tablets Film coated tablets
Unit do
se strength(s) 200 mg/vial 25 and 100 mg 180 µg/0.5 mL 0.5 mg 245 mg 25 mg
Dosage l
evel 200 mg once every 
4 weeks (Q4W) 250 mg once daily 
(qd) 180 µg once weekly 
(QW)** Nucleoside naïve 
patient
s:
0.5 mg qd
L
amivudine refractory
patient
s:
1 mg* qd (b
ut should
preferably be treated
with tenofovir
disoproxil or TAF
instead)
Other indications:
1 mg* qd (m
ust be
agreed upon by the
sponsor)245 mg qd 25 mg qd
Route o
f 
administration Subcutaneous 
injection preferably in 
the abdomen Oral Subcutaneous 
injection (in the
thigh or abdomen)Oral Oral Oral
Use Inve
stigational 
intervention Investigational 
intervention Investigational 
intervention Background 
intervention Background 
intervention Background
intervention
Sourcing
 Provided centrally by 
the sponsor Provided centrally by 
the sponsor Provided centrally 
by the Sponsor*** Provided centrally by 
the sponsor Provided centrally 
by the sponsor Provided centrally by
the sponsor
Packagi
ng and 
Labeling Each unit will be 
labeled with unique 
medication ID number Each unit will be 
labeled with unique 
medication ID number Commercial 
supplies will be 
sourced. Each unit 
will be labeled with 
unique medication 
ID number*** Commercial supplies 
will be sourced. Each 
unit will be labeled with 
unique medication ID 
number Commercial 
supplies will be 
sourced. Each unit 
will be labeled with 
unique medication 
ID number Commercial supplies
will be sourced. Each
unit will be labeled
with unique
medication ID
number
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 88
Status: A
pproved,  Date: 25 November 2021Intervention name JNJ-3989 JNJ-6379**** PegIFN-α2a Entecavir (ETV) 
monohydrate Tenofovir 
disoproxil Tenofovir
alafenamide (TAF)*
In chil
d resistant 
packaging In child resistant 
packaging*** In child resistant 
packaging In child resistant 
packaging In child resistant
packaging
Labels 
will contain inf ormation to meet the applicable regulatory requirements.
Food/Fa
sting 
instructions Regardless of food 
intake Regardless of food 
intake Per the prescribing 
information Per prescribing 
information Per prescribing 
information Per prescribing
information
Q4W: once
 every 4 weeks; qd: once daily ; QW: once weekly
* In countries where TAF is available, it will be one of the NA treatment options.
** For PegIFN-α2a, dose adjustment may be applicable for participants who develop laboratory abnormalities during PegIFN-α2a treatment (refer to Section 6.6) .
*** May vary based on local regulations.
**** Participants enrolled before Protocol Amendment 5 was in effect, may have received JNJ-6379 as part oftheir study intervention. As of Protocol Amendment 5:
study intervention includes JNJ-3989, NA and optionally PegIFN α2a
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 89
Status: 
Approved,  Date: 25 November 20216.2. Preparation/Handling/Storage/Accountability
Preparation/Handling/Storage
All study interventions must be stored as specified on the product specific labeling.
Study-site personnel will instruct participants on how to store study intervention for at-home use
as indicated for this protocol.
Refer to the pharmacy manual/study site investigational product and procedures manual for
additional guidance on study intervention preparation, handling, and storage.
Accountability
The investigator is responsible for ensuring that all study intervention received at the site is
inventoried and accounted for throughout the study. The dispensing of JNJ-6379 (prior to Protocol
Amendment 5) , NA, and PegIFN-α2a (if applicable)  to the participant, and the return of JNJ-6379,
NA, and PegIFN-α2a (if applicable)  from the participant, must be documented on the intervention
accountability form. Participants must be instructed to return all original containers, whether
empty or containing oral study intervention. The JNJ-3989 and, if applicable, PegIFN-α2a
injections administered to the participant must be documented on the intervention accountability
form. All study intervention will be stored and disposed of according to the sponsor's instructions.
Study-site personnel must not combine contents of the study intervention containers.
Participants who stopped JNJ-6379 per Protocol Amendment 5, must return their JNJ-6379 supply
at the next scheduled visit. The return of JNJ-6379 from the participant must be documented on
the intervention accountability form.
Study intervention must be handled in strict accordance with the protocol and the container label,
and must be stored at the study site in a limited-access area or in a locked cabinet under appropriate
environmental conditions. Unused study intervention, and oral study intervention returned by the
participant, must be available for verification by the sponsor's study site monitor during on-site
monitoring visits. The return to the sponsor of unused study intervention, or used returned study
intervention for destruction, will be documented on the intervention return form. When the study
site is an authorized destruction unit and study intervention supplies are destroyed on-site, this
must also be documented on the intervention return form.
Potentially hazardous materials containing hazardous liquids, such as used ampules, needles,
syringes and vials, should be disposed of immediately in a safe manner and therefore will not be
retained for intervention accountability purposes. Details on handling of used PegIFN-α2asyringes
are described in Section 6.1, Study Intervention(s)  Administered.
Study intervention should be dispensed under the supervision of the investigator or a qualified
member of the study-site personnel, or by a hospital/clinic pharmacist. Study intervention will be
supplied only to participants participating in the study. Returned study intervention must not be
dispensed again, even to the same participant. Whenever a participant brings his or her oral study
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 90
Status: 
Approved,  Date: 25 November 2021intervention to the study site for pill count, this is not seen as a return of supplies. Study
intervention may not be relabeled or reassigned for use by other participants. The investigator
agrees neither to dispense the study intervention from, nor store it at, any site other than the study
sites agreed upon with the sponsor. Further guidance and information for the final disposition of
unused study interventions are provided in the Study Reference Manual.
6.3. Measures to Minimize Bias: Randomization and Blinding
Intervention Allocation
Procedures f or Randomization and Stratif ication
Prior to Protocol Amendment 5, central randomization was implemented in this study. Participants
were randomly assigned within each panel to 1 of 2 intervention arms in a 1:1 ratio (Arm 1
[JNJ-3989+JNJ-6379+NA]:Arm 2 [JNJ-3989+NA])  based on a computer-generated
randomization schedule prepared before the study by or under the supervision of the sponsor. The
randomization was balanced by using randomly permuted blocks and was stratified within each
panel by Fibroscan score (<7 kPa vs ≥7 kPa) . The interactive web response system (IWRS)
assigned a unique intervention code, which dictated the intervention assignment and matching
study interventionkit for the participant. The requestor had to use his or her own user identification
and personal identification number when contacting the IWRS and had to give the relevant
participant details to uniquely identify the participant.
As of Protocol Amendment 5, all participants will enroll without randomization within a study
panel. The interactive web response system (IWRS)  will assign a unique intervention code with
matching study intervention kit for the participant. The requestor must use his or her own user
identification and personal identification number when contacting the IWRS and will then give the
relevant participant details to uniquely identify the participant.
Blinding
As this is an open label study, blinding procedures are not applicable.
6.4 . Study Intervention Compliance
JNJ-3989 will be administered at the study site as a SC injection by qualified study-site personnel
to assure compliance with study requirements.
The participants will be requested to bring unused oral study interventions and empty packaging
to the study site at each visit.
Every effort should be made to have the participant take the study interventions as indicated in the
Schedule of Activities .
 If an injection of JNJ-3989 was missed, the injection should be given as soon as possible but
within 3 weeks after the scheduled time. Otherwise, the injection should be skipped and the
next injection should be given at the next scheduled time point per the initial injection
schedule.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 91
Status: 
Approved,  Date: 25 November 2021 If a dose of NA is missed, the participant should follow the guidelines in the package insert.
 If an injection of PegIFN-α2a is missed, the participant should follow the guidelines in the
prescribing information.
If a participant’s study intervention intake is not according to the protocol, the investigator will
take the necessary measures to ensure future adherence to the protocol.
An optional medication diary to document oral study intervention intake can be made available for
participants with an observed or known risk for study intervention non-compliance. The completed
diaries are reviewed by the site staff and discussed with the participants for compliance monitoring
and counseling. Completed diaries will be returned to the site staff to add to the source documents.
6.5. Concomitant Therapy
Note: With the removal of JNJ-6379 as study intervention in Protocol Amendment 5, JNJ-
6379-specific disallowed medications and concomitant medications to be used with caution are no
longer applicable and have been removed.
Prestudy therapies administered up to 30 days before the start of screening must be recorded at
screening. If applicable, the participant’s last anti-HBV treatment prior to screening must also be
recorded.
Concomitant therapies must be recorded throughout the study, from signing of the ICF until
completion of the participant’s last study-related procedure. Concomitant therapies should also be
recorded beyond the last study-related procedure only in conjunction with new or worsening
S(AE) s.
All therapies (prescription or over-the-counter medications, including vaccines, vitamins, herbal
supplements; non-pharmacologic therapies such as electrical stimulation, acupuncture, special
diets, exercise regimens, or other specific categories of interest)  different from the study
intervention must be recorded in the CRF. Recorded information will include a description of the
type of therapy, duration of use, dosing regimen, route of administration, and indication.
Modification of an effective preexisting therapy should not be made for the explicit purpose of
entering a participant into the study.
Local guidelines on the use of live vaccines in participants receiving PegIFN-α2a should be
followed, including for the second dose of Sputnik V (which contains rAd5, with a theoretical risk
of replication competence) . Sputnik Light, which is the first dose of Sputnik V (with rAd26)  is not
considered a live vaccine. See below for further guidance on the use of COVID-19 vaccines.
Note that locally approved COVID-19 vaccines (including those that received emergency use
authorization or conditional marketing authorization)  are allowed throughout the study. For
participants receiving PegIFN-α2a, the following recommendations should be applied to
accommodate COVID-19 vaccination during PegIFN-α2a treatment:
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 92
Status: 
Approved,  Date: 25 November 2021 COVID-19 vaccine and PegIFN-α2a should not be administered on the same day.
 If required, PegIFN-α2a injection can be delayed with 2 days. The next PegIFN-α2a injection
should be performed at the scheduled time.
 If required, skipping a PegIFN-α2a injection may be considered after consultation with the
Sponsor.
 Vaccination with Sputnik V should take above-mentioned consideration about live vaccines
into account.
All COVID-19 vaccination-related data (eg, COVID-19 vaccination, AEs, AE management)
should be appropriately captured in the CRF and source documents. Refer to the COVID-19
vaccine and/or PegIFN-α2a prescribing information for more details.
An overview of disallowed medication is provided in Table 4 .
Table 4: Disallowed Medication
Disallowed at any time prior to screening until end of follow-up:
 Any CA
M and oligonucleotide-based treatment (eg, siRNA and antisense oligonucleotides, nucleic acid
polymers, etc.) , other than the study intervention taken in the context of this study.
Disallo
wed from 6 months prior to screening until end of follow-up:
 Any in
vestigational agent, investigational vaccine, invasive investigational medical device, or
investigational biological product (other than the study intervention taken in the context of this study) .
Note: For investigational COVID-19 vaccines administered within 6 months prior to screening, an
exception will be made as long as the vaccine has been approved (or received emergency use authorization
or conditional marketing authorization)  at the time of screening.
Disallo
wed from 6 months prior to baseline until end of follow-up:
 For par
ticipants currently not being treated: Any anti-HBV drug (including vaccines)  other than the study
interv
ention taken in the context of this study.
Note: Prior hepatic treatment with herbal or nutritional products is allowed but should be stopped at
screening.
 Any systemically (eg, intravenously, intramuscularly, orally, subcutaneously)  administered medication
that directly or indirectly interferes with immune responses (eg, cyclosporine, interleukins, IFN, systemic
corticosteroids exceeding 5 mg of prednisolone equivalent/day) .
Disallo
wed from 1 month prior to screening until end of follow-up:
 Antico
agulants and antiplatelet agents.
Note: The use of citrate-based anticoagulant is allowed for participants during the leukapheresis
procedure. Use of heparin for anticoagulation is not allowed.
Note:The use of ibuprofen or paracetamol is allowed. Use of low-dose aspirin is allowed with exception
of 7 days prior to biopsies.
Disallo
wed from screening until end of follow-up:
 Any an
ti-HBV drug (including vaccines)  other than the study intervention taken in the context of this
study.
Note:NA standard of care treatment is allowed for virologically suppressed participants.
 Biotin (>1 mg daily dose) , either taken alone or as part of a multivitamin formulation.
Note:The use of other vitamins is allowed.
 Topical steroids (>7 days)  under occlusive dressing.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 93
Status: 
Approved,  Date: 25 November 2021Note: The list of disallowed medication is not exhaustive; for products falling in one of the
categories and not mentioned by name, the sponsor should be contacted to determine whether the
product can be allowed.
The sponsor must be notified in advance (or as soon as possible thereafter)  of any instances in
which prohibited therapies are administered.
The prescribing information for ETV, tenofovir disoproxil, TAF, and PegIFN-α2a should be
consulted for any additional prohibited medication. In case of flu-like symptoms after
administration of PegIFN-α2a, paracetamol up to a maximum of 2 g per 24 hours and a maximum
of 6 g per week is allowed.
Medications requiring SC injection (other than JNJ-3989 and PegIFN-α2a; eg, insulin)  should be
administered away from the JNJ-3989 and PegIFN-α2a injection sites.
6.6. Dose Modification
Dose modifications of JNJ-3989 and NA (increase or decrease of dose level)  are not permitted
during the study.
For PegIFN-α2a, dose adjustment guidelines are applicable for participants who develop
laboratory abnormalities during PegIFN-α2a treatment, as recommended in the locally approved
prescribing information for PegINF-α2a and upon investigator’s assessment.
Refer to the example from the Pegasys USPI and SmPC (see Table 5 ) .
Table 5: PegIFN-α2a Hematological Dose Modification Guidelines
Laboratory Values Recommended Dose
ANC <750
 cells/mm³ Reduce to 135µg
ANC <500
 cells/mm³ Discontinue treatment until ANC values return to more than 1,000 cells/mm³.
Reinstitute at 90µg and monitor ANC.
Platelet <50,000 cells/mm³ Reduce to 90µg
Platel
et <25,000 cells/mm³ Discontinue treatment
ANC: ab
solute neutrophil count
Source: Pegasys USPI and SmPC
For participants who prematurely discontinue PegIFN-α2a, treatment with PegIFN-α2a may be
restarted according to the recommendations from the locally approved prescribing information for
PegIFN-α2a.
6.6.1. Study Intervention Completion at Week 4 8
With the implementation of Protocol Amendment 5, all participants had to stop JNJ-6379
treatment immediately.
Participants will complete treatment with JNJ-3989 after a fixed duration of 48 weeks. If all of the
below criteria are met based on clinical laboratory tests performed at Week 44, treatment with NA
will also be completed at the next scheduled visit (ie, Week 48) :
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 94
Status: 
Approved,  Date: 25 November 2021 The participant has ALT <3x ULN, AND
 The participant has HBV DNA <LLOQ, AND
 The participant is HBeAg negative, AND
 The participant has HBsAg <10 IU/mL.
Note: In case of ALT elevation ≥3x ULN at Week 44 the investigator must consider different
potential causes of increased ALT to ensure appropriate work up and management as needed. If
the ALT elevation is unrelated to HBV activity and/or <3x ULN by Week 48, NA completion may
be considered at the discretion of the investigator and in consultation with the sponsor.
Participants who do not meet the above criteria at Week 48 should continue NA treatment during
the 48-week follow-up phase. Participants who are receiving optional treatment with PegIFN-α2a
and who have not met NA treatment completion criteria at Week 48 may have NA treatment
completion criteria assessed at the end of treatment with PegIFN-α2a and stop NA if criteria are
met.
If a participant prematurely discontinues investigational intervention before Week 48, follow-up
assessments should be obtained as per the Schedule of Activities until 48 weeks after the end of
investigational intervention unless the participant withdraws consent. In this case, NA treatment
may be continued or, in consultation with the sponsor, discontinued, based on the above-mentioned
NA treatment completion criteria.
With the implementation of Protocol Amendment 5, the follow-up period will be extended for
participants who are receiving optional treatment with PegIFN-α2a and who meet NA treatment
completion criteria at the end of treatment with NA and PegIFN-α2a to ensure all participants have
at least one year of follow-up after NA treatment cessation.
The investigator should consider to re-start NA treatment per local standard of care at the EOS
visit (Follow-up Week 48 up to maximum Follow-up Week 72)  for participants who met the NA
treatment completion criteria at Week 48 or for participants who met NA treatment completion
criteria at the end of treatment with PegIFN-α2a during the follow-up phase, who did not re-start
NA treatment during the follow-up phase, and who did not achieve and maintain HBsAg
seroclearance. NA will not be provided by the sponsor after the final study visit.
6.6.2. NA Re-treatment Criteria and Monitoring after Stopping of NA
Participants who meet the NA treatment completion criteria outlined in Section 6.6.1 will be
monitored closely during the follow-up phase.
After stopping NA treatment, participants should be monitored as follows:
 Regular monitoring visits will be every 4 weeks during the follow-up phase in accordance
with the Schedule of Activities .
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 95
Status: A
pproved,  Date: 25 November 2021 A post-treatment HBV DNA value of >20,000 IU/mL should trigger re-testing of ALT/AST,
HBV DNA, and total and direct bilirubin within a maximum of 7 days from receipt of the data
and further repeats as necessary (ie, weekly until HBV DNA returns to <20,000 IU/mL) .
 A post-treatment HBV DNA value of >2,000 IU/mL (but <20,000 IU/mL)  should trigger a re-
test within 14 days from receipt of the data and further repeats as necessary (ie, every other
week until HBV DNA returns to <2,000 IU/mL) .
 A post-treatment ALT value of >5x ULN should trigger re-testing of ALT, AST, ALP, total
and direct bilirubin, INR, albumin, and HBV DNA on a weekly basis until ALT and AST
levels have returned to <5x ULN.
After stopping NA treatment, participants should re-start NA treatment:
 Immediately with signs of decreasing liver function based on laboratory findings (eg, INR,
direct bilirubin)  or clinical assessment (eg, ascites, hepatic encephalopathy) ,
 Immediately with an HBV DNA value of >100,000 IU/mL (irrespective of confirmation
and/or ALT increase) .
 With confirmed post-treatment HBeAg seroreversion (HBeAg positive after it was negative
at NA completion)
 With confirmed* post-treatment increases in HBV DNA >2,000 IU/mL and ALT >5x ULN
 With confirmed* post-treatment increases in HBV DNA >20,000 IU/mL.
* At least 4 weeks apart f requency of  visits as described above
Note:
Additional re-testing and/or earlier restarting of NA treatment is at the investigator’s discretion,
even if the above cut-offs are not yet met.
To avoid delays in decision making, sites are encouraged to run local re-testing in parallel with
central re-testing in the situations described above that require more frequent re-testing. Local test
results are to be recorded in the CRF and/or source documents, including information on the HBV
DNA assay used. In addition, to avoid delays in NA re-treatment, it should be considered to
dispense NA to participants who potentially met the NA re-treatment criteria (eg, pending
confirmation)  and who will not be available to come to the study site immediately at the time the
confirmatory test results will become available. This should ensure that the participant can
immediately re-start NA treatment if indicated, upon direct confirmation by the investigator.
In case NA treatment is re-started, participants will be followed until the end of the study or until
clinical stabilization, whichever comes later.
Refer to Appendix 12 in Section 10.12for a graphical representation.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 96
Status: 
Approved,  Date: 25 November 20216.7. Study Intervention After the End of the Study
Participants will be instructed that study intervention will not be made available to them after they
have completed/discontinued study intervention and that they should return to their primary
physician to determine standard of care.
The investigator should consider to re-start NA treatment per local standard of care at the EOS
visit (Follow-up Week 48 up to maximum Follow-up Week 72)  for participants who met the NA
treatment completion criteria at Week 48 or for participants who met NA treatment completion
criteria at the end of treatment with PegIFN-α2a during the follow-up phase, who did not re-start
NA treatment during the follow-up phase, and who did not achieve and maintain HBsAg
seroclearance. NA will not be provided by the sponsor after the final study visit.
7. DISCONTINUATION OF INVESTIGATIONAL INTERVENTION AND
PARTICIPANT DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study Intervention
With the implementation of Protocol Amendment 5, all participants had to stop JNJ-6379
treatment immediately.
Treatment with JNJ-3989 and/or PegIFN-α2a must be discontinued if any of the criteria listed
below 
apply. If JNJ-3989 is discontinued, PegIFN-α2a should also be discontinued. If PegIFN-
α2a is
 discontinued, JNJ-3989 should be continued. NA treatment may be continued or, in
consultation with the sponsor or discontinued based on investigator judgement.
 The participant withdraws consent to receive study intervention.
 The investigator believes that for safety reasons or tolerability reasons (eg, AE)  it is in the
best i
nterest of the participant to discontinue JNJ-3989 (and, if applicable, PegIFN-α2a) .
 The participant becomes pregnant.
 The participant has a ≥grade 3 rash (see Section 10.5, Appendix 5, Rash Management)  or
allergic reaction (see Section 8.5.7.2 ) .
 The participant has signs of hepatic decompensation (ie, clinical evidence of ascites, bleeding
varices, or hepatic encephalopathy) or an increase in direct bilirubin >1.5x ULN in
combination with INR ≥1.5x ULN or albumin <3.0 g/dL.
 The participant has a confirmed ≥grade 3 eGFR cr abnormality and a drop from baseline of
>10 mL/m
in/1.73 m2, considered at least possibly related to JNJ-3989 (or PegIFN-α2a) that
persists despite changing tenofovir disoproxil to ETV or TAF (if the patient was receiving
tenofovir disoproxil)(see Section 8.5.6.4 ) .
 The participant has a confirmed QTcF prolongation (defined as a QTcF value of >500 ms, or
an increase from baseline of >60 ms)  at any given time point.
 The participant requires ≥7 days of treatment with any of the disallowed medications listed in
Section 6.5and does not intend to discontinue treatment with the disallowed medication.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 97
Status: 
Approved,  Date: 25 November 2021 The participant has confirmed HBV virologic breakthrough (ie, confirmed on-treatment HBV
DNA increase by >1 log 10IU/mL from nadir or confirmed on-treatment HBV DNA level >200
IU/mL in participants who had HBV DNA level <LLOQ of the HBV DNA assay) . In case of
virologic breakthrough, the same assessments will be done at an unscheduled visit as will be
done in case of an ALT flare, but no PBMC sample will be taken (see Section 8.5.6.1 and
Schedule of Activities ) , changing the NA should be considered in consultation with the
sponsor.
If virologic breakthrough occurs during JNJ-3989 and PegIFN-α2a administration, this does
not automatically lead to stop of JNJ-3989 and/or PegIFN-α2a but should be
assessed/discussed with the Sponsor.
In case of virologic breakthrough, a viral sequencing sample will be collected at the next visit.
 The participant has ALT/AST elevations, as described in Section 8.5.6.2 .
 The participant has confirmed ≥grade 3 hematologic abnormalities as described in
Section 8.5.6.5 .
NOTE: The grades are based on the DAIDS Toxicity Grading Scale (see Section 10.9,
Appendix 9, DAIDS Table) .
In add
ition, PegIFN-α2a (if applicable)  must immediately be discontinued for any of the following
reason
s:
 Partic
ipant has platelet count <25,000 cells/mm3
 Partic
ipant has ANC <500 cells/mm3
Note: Pe
gIFN-α2a treatment can be restarted when ANC values return to more than 1,000
cells/
mm3 (see details in Section 6.6, Dose Modification)
 Partic
ipant develops evidence of hepatic decompensation during treatment, or ALT increase
clinic
ally significant or accompanied by direct bilirubin increase
 Partic
ipant develops thyroid disorders or diabetes during treatment and cannot be controlled
with m
edication
 Partic
ipant develops new or worsening ophthalmologic disorders
 Partic
ipant develops any deterioration of cardiovascular status
 Partic
ipant develops serious, acute hypersensitivity reaction (eg, urticaria, angioedema,
bronch
oconstriction, anaphylaxis)
 Partic
ipant develops serious infection (bacterial, viral, fungal)  and/or sepsis
 Partic
ipant develops persistent or unexplained pulmonary infiltrates or pulmonary function
impair
ment
 Partic
ipant with onset or worsening of psoriatic lesion
 Partic
ipant develops moderate or severe depression, or other psychiatric symptoms (for mild
depres
sion, treatment discontinuation may be considered)
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 98
Status: 
Approved,  Date: 25 November 2021Note: Pa
rticipants who develop a neuropsychiatric AE during optional PegIFN-α2a
treatm
ent, will be monitored closely until the neuropsychiatric AE resolves, with frequent
(at le
ast weekly)  follow-up phone calls.
 Partic
ipant develops colitis symptoms (such as but not limited to abdominal pain, bloody
diarrh
ea, and fever)
 Partic
ipant develops symptoms or signs suggestive of pancreatitis
If a participant discontinues investigational intervention for any reason before Week 48, then the
early withdrawal assessments should be obtained. The participant will enter the follow-up phase
and complete the follow-up schedule unless the participant withdraws consent. Participants who
withdraw consent will be offered an optional safety follow-up visit to occur on the day of consent
withdrawal. Study intervention assigned to the participant who discontinued study intervention
may not be assigned to another participant.
In case a participant withdraws consent for the second biopsy, the study participant may continue
the study intervention and visit schedule as outlined in the Schedule of Activities .
7.2. Participant Discontinuation/Withdrawal From the Study
A participant will NOT be automatically withdrawn from the study if he or she has to discontinue
study intervention before Week 48.
A participant will be withdrawn from the study for any of the following reasons:
 Lost to follow-up,
 Withdrawal of consent,
 Death.
When a participant withdraws before study completion, the reason for withdrawal is to be
documented in the CRF and in the source document. If the reason for withdrawal from the study
is withdrawal of consent then no additional assessments are allowed. No additional participants
will be enrolled in case a participant withdraws from the study.
Withdrawal of Consent
A participant declining to return for scheduled visits does not necessarily constitute withdrawal of
consent. Alternate follow-up mechanisms that the participant agreed to when signing the consent
form apply as local regulations permit.
7.2.1. Withdrawal From the Use of Research Samples
Withdrawal From the Use of Samples in Future Research
The participant may withdraw consent for use of samples for research (refer to Long-Term
Retention of Samples for Additional Future Research in Section 10.3, Appendix 3, Regulatory,
Ethical, and Study Oversight Considerations) . In such a case, samples will be destroyed after they
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 99
Status: 
Approved,  Date: 25 November 2021are no longer needed for the clinical study. Details of the sample retention for research are
presented in the main ICF and in the separate ICF for optional research samples.
7.3. Lost to Follow-up
To reduce the chances of a participant being deemed lost to follow-up, prior to randomization
attempts should be made to obtain contact information from each participant, eg, home, work, and
mobile telephone numbers and email addresses for both the participant as well as appropriate
family members.
A participant will be considered lost to follow-up if he or she repeatedly fails to return for
scheduled visits and is unable to be contacted by the study site. A participant cannot be deemed
lost to follow-up until all reasonable efforts made by the study-site personnel to contact the
participant are deemed futile. The following actions must be taken if a participant fails to return to
the study site for a required study visit:
 The study-site personnel must attempt to contact the participant to reschedule the missed visit
as soon as possible, to counsel the participant on the importance of maintaining the assigned
visit schedule, to ascertain whether the participant wishes to or should continue in the study.
 Before a participant is deemed lost to follow-up, the investigator or designee must make every
reasonable effort to regain contact with the participant (where possible, 3 telephone calls, e-
mails, fax, and, if necessary, a certified letter to the participant’s last known mailing address,
or local equivalent methods) . These contact attempts should be documented in the
participant’s medical records.
 Should the participant continue to be unreachable, he or she will be considered to have
withdrawn from the study.
Should a study site close, eg, for operational, financial, or other reasons, and the investigator cannot
reach the participants to inform them, their contact information will be transferred to another study
site.
8. STUDY ASSESSMENTS AND PROCEDURES
Overview
The Schedule of Activities summarizes the frequency and timing of efficacy, PK, PD, immune,
biomarker, pharmacogenomic and safety measurements applicable to this study.
If applicable, ECGs should be completed before any tests, procedures, or other consultations for
that visit. Blood collections for PK and PD assessments should be kept as close to the specified
time as possible. Samples obtained within 20% of the nominal time from dosing (eg, ±12 minutes
of a 60-minute time point)  will not be captured as a protocol deviation if the exact time of the
sample collection is noted on the source document and CRF. Other measurements may be done
earlier than specified time points if needed. Actual dates and times of assessments will be recorded
in the source documentation and CRF.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 100
Status: 
Approved,  Date: 25 November 2021Additional serum or urine pregnancy tests may be performed, as determined necessary by the
investigator or required by local regulation, to establish the absence of pregnancy at any time
during the participation in the study.
The amount of blood drawn from each participant over the entire course of this study will be
approximately 1200 mL.
During the leukapheresis procedure, WBCs will be separated from the blood, while the rest of the
blood is returned to circulation. This process typically yields approximately 200 ml of cells. For
participants undergoing all 3 optional leukapheresis procedures, approximately 600 ml will be
collected.
For pa
rticipants receiving optional PegIFN-α2a treatment, an additional amount of maximum
50 mL of bl
ood will be drawn. In case participants continue NA treatment during the optional
PegIFN-α
2a treatment, an additional amount of maximum 200 mL of blood will be drawn during
additi
onal visits every 4 weeks to ensure at least one year of follow-up after NA treatment cessation
(exten
ded follow-up phase up to 72 weeks) .
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the
samples.
Sample Collection and Handling
The actual dates and times of sample collection, as well as the actual start and stop times of the
leukapheresis procedure, must be recorded in the CRF or laboratory requisition form.
Refer to the Schedule of Activities for the timing and frequency of all sample collections.
Instructions for the collection, handling, storage, and shipment of samples are found in the
laboratory manual that will be provided. Collection, handling, storage, and shipment of samples
must be under the specified, and where applicable, controlled temperature conditions as indicated
in the laboratory manual.
Study-specific Materials
The investigator will be provided with the following supplies:
 IB and any addenda for JNJ-3989,
 Prescribing Information for ETV, tenofovir disoproxil, TAF, and PegIFN-α2a,
 Pharmacy manual/study site investigational product and procedures manual,
 Laboratory manuals,
 IWRS Manual,
 CRF Completion Guidelines,
 Sample ICF,
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 101
Status: 
Approved,  Date: 25 November 2021 Contact information page(s) .
8.1. Liver Biopsy and Fine Needle Aspiration Biopsy
Percutaneous core liver biopsies and FNABs will be performed at the time points indicated in the
Schedule of Activities . If participants agree to undergo an optional liver biopsy, additional FNAB
and/or core liver biopsy samples may be taken at the selected location at Follow-up Week 24 or at
the time points clinically indicated.
Following local standard practice the biopsy location will be identified with ultrasound (which will
also be used to rule out contraindicating conditions for a biopsy)  and after application of local
anesthesia the FNAB samples and core liver biopsy samples will be collected.
The liver biopsy procedure should be preceded and followed by standard medical monitoring
according to local medical practice. This may include an overnight stay at the investigator’s
discretion. The use of low-dose aspirin is allowed with exception of 7 days prior to biopsies (see
Section 6.5) .
The liver tissue will be used to assess HBsAg. Changes from baseline in the proportion of HBsAg
positive hepatocytes under therapy will be assessed.
In addition, the liver tissue may also be used to assess other HBV markers in the liver such as, but
not limited to, total intracellular HBV RNA and DNA, HBeAg, and HBc. Changes in the quantity
and potentially changes in the spatial distribution of these markers (including HBsAg) under
therapy may be assessed. Viral genome (RNA or DNA)  or transcript sequencing/analyses as well
as assessment of HBV integrants in the host genome may be performed.
Intrahepatic immune status at baseline and response to treatment will be assessed. Both innate and
adaptive immune compartment will be characterized, by measuring the relative number of specific
cells and the expression of functional markers in each cell population using various single cell
approaches, such as single cell transcriptomics in FNABs and Immunofluorescence staining, and
transcriptomics and proteomics profiling in core needle biopsies. Depending on the latest platform
developments (spatial transcriptomics, in situ sequencing approaches, etc.) , methods for immune
cells characterization might be adjusted.
Hepatitis B virus-specific T-cells, although very rare in FNABs, maybe characterized and counted
by multimers binding assays, staining and sorting for positive cells. Downstream profiling of
collected HBV-specific T-cells may be performed by T-cell receptor sequencing and RNA
sequencing.
Infiltrating immune cells will be used for the evaluation of innate and adaptive immune responses,
which can be compared to responses in PBMCs.
Intrahepatic virologic status at baseline and response to treatment will be assessed with a range of
methods.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 102
Status: 
Approved,  Date: 25 November 2021Hepatitis B virus cccDNA levels may be assessed using quantitative polymerase chain reaction
(qPCR)  methods on a single cell level using laser capture microdissection or bulk analyses. The
exact protocol of cccDNA measurement will be determined based on the latest method available
considering the performance characteristics and the validation status of the assay. Southern
Blot-based methods or novel methods for cccDNA detection (eg, fluorescent in situ hybridization
[FiSH])  might be used depending on the availability of sample and established methodology.
Quantification of intracellular pre-genomic HBV RNA can be used to determine transcriptional
activity of HBV cccDNA by assessing the ratio of pgRNA levels over cccDNA levels.
Immune and virologic markers in the liver and/or changes thereof under therapy will be used to
assess association with blood markers and/or treatment response and outcome.
Remaining samples may be used for determination of liver JNJ-3989 (ie, JNJ-3976 and JNJ-3924)
and/or JNJ-6379 concentrations and/or research on viral and host biomarkers and immune markers
at the viral and/or host RNA/DNA, protein, and cell level.
Samples can only be used for research related to JNJ-3989, JNJ-6379, NA, chronic HBVinfection,
or chronic HBV infection related disease or may be used to develop tests/assays related to JNJ-
3989, JNJ-6379, NA, or chronic HBV infection.
These latter exploratory analyses will be performed at the sponsor’s discretion and will always be
under the sponsor's supervision.
8.2. Blood Efficacy Assessments
Efficacy assessments will be performed at the time points indicated in the Schedule of Activities .
Qualitative and quantitative HBsAg and HBeAg, and quantitative HBcrAg as well as antibodies
against HBsAg and HBeAg will be determined using validated serologic assays in a central
laboratory. Samples for the determination of HBsAg and HBeAg will be processed in real-time.
Samples for the determination of HBcrAg can be analyzed in batch and at the sponsor’s discretion.
Hepatitis B virus DNA and HBV RNA will be quantified at central laboratories using validated
assays for the quantification of HBV DNA and HBV RNA. Samples for the determination of HBV
DNA will be processed in real-time. Samples for the determination of HBV RNA can be analyzed
in batch and at the sponsor’s discretion.
Hepatitis B virus DNA, HBsAg, HBeAg, anti-HBs, and anti-HBe antibody testing results will be
provided to the investigator and the sponsor from screening until the end of follow-up.
It is the responsibility of the investigator:
 To monitor HBV DNA results and ensure that investigational intervention is discontinued in
participants with virologic breakthrough (see Section 7.1) ,
 To assess if NA treatment completion criteria are met (see Section 6.6.1) ,
 To assess whether re-start of NA treatment during follow-up is needed (see Section 6.6.2) .
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 103
Status: 
Approved,  Date: 25 November 2021In participants enrolled at a site with an on-site Fibroscan device, Fibroscan assessments will be
performed to determine changes in fibrosis levels.
Samples may be used by the sponsor for additional exploratory assessments analyzing the
serologic and virologic characteristics of HBV infection and efficacy or safety of the study
intervention.
8.2.1. Sequencing
Viral genome sequence analysis will be performed to evaluate mutations associated with the study
intervention.
Sequencing of the HBV genome will be performed to monitor HBV variants present at the time
points indicated in the Schedule of Activities . The sequencing of samples may be triggered by the
sponsor virologist based on changes in HBV DNA levels observed in each individual participant
and the limits of the sequencing assay.
Samples may be used by the sponsor for additional assessments analyzing the serologic and
virologic characteristics of the HBV infection and efficacy of the study intervention, including
viral genotypic and phenotypic assessments.
8.3. Blood Immune Assessments
8.3.1. Peripheral Blood Mononuclear Cell Immune Analyses
Samples for PBMC immune analyses will be collected during the study intervention and follow-up
phases and will be analyzed centrally for HBV-specific responses by enzyme-linked immunospot
(ELISpot)  and/or intracellular cytokine staining (ICS)  after stimulation with HBV-specific
antigens. ELISpot detects T-cells that secrete gamma interferon (IFN-γ)  in response to a specific
antigenic stimulation, whereas ICS determines the frequency of CD4+ and CD8+ T-cells secreting
cytokines such as IFN-γ, interleukin (IL) -2 and tumor necrosis factor (TNF) -α in response to a
specific antigenic stimulation. Hepatitis B virus-specific T-cells may be characterized in PBMCs
by binding assays (multimer staining)  combined with downstream TCR and transcriptome
profiling.
Additional experiments may be performed to further phenotypically and functionally characterize
PBMCs using proliferation or cytotoxic assays or other methods such as cytometry by time of
flight to evaluate innate and adaptive immune responses. Leftover samples may be used at the
sponsor’s discretion for additional exploratory research related to HBV infection or study
intervention (safety/efficacy) .
Additional PBMC samples may be taken in case of ALT flare, upon discussion with the sponsor,
which may require an unscheduled visit.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 104
Status: 
Approved,  Date: 25 November 20218.3.2. Leukapheresis (Optional With Separate Consent)
Leukapheresis allows to selectively collect higher quantities of PBMCs from participants without
withdrawing large volumes of blood.
Leukapheresis will only be performed for participants who consent separately to this component
of the study. Participants may withdraw such consent at any time without affecting their
participation in other aspects of the study.
Leukapheresis may be done at least 1 week (and up to 3 weeks)  after the liver biopsies (see
Schedule of Activities ) . Prior to the procedure, the participant’s wellbeing will be checked and
leukapheresis will only be offered if there is no clinical reason against it. If a participant has had a
recent febrile illness, the leukapheresis should be postponed until body temperature is normal for
at least 72 hours.
The leukapheresis procedure should mainly follow local standard procedures. Additional
guidelines will be provided via a separate manual in order to standardize this process across sites.
One leukapheresis session is expected to last between 1.5 - 5 hours.
During the procedure, the participant will receive intravenous saline infusions and citrate-based
anticoagulant. Use of heparin for anticoagulation is not allowed. A specialized leukapheresis
trained research nurse or physician will be in attendance and in charge of the participant’s
immediate medical care to monitor the leukapheresis.
After completion of the leukapheresis procedure, participants will stay at the site for at least
30 minutes to monitor for any relevant safety events. Additional safety procedures may be
performed at the discretion of the site staff. Participants are advised to refrain from exercise and
strenuous activities for 3 day after the leukapheresis visit.
8.4 . Safety Assessments
Safety and tolerability will be assessed throughout the study from the time that the ICF is signed
until completion of the last study-related activity, which may include contact for follow-up of
safety. The evaluations of safety and tolerability will include monitoring of (S) AEs, physical
examinations (including body weight) , vital signs measurements, triplicate 12-lead ECGs, and
clinical laboratory tests (including hematology, blood biochemistry, blood coagulation, urinalysis,
urine chemistry, and renal biomarkers)  at predefined time points as specified in the Schedule of
Activities . Any clinically relevant changes occurring during the study must be recorded on the
Adverse Event section of the CRF.
Adverse events will be reported and followed by the investigator as specified in Section 8.5and
Section 10.4, Appendix 4, Adverse Events: Definitions and Procedures for Recording, Evaluating,
Follow-Up, and Reporting.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 105
Status: A
pproved,  Date: 25 November 2021Specific toxicity management plans in line with the known pharmacological profile of the study
intervention (and the drug classes)  evaluated in this study are implemented (Sections 8.5.6 and
8.5.7) .
Any clinically significant abnormalities persisting at the end of the study/early withdrawal will be
followed by the investigator until resolution or until a clinically stable condition is reached.
Details regarding the IFLEP are provided in Section 9.6 and in the Committees Structure in
Section 10.3, Appendix 3, Regulatory, Ethical, and Study Oversight Considerations.
8.4 .1. Physical Examinations
A complete physical examination (including height [at screening only], body weight, skin
examination, and other body systems)  will be performed at screening, Week 24, and Week 48. A
symptom-directed physical examination (including body weight)  will be performed at the time
points indicated in the Schedule of Activities .
A complete physical examination includes the following: general appearance, eyes, ears, nose,
throat, cardiovascular system, respiratory system, gastro-intestinal system, head, neck, thyroid,
and skin and mucous membranes. A neurological and musculoskeletal examination will be
performed, as well as an examination of the lymph nodes. Body weight and temperature will be
measured. Height will be measured at the screening visit only.
8.4 .2. Vital Signs
Body temperature, pulse rate, and supine SBP and DBP will be assessedat the time points indicated
in the Schedule of Activities .
Blood pressure and pulse rate measurements will be assessed with a completely automated device.
Manual techniques will be used only if an automated device is not available.
Blood pressure and pulse/heart rate measurements should be preceded by at least 5 minutes of rest
in a quiet setting without distractions (eg, television, cell phones) .
Clinically relevant abnormalities in vital signs are defined in Section 10.7, Appendix 7,
Cardiovascular Safety Abnormalities.
8.4 .3. Electrocardiograms
Twelve-lead triplicate ECGs will be collected at the time points indicated in the Schedule of
Activities and when clinically indicated.
During the collection of ECGs, participants should be in a quiet setting without distractions (eg,
television, cell phones) . Participants should rest in a supine position for at least 5 minutes before
ECG collection and should refrain from talking or moving arms or legs.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 106
Status: A
pproved,  Date: 25 November 2021At each time point at which triplicate ECGs are required, 3 individual ECG tracings should be
obtained as closely as possible in succession, but no more than 2 minutes apart. The full set of
triplicates should be completed in less than 10 minutes.
Evaluation of the triplicate 12-lead ECGs will be based on the mean value of the triplicate
parameters.
All ECGs will be read centrally. Only on Day 1, pre-dose ECG assessment will also be done locally
on-site. Preferably, all ECGs will be read and interpreted under supervision of one and the same
qualified person.
Clinically relevant abnormalities in ECG are defined in Section 10.7, Appendix 7, Cardiovascular
Safety Abnormalities.
8.4 .4 . Clinical Safety Laboratory Assessments
Blood samples for serum chemistry and hematology and a urine sample for urinalysis will be
collected as noted in Section 10.2, Appendix 2, Clinical Laboratory Tests. The investigator must
review the laboratory results, document this review, and record any clinically relevant changes
occurring during the study in the adverse event section of the CRF. The laboratory reports must be
filed with the source documents.
Participants need to have fasted for at least 10 hours before biochemistry samples are taken for
measurement of phosphate, calcium, creatinine, and lipids. Participants are to bring their oral study
intervention with them to each study visit and have that day’s intake at the site.
In case a grade 3 or grade 4 laboratory abnormality occurs, that is considered to be clinically
significant by the investigator, a confirmatory test must be performed preferably within 48 hours
but no later than 72 hours after the results have become available.
For this study, the laboratory abnormality of cholesterol increase is identified as laboratory
abnormality of interest.
Note: cholesterol increase is a laboratory abnormality of interest specific for JNJ-6379, which was
part of the study intervention up to Protocol Amendment 4. Because participants who were
enrolled before Protocol Amendment 5 was in effect, also received JNJ-6379 as part of their study
intervention, monitoring of cholesterol increases will be continued.
8.5. Adverse Events and Serious Adverse Events
Special attention will be paid to those participants who discontinue the study for an AE, or who
experience an AE of at least grade 3, or an SAE. The grades are based on the DAIDS Toxicity
Grading Scale (Section 10.9, Appendix 9, DAIDS Table) .
Timely, accurate, and complete reporting and analysis of safety information from clinical studies
are crucial for the protection of participants, investigators, and the sponsor, and are mandated by
regulatory agencies worldwide. The sponsor has established Standard Operating Procedures in
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 107
Status: 
Approved,  Date: 25 November 2021conformity with regulatory requirements worldwide to ensure appropriate reporting of safety
information; all clinical studies conducted by the sponsor or its affiliates will be conducted in
accordance with those procedures.
Adverse events will be reported by the participant (or, when appropriate, by a caregiver, surrogate,
or the participant's legally acceptable representative)  for the duration of the study.
For further details on AEs and SAEs (Definitions and Classifications; Attribution Definitions;
Severity Criteria; Special Reporting Situations; Procedures)  as well as product quality complaints,
refer to Section 10.4, Appendix 4, Adverse Events: Definitions and Procedures for Recording,
Evaluating, Follow-Up, and Reporting.
8.5.1. Time Period and Frequency for Collecting Adverse Event and Serious
Adverse Event Information
All Adverse Events
All adverse events and special reporting situations, whether serious or non-serious, will be reported
from the time a signed and dated ICF is obtained until completion of the participant's last study-
related procedure, which may include contact for follow-up of safety. SAEs, including those
spontaneously reported to the investigator within 30 days after the last dose of study intervention,
must be reported using the SAE Form. The sponsor will evaluate any safety information that is
spontaneously reported by an investigator beyond the time frame specified in the protocol.
Serious Adverse Events
All SAEs occurring during the study must be reported to the appropriate sponsor contact person
by study-site personnel immediately and within 24 hours of their knowledge of the event.
Information regarding SAEs will be transmitted to the sponsor using the SAE Form, which must
be completed and signed by a physician from the study site, and transmitted to the sponsor within
24 hours. The initial and follow-up reports of a SAE should be made by facsimile (fax) .
8.5.2. Method of Detecting Adverse Events and Serious Adverse Events
Care will be taken not to introduce bias when detecting AEs or SAEs. Open-ended and nonleading
verbal questioning of the participant is the preferred method to inquire about adverse event
occurrence.
Solicited Adverse Events
Solicited AEs are predefined local (at the injection site) for which the participant is specifically
questioned. Information on ISRs (Section 8.5.6.1 )  will be solicited.
Unsolicited Adverse Events
Unsolicited adverse events are all adverse events for which the participant is not specifically
questioned.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 108
Status: 
Approved,  Date: 25 November 20218.5.3. Follow-up of Adverse Events and Serious Adverse Events
Adverse events, including pregnancy, will be followed by the investigator as specified in
Section 10.4, Appendix 4, Adverse Events: Definitions and Procedures for Recording, Evaluating,
Follow-up, and Reporting.
8.5.4 . Regulatory Reporting Requirements for Serious Adverse Events
The sponsor assumes responsibility for appropriate reporting of adverse events to the regulatory
authorities. The sponsor will also report to the investigator (and the head of the investigational
institute where required)  all suspected unexpected serious adverse reactions (SUSARs) . The
investigator (or sponsor where required)  must report SUSARs to the appropriate Independent
Ethics Committee/Institutional Review Board (IEC/IRB)  that approved the protocol unless
otherwise required and documented by the IEC/IRB.
8.5.5. Pregnancy
All initial reports of pregnancy in female participants or partners of male participants must be
reported to the sponsor by the study-site personnel within 24 hours of their knowledge of the event
using the appropriate pregnancy notification form. Abnormal pregnancy outcomes (eg,
spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy)  are
considered SAEs and must be reported using the SAE Form. Any participant who becomes
pregnant during the study must discontinue further investigational intervention (JNJ-3989) .
Follow-up information regarding the outcome of the pregnancy and any postnatal sequelae in the
infant will be required.
8.5.6. Adverse Events of Special Interest
Events of Special Interest are significant AEs that are judged to be of special interest because of
clinical importance, known class effects or based on nonclinical signals. Events of Special Interest
that will be carefully monitored during the study include ISRs, ALT/AST elevations, renal
complications, hematological abnormalities, and events related to cholesterol increase
(Section 8.4.4, Clinical Safety Laboratory Assessments) . In addition, the following toxicities will
also be carefully monitored: rash and acute systemic allergic reactions.
For participants reporting ALT/AST elevations, rash, ISRs, acute systemic allergic reactions, renal
complications, and hematological abnormalities as specified in the DAIDS Toxicity Grading Scale
(see Section 10.9, Appendix 9, DAIDS Table) , the following should be done.
Note: renal complications and cholesterol increase are AESIs specific for JNJ-6379, which was
part of the study intervention up to Protocol Amendment 4 and has been removed with the
implementation of Protocol Amendment 5. Because participants who were enrolled before
Protocol Amendment 5 was in effect, also received JNJ-6379 as part of their study intervention,
the AESIs have not been revised with the removal of JNJ-6379. For all participants having received
at least one dose of JNJ-6379, renal safety monitoring will be continued.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 109
Status: 
Approved,  Date: 25 November 20218.5.6.1. Injection Site Reactions
At the time points specified in the Schedule of Activities or at an unscheduled visit if needed, an
evaluation of the injection site will be performed based on participant’s descriptionand/or physical
examination. Evaluations will be recorded in the source documents and will include at a minimum
the time of occurrence, time of resolution and a description of the abnormality including its
maximal diameter. For each ISR, information on pain, erythema, induration and pruritus should
be obtained as specified in the DAIDS scale (see Section 10.9, Appendix 9, DAIDS Table) .
All ISRs (including ISRs below grade 1)  should be recorded in the special events section of the
CRF.
Digital pictures will be taken when considered appropriate; all efforts should be made to collect
images in case of grade 3 and 4 ISRs. Digital pictures will only be taken and collected from
participants who consent separately to this component of the study. If digital pictures are required,
they should be de-identified and provided to the sponsor.
8.5.6.2. Intervention-emergent ALT/AST Elevations
Elevated liver enzyme activity can be triggered by the underlying HBV disease as well as by the
study intervention.
Management of intervention-emergent ALT/AST elevations is presented graphically in
Section 10.6, Appendix 6, Intervention-emergent ALT/AST Elevations, and is described below.
Any intervention-emergent elevation of ALT and/or AST ≥3x ULN and ≥3x nadir (ie, lowest value
during study participation)  should trigger an assessment of confounding factors (alcohol intake,
change in concomitant medication, and comorbidities)  and should trigger a confirmatory study
visit to repeat laboratory testing of ALT, AST, ALP, AFP, bilirubin (total and direct) , INR,
albumin, and HBV DNA. Additional tests should be considered based on clinical judgement (refer
to Section 10.6, Appendix 6, Intervention-emergent ALT/AST Elevations) . The confirmatory visit
should be scheduled as soon as possible, preferably within 7 days of the receipt of the initial
ALT/AST results. In case the repeat laboratory testing shows an isolated ALT/AST elevation (ie,
with stable albumin, bilirubin [total and direct], and INR)  the participant may continue study
intervention. In case of confirmed ALT elevation >1,000 U/Land ≥3x the baseline value, JNJ-3989
(and PegIFN-α2a, if applicable) should be discontinued. In both cases, NA treatment should be
continued. The participant will be monitored on a weekly basis (laboratory testing of ALT, AST,
ALP, AFP, bilirubin [total and direct], INR, albumin, and HBV DNA) until ALT and AST levels
have returned to <5x ULN and HBV DNA is <20,000 IU/mL.
If the ALT and/or AST level is ≥3x ULN and ≥3x nadir and is associated with any of the following
laboratory results or clinical symptoms:
 INR ≥1.5, OR
 direct bilirubin >1.5x ULN, OR
 serum albumin <3.0 g/dL, OR
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 110
Status: A
pproved,  Date: 25 November 2021 ascites, hepatic encephalopathy, or liver-related symptoms (eg, severe fatigue, nausea,
vomiting, right upper quadrant pain in the absence of an alternative medical explanation) , OR
 other indication of reduced liver function
the participant should discontinue JNJ-3989 (and PegIFN-α2a, if applicable)  and should be
monitored on a weekly basis or as per good clinical practice until ALT and AST levels have
returned to <5x ULN and HBV DNA is <20,000 IU/mL and, if present, liver-related symptoms
have improved. NA treatment should be continued. Additional tests should be considered based
on clinical judgement (refer to Section 10.6, Appendix 6, Intervention-emergent ALT/AST
Elevations) .
In case of prolonged ALT elevation >3x ULN AND >2x nadir, which lasts at least 12 weeks, the
decision to continue JNJ-3989 and/or PegIFN-α2a should be based upon virologic parameters (eg,
HBsAg, HBV DNA)  and should be made in consultation with the sponsor.
PegIFN-α2a may need to be discontinued in clinically significant cases of ALT increase or in
combined increase of ALT and direct bilirubin. Refer to the prescribing information for PegIFN-
α2a.41,42
The NA re-treatment criteria during follow-up are presented in Section 6.6.2.
8.5.6.3. Complications From Liver Biopsy
Participants should be closely monitored for liver biopsy complications. Infection and internal
bleeding and/or puncture of other internal organs (gall bladder, lung, intestine or kidney)  can lead
to serious complications (uncommon 1 in 1000 to 1 in 100)  including the need for emergency
surgery, blood transfusion or removal of organs. Deaths directly related to liver biopsyoccur rarely
(approximately 1 in every 10,000 biopsies) . Criteria for participant selection and laboratory
assessments are in place to minimize these risks. Additional investigations can be performed at the
investigator’s discretion. Participants must be treated as clinically appropriate.
8.5.6.4 . Renal Complications
If renal complications develop, participants should be closely monitored for disturbances in
creatinine clearance. Additional investigations can be performed at the investigator’s discretion.
Participants must be treated as clinically appropriate.
Participants who develop confirmed grade 3 or 4 eGFR cr abnormalities with reduction from
baseline by at least 10 mL/min/1.73 m2 will change their NA from tenofovir disoproxil to ETV or
TAF (if the patient was receiving tenofovir disoproxil) , according to the prescribing information.
If the abnormality persists despite change of NA or if the patient is not receiving tenofovir
disoproxil, he or she will permanently discontinue the intake of JNJ-3989 (and PegIFN-α2a, if
applicable) if the abnormality is considered at least possibly related to JNJ-3989, and should be
followed appropriately until resolution of AE or toxicity. Rechallenge is not allowed.
For all participants having received at least one dose of JNJ-6379, renal safety monitoring will be
continued.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 111
Status: 
Approved,  Date: 25 November 20218.5.6.5. Hematologic Abnormalities
Mild thrombocytopenia was observed in recently conducted non-clinical toxicology studies with
the combination of JNJ-3989 and JNJ-6379. In addition, in a 3-month combination study with
80 rats, 1 rat developed pancytopenia related to bone marrow depletion after 23 days of dosing.
Previously, in a 9-month dog study in 24 dogs treated with JNJ-6379 alone, pancytopenia which
correlated with a marked increase in plasma cell-like cells in the bone marrow was observed in
1 dog after 60 days of dosing.
No thrombocytopenia or pancytopenia has been observed in the ongoing JADE study
(56136379HPB2001)  investigating JNJ-6379/Placebo with or without NA treatment. All 232
participants have completed at least 24 weeks of study intervention. In a Phase 1 study with JNJ-
3989, mild (Grade 1) transient thrombocytopenia was observed in 6 out of 84 participants
receiving 3 SC injections of JNJ-3989 alone over a period of up to 12 weeks with background of
NA. The transient thrombocytopenia was not considered clinically significant. No
thrombocytopenia or pancytopenia was observed in 12 participants when JNJ-3989 and JNJ-6379
were given in combination over a 12-week period.
Based on the non-clinical findings, any relevant abnormalities in hematologic parameters will be
carefully monitored as described below:
 Platelet counts: <100, 000 cells/mm3 (at least Grade 2 [DAIDS])  or <100 GI/L or reduction
from baseline by at least 50% baseline
 Hemoglobin: Decrease from baseline of at least 2 g/dL from baseline or at least Grade 2
(DAIDS)
 Reticulocyte count: Reduction to <0.5% of the RBC count
 Neutrophil count: Treatment-emergent reduction to at least Grade 2 (DAIDS)
In case any one of the above criteria are met, a confirmatory visit should be scheduled as soon as
possible, preferably within 7 days of the receipt of the initial results. Confirmation of the results
will trigger weekly or biweekly (every other week) unscheduled visits until improvement or
stabilization of the respective parameter(s) . Stabilization is defined as no further significant
reduction over two consecutive visits.
In case of confirmed Grade 3 or Grade 4 hematologic abnormalities, discontinuation of JNJ-3989
(and PegIFN-α2a, if applicable])  should be considered. In case of discontinuation, NA treatment
should be continued.
8.5.7. Other Toxicities
8.5.7.1. Rash
Participants should be informed that they should contact their doctor immediately when they notice
any generalized skin reaction. This skin reaction should be evaluated in the clinic the same day (if
possible)  or the next day.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 112
Status: 
Approved,  Date: 25 November 2021All rash events should be captured in the special events section of the CRF. A set of separate Rash
pages will be completed in case of a rash event.
Monitoring of the evolution of rash events will be performed as described in Table 6 in
Section 10.5, Appendix 5, Rash Management.
When safety blood samples are drawn as per the rash management guidelines, these should be
processed by the local laboratory. The following parameters will need to be tested: AST, ALT,
sedimentation rate, complete blood cell count (including hemoglobin, hematocrit, RBC count,
WBC count, differential count [neutrophils, lymphocytes, monocytes, eosinophils, and basophils],
and platelet count) , and creatinine. The values of the local laboratory assessments need to be
transcribed in the CRF by the study site personnel.
The participant may be treated symptomatically until the rash resolves. Oral antihistamines (eg,
cetirizine, levocetirizine)  and/or topical corticosteroids may provide symptomatic relief but
effectiveness of these measures has not been established. If systemic corticosteroids exceeding
5 mg of prednisolone equivalent/day are required for treatment of rash, JNJ-3989 (and
PegIFN-α2a, if applicable)  needs to be permanently discontinued. NA treatment can be continued.
If the rash is considered to be most likely due to concomitant illness or non-study interventions,
standard management, including discontinuation of the likely causative agent, should be
undertaken.
8.5.7.2. Acute Systemic Allergic Reactions
Grade 1 (Localized Urticaria [Wheals] With no Medical Intervention Indicated)
Participants may continue the intake of study interventions.
Cetirizine, levocetirizine, topical corticosteroids or antipruritic agents may be prescribed.
Participants should be advised to contact the investigator immediately if there is any worsening of
the acute systemic allergic reaction.
Grade 2 (Localized Urticaria With Intervention Indicated, or Mild Angioedema With no
Intervention Indicated)
Participants may continue the intake of study interventions.
Cetirizine, levocetirizine, topical corticosteroids or antipruritic agents may be prescribed.
Participants should be advised to contact the investigator immediately if there is any worsening of
the acute systemic allergic reaction, in which case the participant will permanently discontinue the
intake of JNJ-3989 (and PegIFN-α2a, if applicable) . Rechallenge is not allowed. The participant’s
NA treatment may be discontinued based on investigator judgement in consultation with the
sponsor.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 113
Status: 
Approved,  Date: 25 November 2021Grade 3 (Generalized Urticaria, Angioedema With Intervention Indicated, or Symptoms of
Mild Bronchospasm) and Grade 4 (Acute Anaphylaxis, Life-Threatening Bronchospasm, or
Laryngeal Edema)
Participants will permanently discontinue the intake of JNJ-3989 (and PegIFN-α2a, if applicable) .
Rechallenge is not allowed. The participant’s NA treatment may be discontinued based on
investigator judgement in consultation with the sponsor.
Participants will be treated as clinically appropriate. Participants should be followed until
resolution of the AE and standard management should be undertaken.
8.6. Treatment of Overdose
For this study, any dose of JNJ-3989 greater than the protocol-specified dose (refer to Section 6.1)
will be considered an overdose; any dose of NA (ETV, tenofovir disoproxil, or TAF)  and PegIFN-
α2a greater than the prescribed dose will be considered an overdose. The sponsor does not
recommend specific therapeutic intervention for an overdose.
In the event of an overdose, the investigator or treating physician should:
 Contact the Medical Monitor immediately.
 Closely monitor the participant for AE/SAE and laboratory abnormalities.
 Obtain a plasma sample for PK analysis as soon as possible from the date of the last dose of
study intervention if requested by the Medical Monitor (determined on a case-by-case basis) .
 Document the quantity of the excess dose as well as the duration of the overdosing in the CRF.
Decisions regarding dose interruptions or modifications will be made by the investigator in
consultation with the Medical Monitor based on the clinical evaluation of the participant.
8.7. Pharmacokinetics
Plasma samples will be used to evaluate the PK ofJNJ-3989 (ie, JNJ-3976 and JNJ-3924) , and,
optionally, JNJ-6379, NA  and/or PegIFN-α2a, as applicable. Serum collected for PK may
additionally be used to evaluate safety or efficacy aspects that address concerns arising during or
after the study period. Genetic analyses will not be performed on these samples. Participant
confidentiality will be maintained.
8.7.1. Evaluations
Venous blood samples will be collected for measurement of plasma concentrations of JNJ-3976,
JNJ-3924, NA (ETV, TAF, or tenofovir) and PegIFN-α2a, as applicable, at time points specified
in the Schedule of Activities . Bioanalysis of NA and PegIFN-α2a is optional at the discretion of
the sponsor. Bioanalysis of JNJ-6379 may also be done on samples collected from participants
who received JNJ-6379 up to Protocol Amendment 4.
All participants will have sparse PK sampling on Day 1 and at Weeks 4, 12, and 24 (and at early
withdrawal) . All participants who consent to participate in the intensive PK substudy (optional)
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 114
Status: 
Approved,  Date: 25 November 2021will undergo intensive PK sampling at Week 4. If necessary (eg, for operational reasons) , this visit
may be scheduled at Week 8, 12, or 16.
8.7.2. Analytical Procedures
Pharmacokinetics
Plasma samples will be analyzed to determine concentrations of JNJ-3976 and JNJ-3924 using a
validated, specific, and sensitive liquid chromatography-fluorescence hybridization method under
the supervision of the sponsor.
At the sponsor’s discretion, plasma samples may be analyzed to determine concentrations of
JNJ-6379 and/or NA and/or PegIFN-α2a using a validated, specific, and sensitive liquid
chromatography-mass spectrometry method under the supervision of the sponsor.
Plasma PK samples may be stored for future exploratory analysis of protein binding or the
metabolite profile. Genetic analyses will not be performed on these plasma samples. Participant
confidentiality will be maintained.
8.7.3. Pharmacokinetic Parameters and Evaluations
Parameters
Plasma concentration-time data for JNJ-3989 (ie, JNJ-3976 and JNJ-3924)  and, optionally,
JNJ-6379, NA and/or PegIFN-α2a will be analyzed via noncompartmental methods for all
participants who underwent intensive PK sampling. The main PK parameter will be area under the
plasma concentration-time curve over 24 hours (AUC 24h) , Cmax, tmax, plasma trough concentration
(C0h) , plasma concentration at the end of the dosing interval (τ)  (C τ) , and minimum plasma
concentration (C min) . Additional exposure parameters may be calculated if applicable.
Data from this study may be combined with data from a selection of Phase 1 and 2 studies via
population PK modelling. Individual estimates of PK parameters may be generated from the
population PK analysis for potential use in exposure-response analysis.
8.8. Pharmacokinetics/Pharmacodynamics
Relationships of individual PK parameters for JNJ-3976, JNJ-3924, and, optionally, JNJ-6379,
NA and/or PegIFN-α2a, with selected liver and blood biomarkers, and/or with selected safety
endpoints may be evaluated.
8.9. Host Genetics
A pharmacogenomic blood sample will be collected (preferably at baseline) to allow for the
identification of genetic factors that may influence the efficacy, safety, or PK of the study
intervention, to identify genetic factors associated with HBV infection, or to develop assays for
the study intervention or HBV infection.
A blood sample will be taken for HLA typing as indicated in the Schedule of Activities . In addition,
host DNA blood samples to allow for epigenetic analyses will be collected.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 115
Status: 
Approved,  Date: 25 November 20218.10. Host Biomarkers
The study includes collection of blood samples for exploratory analysis of host blood biomarkers
at the host RNA, protein, and cell level. Sampling will be performed in all participants at the time
points indicated in the Schedule of Activities .
Samples can only be used for research related to study intervention or HBV infection or may be
used to develop tests/assays related to study intervention or HBV infection.
Blood samples will be taken at the time points indicated in the Schedule of Activities which can
be used to explore immunogenicity of JNJ-3989. The emergence of antibodies to JNJ-3989
(antidrug antibodies)  might be analyzed using assays such as an enzyme-linked immunosorbent
assay.
8.11. Medical Encounters
Eventual medical encounters will be collected in the CRF by the investigator and study site
personnel for all participants throughout the study.
9. STATISTICAL CONSIDERATIONS
Statistical analysis will be done by the sponsor or under the authority of the sponsor. A general
description of the statistical methods to be used to analyze the efficacy and safety data is outlined
below. Specific details will be provided in the Statistical Analysis Plan.
The primary analysis will be performed at the time when all participants have completed Week 48
or discontinued earlier. The final analysis will be performed when all participants have completed
the last study visit (Follow-up Week 48)  or discontinued earlier. For the IAs, please refer to
Section 9.5.
9.1. Statistical Hypotheses
As this is an exploratory study, no hypothesis will be tested.
9.2. Sample Size Determination
This study aims to enroll 18 to 24 participants in total across Panels 1 and 2, ie, 8 to 12 participants
per study panel.
Due to the exploratory nature of the study, the sample size was determined based on clinical and
feasibility considerations related to the liver biopsy procedures performed multiple times during
the study, rather than a formal statistical calculation. Nevertheless, a sample size of 8 to 12
participants each in Panel 1 and 2 is considered sufficient to provide adequate precision of the
estimate of the primary endpoint (change from baseline to Week 40 in the proportion of HBsAg-
positive hepatocytes)  as estimated by the 80% confidence interval (CI) .
For the estimation of the absolute change in the proportion of HBsAg-positive hepatocytes from
baseline to Week 40 for the overall study population (Panels 1 and 2 combined) , the following
assumptions were made. Assuming an absolute reduction of 70% in Panel 1 (75% at baseline
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 116
Status: A
pproved,  Date: 25 November 2021versus 5% at Week 40)  and 29% in Panel 2 (30% at baseline versus to 1% at Week 40) , and
assuming an inter-subject variability of the change equal to 0.5 on the logit scale in both panels, a
binomial model40 including visit as covariate with normal random effects provides an expected
width of the 80% CI of 16.7% for N 24, a width of 17.9% for N 20, and a width of 20.3% for
N 16. The point estimates (two-sided 80% CI)  are 50.8% (42.5%; 59.1%)  with N 24, 50.7%
(41.8%; 59.7%)  with N 20, and 50.6% (40.5%; 60.8%)  with N 16.
For the between-panel difference in the absolute reduction in the proportion of HBsAg-positive
hepatocytes from baseline to Week 40 using the binomial model described above augmented with
panel as an additional covariate and the same inter-subject variability, the estimated width of the
two-sided 80% CI around the difference (Panel 1 Panel 2)  is 17.6% for N 24 (12 per panel) ,
19.3% for N 20 (10 per panel) , and 21.2% for N 16 (8 per panel) . The point estimates (80% CI)
are 40.4% (31.5%; 49.2%)  for N 24, 39.2% (29.6%; 48.9%)  for N 20, and 39.4% (28.8%; 50.0%)
for N 16.
In addition, N 20 would also be sufficient to provide adequate precision for a between-panel
difference in the relative change from baseline of at least 26% in case of large inter-subject
variability.
Assuming a drop rate of 20%, the sample size will be therefore set to 12 participants per panel for
Panels 1 and 2.
9.3. Populations for Analyses
For purposes of analysis, the following populations are defined:
Population Description
Randomi
zed All participants who were randomized in the study
Enrolle
d All participants who were enrolled in the study
Intent-
to-treat 
(ITT) All participants who were either randomly assigned or enrolled to an intervention arm and
received at least 1 dose of study intervention. Participants will be analyzed according to the
study intervention they were randomly assigned or enrolled to.
Safety Al
l participants who received at least 1 dose of study intervention. Participants will be
analyzed according to the study intervention they actually received.
9.4 . Statist
ical Analyses
The Statistical Analysis Plan will include a more technical and detailed description of the statistical
analyses described in this section. This section is a summary of the planned statistical analyses of
the most important endpoints including primary and key secondary endpoints.
Given the exploratory nature of the study and the limited sample size per panel, no statistical
testing will be performed. All data will be summarized descriptively including 80% confidence
intervals as appropriate.
9.4 .1. Analysis of Efficacy and Antiviral Activity
To evaluate the efficacy and antiviral activity in blood and liver, the primary analysis set will be
the ITT population. Efficacy and antiviral activity will be assessed for participants in Panels 1
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 117
Status: 
Approved,  Date: 25 November 2021and 2. For all efficacy and antiviral activity endpoints, unless specified otherwise, the following
comparisons will be addressed:
1. Overall population, pooling all participants regardless of panels.
Between Panels 1 and 2: HBeAg-positive patients who are not currently being treated
versus HBeAg-negative patients being virologically suppressed by NA treatment.
All efficacy summaries will be presented with descriptive statistics, overall and by study panel.
If the endpoint is continuous, the descriptive statistics will include the number of participants,
mean, standard deviation (SD) , median, range, and interquartile range. If the endpoint is binary or
categorical, the frequency distribution with the number and percentage of participants in each
category will be calculated.
Graphic displays will also be used to summarize the data and to visualize trends by study panel.
Where applicable, additional specifics for analyses of primary, secondary, and exploratory
endpoints are detailed below.
9.4 .1.1. Analysis of the Primary Endpoint
The primary endpoint is the change between baseline and on-treatment liver biopsy (Week 40)  in
terms of the proportion of HBsAg positive hepatocytes. The primary endpoint will be summarized
descriptively and modelled with an appropriate statistical model accounting for the number of
hepatocytes sampled in each liver biopsy. The change from baseline will be summarized for the
overall study population and within each panel, together with the between-panel difference in the
change..
No imputation rule will be applied for the analysis on the ITT population since only complete
cases will be considered. In addition, the treatment policy strategy will be followed to account for
the occurrence of intercurrent events, such as treatment discontinuation prior to Week 40, ie, all
biopsies collected at Week 40 will be used, regardless of occurrence of treatment discontinuation
prior to Week 40. This strategy is supported by the small sample size, the exploratory nature of
the study and ethical considerations.
In addition, a sensitivity analysis on the ITT population will be combining a treatment policy
strategy with the Baseline Observation Carried Forward (BOCF)  approach.
9.4 .1.2. Analysis of Secondary Endpoints
Secondary endpoints will be analyzed on the ITT population.
Changes in Intrahepatic Immune Response
Variation in proportion of major cell populations, such as but not limited to CD45+ T-cells, CD4+
T-cells, CD8+ T-cells, Natural Killer cells, and dendritic cells, defined by single cell
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 118
Status: 
Approved,  Date: 25 November 2021transcriptomics (in FNABs)  and immunofluorescence staining (in core needle biopsies) , will be
assessed at Week 40 and compared to baseline, overall and by study panel.
The functional characterization of major cell populations will be assessed by transcriptomics
and/or proteomics for major cell populations of interest at Week 40 and compared to baseline
similarly.
Changes in Intrahepatic Viral Nucleic Acids and Proteins
Changes from baseline in cccDNA level and/or transcriptional activity will be assessed using the
general considerations outlined above.
Furthermore, the difference in the level of infected hepatocytes at baseline will be assessed by
comparing cccDNA level and/or transcriptional activity.
Analyses of other viral markers will be performed descriptively. Statistical analyses will depend
on the assay technology applied and the scope of the analyses.
9.4 .1.3. Analysis of Exploratory Endpoints
Exploratory endpoints will be analyzed on the ITT population.
The association between intrahepatic markers and blood (immune and viral)  markers will be
explored both at baseline and on-treatment by study panel using graphical displays and relevant
correlation coefficients.
Impact of baseline characteristics on selected efficacy variables and their association with
intrahepatic and blood markers will also be evaluated using similar methods.
Identification of markers (either intrahepatic or blood)  that could potentially be associated with
selected efficacy variables (such as decrease in blood HBsAg levels, intrahepatic cccDNA levels
or any other relevant variables)  will be conducted. Impact of treatment on different blood and
hepatic markers will also be evaluated.
9.4 .2. Safety Analyses
All safety analyses will be made on the Safety Population (Section 9.3) .
Safety will be evaluated by means of descriptive summaries of AEs including AEs of special
interest to any of the study interventions, clinical laboratory tests, ECGs, vital signs, and physical
examinations. The safety analysis will be done by study phase. Results will be presented in tabular
format and/or graphically over time, as appropriate.
Adverse Events
The verbatim terms used in the CRF by investigators to identify AEs will be coded using the
Medical Dictionary for Regulatory Activities (MedDRA) . Intervention-emergent AEs are AEs
with onset during the intervention phase or that are a consequence of a pre-existing condition that
has worsened since baseline. All reported intervention-emergent AEs will be included in the
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 119
Status: 
Approved,  Date: 25 November 2021analysis. For each AE, the percentage of participants who experience at least 1 occurrence of the
given event will be summarized.
Summaries, listings, datasets, or participant narratives may be provided, as appropriate, for those
participants who die, who discontinue intervention due to an AE, or who experience a severe or a
serious AE.
Adverse Events Related to the Applied Study Procedures
Summaries, listings, datasets, or participant narratives will be provided, as appropriate, for those
enrolled participants who die, or who experience an AE or a severe or a serious AE related to the
applied study procedures.
All AE’s linked to the study procedure will be evaluated in conjunction with other systemic
symptoms and laboratory abnormalities: information on time of onset, duration of events, time to
resolution, concomitant therapies, and relationship to study procedures (eg, liver biopsies, blood
collection and leukapheresis)  will be summarized and described in the report.
Clinical Laboratory Tests
Laboratory data will be summarized by type of laboratory test. Descriptive statistics will be
calculated for each laboratory analyte at baseline and for observed values and changes from
baseline at each scheduled time point by study phase. A graphical presentation of changes from
baseline over time in selected laboratory tests will be also used.
The laboratory abnormalities will be determined according to the criteria specified in the DAIDS
Toxicity Grading Scale (see Section 10.9, Appendix 9, DAIDS Table)  or in accordance with the
normal ranges of the clinical laboratory if no gradings are available. The number and percentage
of the participants who experience (worst)  laboratory abnormalities will be tabulated by
intervention arm and study phase. Shifts in toxicity grades will be tabulated by study phase.
Electrocardiogram
Electrocardiogram data will be summarized by ECG  parameter. Descriptive statistics will be
calculated at baseline and for observed values and changes from baseline at each scheduled time
point. Frequency tabulations of the abnormalities will be made.
The ECG variables that will be analyzed are heart rate, PR interval, QRS interval, QT interval, and
QTcF.13
Descriptive statistics of QTc intervals and changes from baseline will be summarized at each
scheduled time point. The percentage of participants with QTc interval >450 milliseconds,
>480 milliseconds, or >500 milliseconds will be summarized, as will the percentage of participants
with QTc interval increases from baseline >30 milliseconds or >60 milliseconds. Shifts in QTc
interval categories will be tabulated by study phase.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 120
Status: 
Approved,  Date: 25 November 2021All clinically relevant abnormalities in ECG waveform that are changes from the baseline readings
will be reported (eg, changes in T-wave morphology or the occurrence of U-waves.
Vital Signs
Vital signs including temperature, pulse rate, and supine blood pressure (SBP and DBP)  will be
summarized over time, using descriptive statistics and/or graphically. The percentage of
participants with values beyond clinically important limits will be summarized.
Physical Examinations
Physical examination findings will be summarized at each scheduled time point. Descriptive
statistics will be calculated at baseline and for observed values and changes from baseline at each
scheduled time point. Frequency tabulations of the abnormalities will be made.
9.4 .3. Other Analyses
Pharmacokinetic Analyses
Descriptive statistics (number of participants, mean, SD, coefficient of variation, geometric mean,
median, minimum, and maximum)  will be calculated for the plasma concentrations of JNJ-3976,
JNJ-3924, and optionally, JNJ-6379, NA and/or PegIFN-α2a, as applicable, and for the derived
plasma PK parameters (noncompartmental analysis) .
Special attention will be paid to the plasma concentrations and PK parameters of those participants
who discontinued the study for an AE, or who experienced an AE ≥Grade 3 or an SAE.
For each participant with intensive PK sampling, plasma concentration-time data of JNJ-3976,
JNJ-3924, and/or JNJ-6379, and/or NA and/or PegIFN-α2a will be graphically presented.
Similarly, graphs of the mean plasma concentration-time profiles and overlay graphs with
combined individual plasma concentration time profiles will be produced. Pharmacokinetic
parameters will be subjected to an exploratory graphical analysis, including various
transformations, to get a general overview.
Population PK analysis of plasma concentration-time data of JNJ-3976, JNJ-3924, and optionally,
JNJ-6379, NA and/or PegIFN-α2a may be performed using nonlinear mixed-effects modeling.
Data may be combined with those from Phase 1 and/or 2 studies to support a relevant structural
model. Available baseline characteristics (eg, demographics, laboratory variables, genotypes)  may
be included in the model as necessary. Details will be given in a population PK analysis plan and
results of the population PK analysis, if applied, will be presented in a separate report.
Individual estimates of PK parameters may be generated from the population PK analysis for
potential use in exposure-response analysis.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 121
Status: 
Approved,  Date: 25 November 2021Pharmacokinetic/Pharmacodynamic Analyses
Relationships of PK parameters for JNJ-3976, JNJ-3924, and optionally, JNJ-6379, NA and/or
PegIFN-α2a with selected efficacy and with selected safety endpoints may be evaluated and
graphically displayed.
Modeling of key PD parameters (eg, HBsAg, HBV DNA)  may be performed using population
PK/PD. If PK/PD modeling of key efficacy endpoints is performed, treatment effect and possible
covariates such as disease progression may be investigated. Other biomarkers may be explored at
the sponsor’s discretion.
Resistance Analysis
The results of HBV viral sequencing will be evaluated by the sponsor virologist. Relevant changes
in amino acid and/or nucleic acid variations (eg, substitutions)  in the HBV genome will be
tabulated and described.
Additional exploratory characterization of the HBV viral sequence and phenotype may be
performed and reported separately.
Pharmacogenomic Analysis
The statistical approach for analyzing the exploratory host DNA research, including epigenetic
analyses, may depend on the objective of the analyses (efficacy, safety, and PK)  and possibly
relevant genes at the time of analysis. Analyses will be conducted at the sponsor’s discretion, will
always be under the sponsor’s supervision, and results will be presented either in the clinical study
report or a separate report.
Host Exploratory Biomarker Analysis
Statistical approaches to explore correlations between treatment response/clinical outcome and
blood and liver biomarkers vary and depend on the different data types of the applied technology
platforms, as well as on the extent of observed differences between participants. Analyses will be
conducted at the sponsor’s discretion, will always be under the sponsor’s supervision, and results
will be presented either in the clinical study report or a separate report.
9.5. Interim Analysis
Two IAs may be performed: when all participants have completed Week 20 in the intervention
phase (or discontinued earlier)  and when they have completed Week 72 in the follow-up phase (ie,
Follow-up Week 24)  (or discontinued earlier) . These IAs will be performed by the sponsor to
support interactions with health authorities, as well as to supportinternal decisions about additional
studies and/or investigation of other combination regimens.
Both primary and interim analyses will be based on all data available at the predefined cut-off time
points and may include data at later time points for those participants who have reached subsequent
visits.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 122
Status: 
Approved,  Date: 25 November 20219.6. Independent Flare Expert Panel
An IFLEP will be appointed for this study. The IFLEP is composed of 3 independent medical
experts with experience and expertise in hepatitis B and its treatment. The IFLEP will monitor
ALT flares and will make recommendations regarding flare management based on an analysis of
aggregate data.
In order to allow for an unbiased assessment, members of the committee will not serve as study
investigators.
Further details on the IFLEP process will be included in the IFLEP charter.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 123
Status: 
Approved,  Date: 25 November 202110. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Abbreviations and Definitions of Terms
AE adverse event
AFP alpha-fetoprotein
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC  area under the plasma concentration-time curve
AUC 0-xh area under the plasma concentration-time curve from administration to x h
AUC 0-last area under the plasma concentration-time curve from administration to last quantifiable sampling
point
AUC τ area under the plasma concentration-time curve over the dose interval (tau)  at steady-state
AUC ∞ area under the plasma concentration-time curve to last sampling point from time zero extrapolated
to infinity
bpm  beats per minute
CAM  capsid assembly modulator
cccDNA  covalently closed circular deoxyribonucleic acid
CKD-EPI Chronic Kidney Disease Epidemiology Collaboration
CL/F total apparent oral clearance
Cmax maximum plasma concentration
CRF case report form
CT computed tomography
CYP cytochrome P450
DAIDS Division of Acquired Immunodeficiency Syndrome
DBP diastolic blood pressure
DDI drug-drug interaction
DNA  deoxyribonucleic acid
EASL European Association for the Study of the Liver
ECG  electrocardiogram
eDC  electronic data capture
EFD  embryofetal development
eGFR  estimated glomerular filtration rate
eGFR cr estimated glomerular filtration rate based on serum creatinine
ELISpot enzyme-linked immunospot
EOS end of study
EOSI end of study intervention
ETV  entecavir
FNAB  fine needle aspiration biopsy
FSH  Follicle-stimulating hormone
FU Wx Follow-up Week x
GCP Good Clinical Practice
GLP Good Laboratory Practice
HBc hepatitis B core protein
HBcrAg hepatitis B core-related antigen
HBe hepatitis B e
HBeAg hepatitis B e antigen
HBs hepatitis B surface
HBsAg hepatitis B surface antigen
HBV  hepatitis B virus
HCC  hepatocellular carcinoma
HCV  hepatitis C virus
HDV  hepatitis D virus
HEV  hepatitis E virus
HIV-1(-2) human immunodeficiency virus type 1 (type 2)
HLA  human leukocyte antigen
HRT hormonal replacement therapy
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 124
Status: 
Approved,  Date: 25 November 2021IA  interim analysis
IB  Investigator’s Brochure
ICF informed consent form
ICH  International Council for Harmonisation of Technical Requirements for Pharmaceuticals for
Human Use
ICMJE International Committee of Medical Journal Editors
ICS intracellular cytokine staining
IEC  Independent Ethics Committee
IFLEP Independent Flare Expert Panel
IFN  interferon
IFN-γ gamma interferon
IgM  immunoglobulin M
IL interleukin
INR  International Normalized Ratio
IRB  Institutional Review Board
ISR  injection site reaction
ITT Intent-to-treat
IU/mL International Units Per Milliliter
IWRS interactive web response system
LLN  lower limit of normal
LLOQ  lower limit of quantification
MoA  mode of action
MRI magnetic resonance imaging
NA  nucleos(t) ide analog
NOAEL no observed adverse effect level
(q) PCR  (quantitative)  polymerase chain reaction
PD pharmacodynamic(s)
PegIFN-α2a pegylated interferon alpha-2a
PK pharmacokinetic(s)
PBMC  peripheral blood mononuclear cell
pgRNA  pre-genomic ribonucleic acid
PQC  Product Quality Complaint
Q4W  once every 4 weeks
qd once daily
QTcF QT interval corrected for heart rate according to Fridericia
RBC  red blood cell
RNA  ribonucleic acid
RNAi ribonucleic acid interference
SAE serious adverse event
SBP systolic blood pressure
SC subcutaneous
SD standard deviation
siRNA  small interfering RNA
SUSAR  suspected unexpected serious adverse reaction
t1/2term  terminal half-life
T4 thyroxine
tmax time to reach the maximum plasma concentration
TAF tenofovir alafenamide
TEAE treatment-emergent adverse event
TNF tumor necrosis factor
TSH  thyroid-stimulating hormone
ULN upper limit of normal
WBC  white blood cell
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 125
Status: 
Approved,  Date: 25 November 2021Definitions of Terms
Study intervention Prior to Protocol Amendment 5: JNJ-73763989 (JNJ-3989) , JNJ-56136379 (JNJ-6379) and
NA (either ETV, tenofovir disoproxil, or TAF)
As of Protocol Amendment 5: JNJ-73763989 (JNJ-3989)and NA (either ETV, tenofovir
disoproxil, or TAF)
Functional cure HBsAg seroclearance 24 weeks after end of treatment
HBsAg or HBeAg 
seroclearanceHBsAg or HBeAg negativity, respectively, based on the assay used
HBsAg or HBeAg 
seroconversionHBsAg or HBeAg negativity and anti-HBs or anti-HBe antibody positivity, respectively
Virologic 
breakthrough Confirmed on-treatment HBV DNA increase by >1 log 10 IU/mL from nadir or confirmed
on-treatment HBV DNA level >200 IU/mL in participants who had HBV DNA level
<LLOQ of the HBV DNA assay
ALT/AST nadir Lowest ALT/AST value during study participation
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 127
Status: 
Approved,  Date: 25 November 2021In case of a positive dipstick result, a urine sample will be set aside for additional
examination of the positive parameter at the central laboratory (eg, quantification as
applicable) .
Urine 
C
hemistry 
(quantitative 
measurement)Creatinine 
Sodium  
Phosphate Glucose
Protein
Albumin
Renal 
Bi
omarkers Retinol binding protein
Beta-2-microglobulin
Note:Th
ese renal biomarkers are to assess proximal renal tubular function.
Other T
ests  Serum pregnancy testing for women of childbearing potential at screening.
 Urine pregnancy testing for women of childbearing potential at the time points
indicated in the Schedule of Activities .
 Follicle-stimulating hormone (FSH)  testing for postmenopausal women at
screening.
 Testing for hepatitis A, B, C, D, and E virus and HIV-1 and -2 at screening.
 Testing for HBsAg, HBeAg, HBcrAg, and anti-HBs and anti-HBe antibodies at
the time points indicated in the Schedule of Activities .
 Determination of coagulation parameters will be performed at the time points
indicated in the Schedule of Activities . International Normalized Ratio (INR)will
be calculated by the central laboratory.
 Alpha-fetoprotein at screening.
Other o
ptional 
tests in
response to
ALT flare 
(refer to
Section 10.6,
Appendix 6,
Intervention-
emergent
ALT/AST
Elevations) Testing for HIV-1 and -2, and hepatitis A, C, D, and E.
 Testing for CMV, HSV, EBV infection.
 Ig-electrophoresis
Thyroi
d 
function tests TSH
T4
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 128
Status: 
Approved,  Date: 25 November 202110.3. Appendix 3: Regulatory, Ethical, and Study Oversight Considerations
REGULATORY AND ETHICAL CONSIDERATIONS
Investigator Responsibilities
The investigator is responsible for ensuring that the study is performed in accordance with the
protocol, current International Council for Harmonisation of Technical Requirements for
Pharmaceuticals for Human Use (ICH)guidelines on Good Clinical Practice(GCP) , and applicable
regulatory and country-specific requirements.
Good Clinical Practice is an international ethical and scientific quality standard for designing,
conducting, recording, and reporting studies that involve the participation of human participants.
Compliance with this standard provides public assurance that the rights, safety, and well-being of
study participants are protected, consistent with the principles that originated in the Declaration of
Helsinki, and that the study data are credible.
Protocol Amendments
Neither the investigator nor the sponsor will modify this protocol without a formal amendment by
the sponsor. All protocol amendments must be issued by the sponsor, and signed and dated by the
investigator. Protocol amendments must not be implemented without prior IEC/IRB approval, or
when the relevant competent authority has raised any grounds for non-acceptance, except when
necessary to eliminate immediate hazards to the participants, in which case the amendment must
be promptly submitted to the IEC/IRB and relevant competent authority. Documentation of
amendment approval by the investigator and IEC/IRB must be provided to the sponsor. When the
change(s)  involve only logistic or administrative aspects of the study, the IEC/IRB (where
required)  only needs to be notified.
During the course of the study, in situations where a departure from the protocol is unavoidable,
the investigator or other physician in attendance will contact the appropriate sponsor representative
listed in the Contact Information page(s) , which will be provided as a separate document. Except
in emergency situations, this contact should be made before implementing any departure from the
protocol. In all cases, contact with the sponsor must be made as soon as possible to discuss the
situation and agree on an appropriate course of action. The data recorded in the CRF and source
documents will reflect any departure from the protocol, and the source documents will describe
this departure and the circumstances requiring it.
Regulatory Approval/Notification
This protocol and any amendment(s)  must be submitted to the appropriate regulatory authorities
in each respective country, if applicable. A study may not be initiated until all local regulatory
requirements are met.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 129
Status: 
Approved,  Date: 25 November 2021Required Prestudy Documentation
The following documents must be provided to the sponsor before shipment of study intervention
to the study site:
 Protocol and amendment(s) , if any, signed and dated by the principal investigator
 A copy of the dated and signed (or sealed, where appropriate per local regulations) , written
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if
applicable, participant compensation programs. This approval must clearly identify the
specific protocol by title and number and must be signed (or sealed, where appropriate per
local regulations)  by the chairman or authorized designee.
 Name and address of the IEC/IRB, including a current list of the IEC/IRB members and their
function, with a statement that it is organized and operates according to GCP and the
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, from
the IEC/IRB, a general statement may be substituted for this list. If an investigator or a
member of the study-site personnel is a member of the IEC/IRB, documentation must be
obtained to state that this person did not participate in the deliberations or in the vote/opinion
of the study.
 Regulatory authority approval or notification, if applicable
 Signed and dated statement of investigator (eg, Form FDA 1572) , if applicable
 Documentation of investigator qualifications (eg, curriculum vitae)
 Completed investigator financial disclosure form from the principal investigator, where
required
 Signed and dated clinical trial agreement, which includes the financial agreement
 Any other documentation required by local regulations
The following documents must be provided to the sponsor before enrollment of the first
participant:
 Completed investigator financial disclosure forms from all subinvestigators
 Documentation of subinvestigator qualifications (eg, curriculum vitae)
 Name and address of any local laboratory conducting tests for the study, and a dated copy of
current laboratory normal ranges for these tests, if applicable
 Local laboratory documentation demonstrating competence and test reliability
(eg, accreditation/license) , if applicable
Independent Ethics Committee or Institutional Review Board
Before the start of the study, the investigator (or sponsor where required)  will provide the IEC/IRB
with current and complete copies of the following documents (as required by local regulations) :
 Final protocol and, if applicable, amendments
 Sponsor-approved ICF (and any other written materials to be provided to the participants)
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 130
Status: 
Approved,  Date: 25 November 2021 IB (or equivalent information)  and amendments/addenda
 Sponsor-approved participant recruiting materials
 Information on compensation for study-related injuries or payment to participants for
participation in the study, if applicable
 Investigator's curriculum vitae or equivalent information (unless not required, as documented
by the IEC/IRB)
 Information regarding funding, name of the sponsor, institutional affiliations, other potential
conflicts of interest, and incentives for participants
 Any other documents that the IEC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/IRB has given full approval of the final protocol,
amendments (if any, excluding the ones that are purely administrative, with no consequences for
participants, data or study conduct, unless required locally) , the ICF, applicable recruiting
materials, and participant compensation programs, and the sponsor has received a copy of this
approval. This approval letter must be dated and must clearly identify the IEC/IRB and the
documents being approved.
Approval for the collection of optional samples for research and for the corresponding ICF must
be obtained from the IEC/IRB. Approval for the protocol can be obtained independent of this
optional research component.
During the study the investigator (or sponsor where required)  will send the following documents
and updates to the IEC/IRB for their review and approval, where appropriate:
 Protocol amendments (excluding the ones that are purely administrative, with no
consequences for participants, data or study conduct)
 Revision(s)  to ICF and any other written materials to be provided to participants
 If applicable, new or revised participant recruiting materials approved by the sponsor
 Revisions to compensation for study-related injuries or payment to participants for
participation in the study, if applicable
 New edition(s)  of the IB and amendments/addenda
 Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at
least annually)
 Reports of adverse events that are serious, unlisted/unexpected, and associated with the study
intervention
 New information that may adversely affect the safety of the participants or the conduct of the
study
 Deviations from or changes to the protocol to eliminate immediate hazards to the participants
 Report of deaths of participants under the investigator's care
 Notification if a new investigator is responsible for the study at the site
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 131
Status: 
Approved,  Date: 25 November 2021 Development Safety Update Report and Line Listings, where applicable
 Any other requirements of the IEC/IRB
For all protocol amendments (excluding the ones that are purely administrative, with no
consequences for participants, data or study conduct) , the amendment and applicable ICF revisions
must be submitted promptly to the IEC/IRB for review and approval before implementation of the
change(s) .
At least once a year, the IEC/IRB will be asked to review and reapprove this study, where required.
At the end of the study, the investigator (or sponsor where required)  will notify the IEC/IRB about
the study completion.
Country Selection
This study will only be conducted in those countries where the intent is to launch or otherwise help
ensure access to the developed product if the need for the product persists, unless explicitly
addressed as a specific ethical consideration in Section 4.2.1.
Other Ethical Considerations
For study-specific ethical design considerations, refer to Section 4.2.1.
FINANCIAL DISCLOSURE
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial
information in accordance with local regulations to allow the sponsor to submit complete and
accurate financial certification or disclosure statements to the appropriate regulatory authorities.
Investigators are responsible for providing information on financial interests during the course of
the study and for 1 year after completion of the study.
Refer to Required Prestudy Documentation (above)  for details on financial disclosure.
INFORMED CONSENT PROCESS
Each participant must give written consent according to local requirements after the nature of the
study has been fully explained. The ICF(s)  must be signed before performance of any study-related
activity. The ICF(s)  that is/are used must be approved by both the sponsor and by the reviewing
IEC/IRB and be in a language that the participant can read and understand. The informed consent
should be in accordance with principles that originated in the Declaration of Helsinki, current ICH
and GCP guidelines, applicable regulatory requirements, and sponsor policy.
Before enrollment in the study, the investigator or an authorized member of the study-site
personnel must explain to potential participants the aims, methods, reasonably anticipated benefits,
and potential hazards of the study, and any discomfort participation in the study may entail.
Participants will be informed that their participation is voluntary and that they may withdraw
consent to participate at any time. They will be informed that choosing not to participate will not
affect the care the participant will receive for the treatment of his or her disease. Participants will
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 132
Status: 
Approved,  Date: 25 November 2021be told that alternative treatments are available if they refuse to take part and that such refusal will
not prejudice future treatment. Finally, they will be told that the investigator will maintain a
participant identification register for the purposes of long-term follow-up if needed and that their
records may be accessed by health authorities and authorized sponsor personnel without violating
the confidentiality of the participant, to the extent permitted by the applicable law(s)  or regulations.
By signing the ICF the participant is authorizing such access. It also denotes that the participant
agrees to allow his or her study physician to recontact the participant for the purpose of obtaining
consent for additional safety evaluations, and subsequent disease-related treatments, if needed.
The participant will be given sufficient time to read the ICF and the opportunity to ask questions.
After this explanation and before entry into the study, consent should be appropriately recorded
by means of the participant's personally dated signature. After having obtained the consent, a copy
of the ICF must be given to the participant.
Where local regulations require, a separate ICF may be used for the required DNA component of
the study.
If the participant is unable to read or write, an impartial witness should be present for the entire
informed consent process (which includes reading and explaining all written information)  and
should personally date and sign the ICF after the oral consent of the participant is obtained.
DATA PROTECTION
Privacy of Personal Data
The collection and processing of personal data from participants enrolled in this study will be
limited to those data that are necessary to fulfill the objectives of the study.
These data must be collected and processed with adequate precautions to ensure confidentiality
and compliance with applicable data privacy protection laws and regulations. Appropriate
technical and organizational measures to protect the personal data against unauthorized disclosures
or access, accidental or unlawful destruction, or accidental loss or alteration must be put in place.
Sponsor personnel whose responsibilities require access to personal data agree to keep the identity
of participants confidential.
The informed consent obtained from the participant includes explicit consent for the processing of
personal data and for the investigator/institution to allow direct access to his or her original medical
records (source data/documents)  for study-related monitoring, audit, IEC/IRB review, and
regulatory inspection. This consent also addresses the transfer of the data to other entities and to
other countries.
The participant has the right to request through the investigator access to his or her personal data
and the right to request rectification of any data that are not correct or complete. Reasonable steps
will be taken to respond to such a request, taking into consideration the nature of the request, the
conditions of the study, and the applicable laws and regulations.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 133
Status: 
Approved,  Date: 25 November 2021Exploratory DNA, PK/PD, and biomarker research is not conducted under standards appropriate
for the return of data to participants. In addition, the sponsor cannot make decisions as to the
significance of any findings resulting from exploratory research. Therefore, exploratory research
data will not be returned to participants or investigators, unless required by law or local regulations.
Privacy and confidentiality of data generated in the future on stored samples will be protected by
the same standards applicable to all other clinical data.
LONG-TERM RETENTION OF SAMPLES FOR ADDITIONAL FUTURE RESEARCH
Samples collected in this study may be stored for up to 15 years (or according to local regulations)
for additional research. Samples will only be used to understand JNJ-3989 and JNJ-6379,the NAs
(ETV, tenofovir disoproxil, and TAF) , and PegIFN-α2a, to understand chronic HBV infection, to
understand differential intervention responders, and to develop tests/assays related to JNJ-3989
and JNJ-6379 the NAs (ETV, tenofovir disoproxil, and TAF) , and chronic HBV infection. The
research may begin at any time during the study or the post-study storage period.
Stored samples will be coded throughout the sample storage and analysis process and will not be
labeled with personal identifiers. Participants may withdraw their consent for their samples to be
stored for research (refer to Section 7.2.1) .
COMMITTEES STRUCTURE
Independent Flare Expert Panel
An IFLEP will be appointed for this study. The IFLEP is composed of 3 independent medical
experts with experience and expertise in hepatitis B and its treatment. The IFLEP will monitor
ALT flares and will make recommendations regarding flare management based on an analysis of
aggregate data.
In order to allow for an unbiased assessment, members of the committee will not serve as study
investigators
Further details on the IFLEP process will be included in the IFLEP charter.
PUBLICATION POLICY/DISSEMINATION OF CLINICAL STUDY DATA
All information, including but not limited to information regarding JNJ-3989 and JNJ-6379 or the
sponsor's operations (eg, patent application, formulas, manufacturing processes, basic scientific
data, prior clinical data, formulation information)  supplied by the sponsor to the investigator and
not previously published, and any data, including pharmacogenomic or exploratory biomarker
research data, generated as a result of this study, are considered confidential and remain the sole
property of the sponsor. The investigator agrees to maintain this information in confidence and use
this information only to accomplish this study and will not use it for other purposes without the
sponsor's prior written consent.
The investigator understands that the information developed in the study will be used by the
sponsor in connection with the continued development ofJNJ-3989 and JNJ-6379, and thus may
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 134
Status: 
Approved,  Date: 25 November 2021be disclosed as required to other clinical investigators or regulatory agencies. To permit the
information derived from the clinical studies to be used, the investigator is obligated to provide
the sponsor with all data obtained in the study.
The results of the study will be reported in a Clinical Study Report generated by the sponsor and
will contain data from all study sites that participated in the study as per protocol. Recruitment
performance or specific expertise related to the nature and the key assessment parameters of the
study will be used to determine a coordinating investigator for the study. Results of
pharmacogenomic or exploratory biomarker analyses performed after the Clinical Study Report
has been issued will be reported in a separate report and will not require a revision of the Clinical
Study Report.
Study participant identifiers will not be used in publication of results. Any work created in
connection with performance of the study and contained in the data that can benefit from copyright
protection (except any publication by the investigator as provided for below)  shall be the property
of the sponsor as author and owner of copyright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal
Editors (ICMJE)  guidelines, the sponsor shall have the right to publish such primary (multicenter)
data and information without approval from the investigator. The investigator has the right to
publish study site-specific data after the primary data are published. If an investigator wishes to
publish information from the study, a copy of the manuscript must be provided to the sponsor for
review at least 60 days before submission for publication or presentation. Expedited reviews will
be arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in
writing, the investigator will withhold such publication for up to an additional 60 days to allow for
filing of a patent application. In the event that issues arise regarding scientific integrity or
regulatory compliance, the sponsor will review these issues with the investigator. The sponsor will
not mandate modifications to scientific content and does not have the right to suppress information.
For multicenter study designs and sub-study approaches, secondary results generally should not
be published before the primary endpoints of a study have been published. Similarly, investigators
will recognize the integrity of a multicenter study by not submitting for publication data derived
from the individual study site until the combined results from the completed study have been
submitted for publication, within 18 months after the study end date, or the sponsor confirms there
will be no multicenter study publication. Authorship of publications resulting from this study will
be based on the guidelines on authorship, such as those described in the ICMJE Recommendations
for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals, which
state that the named authors must have made a significant contribution to the conception or design
of the work; or the acquisition, analysis, or interpretation of the data for the work; and drafted the
work or revised it critically for important intellectual content; and given final approval of the
version to be published; and agreed to be accountable for all aspects of the work in ensuring that
questions related to the accuracy or integrity of any part of the work are appropriately investigated
and resolved.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 135
Status: 
Approved,  Date: 25 November 2021Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as required
by law. The disclosure of the final study results will be performed after the end of study in order
to ensure the statistical analyses are relevant.
DATA QUALITY ASSURANCE
Data Quality Assurance/Quality Control
Steps to be taken to ensure the accuracy and reliability of data include the selection of qualified
investigators and appropriate study sites, review of protocol procedures with the investigator and
study-site personnel before the study, periodic monitoring visits by the sponsor, and direct
transmission of clinical laboratory data from a central laboratory to the sponsor's data base. Written
instructions will be provided for collection, handling, storage, and shipment of samples.
Guidelines for CRF completion will be provided and reviewed with study-site personnel before
the start of the study.
The sponsor will review CRF for accuracy and completeness during on-site monitoring visits and
after transmission to the sponsor; any discrepancies will be resolved with the investigator or
designee, as appropriate. After upload of the data into the study database they will be verified for
accuracy and consistency with the data sources.
CASE REPORT FORM COMPLETION
Case report forms are prepared and provided by the sponsor for each participant in electronic
format. All data relating to the study must be recorded in CRF. All CRF entries, corrections, and
alterations must be made by the investigator or authorized study-site personnel. The investigator
must verify that all data entries in the CRF are accurate and correct.
The study data will be transcribed by study-site personnel from the source documents onto an
electronic CRF, if applicable. Study-specific data will be transmitted in a secure manner to the
sponsor.
Worksheets may be used for the capture of some data to facilitate completion of the CRF. Any
such worksheets will become part of the participant's source documents. Data must be entered into
CRF in English. The CRF must be completed as soon as possible after a participant visit and the
forms should be available for review at the next scheduled monitoring visit.
All participative measurements (eg, pain scale information or other questionnaires)  will be
completed by the same individual who made the initial baseline determinations whenever possible.
If necessary, queries will be generated in the electronic data capture (eDC) tool. If corrections to
a CRF are needed after the initial entry into the CRF, this can be done in either of the following
ways:
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 136
Status: 
Approved,  Date: 25 November 2021 Investigator and study-site personnel can make corrections in the eDC tool at their own
initiative or as a response to an auto query (generated by the eDC tool) .
 Sponsor or sponsor delegate can generate a query for resolution by the investigator and study-
site personnel.
SOURCE DOCUMENTS
At a minimum, source documents consistent in the type and level of detail with that commonly
recorded at the study site as a basis for standard medical care must be available for the following:
participant identification, eligibility, and study identification; study discussion and date of signed
informed consent; dates of visits; dates of blood collection, date and time of start and end of
leukapheresis, results of safety and efficacy parameters as required by the protocol; record of all
adverse events and follow-up of adverse events; concomitant medication; intervention
receipt/dispensing/return records; study intervention administration information; and date of study
completion and reason for early discontinuation of investigational interventionor withdrawal from
the study, if applicable.
The author of an entry in the source documents should be identifiable.
Specific details required as source data for the study and source data collection methods will be
reviewed with the investigator before the study and will be described in the monitoring guidelines
(or other equivalent document) .
The following data will be recorded directly into the CRF and will be considered source data:
 Race
 Blood pressure and pulse/heart rate
 Height and weight
 Details of physical examination
The minimum source documentation requirements for Section 5.1and Section 5.2that specify a
need for documented medical history are as follows:
 Referral letter from treating physician or
 Complete history of medical notes at the site
 Discharge summaries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a
minimum by participant interview or other protocol required assessment (eg, physical
examination, laboratory assessment)  and documented in the source documents.
An eSource system may be utilized, which contains data traditionally maintained in a hospital or
clinic record to document medical care (eg, electronic source documents)  as well as the clinical
study-specific data fields as determined by the protocol. This data is electronically extracted for
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 137
Status: 
Approved,  Date: 25 November 2021use by the sponsor. If eSource is utilized, references made to the CRF in the protocol include the
eSource system but information collected through eSource may not be limited to that found in the
CRF.
MONITORING
The sponsor will use a combination of monitoring techniques (central, remote, or on-site
monitoring)to monitor this study.
The sponsor will perform on-site monitoring visits as frequently as necessary. The monitor will
record dates of the visits in a study site visit log that will be kept at the study site. The first
post-initiation visit will be made as soon as possible after enrollment has begun. At these visits,
the monitor will compare the data entered into the CRF with the source documents
(eg, hospital/clinic/physician’s office medical records) ; a sample may be reviewed. The nature and
location of all source documents will be identified to ensure that all sources of original data
required to complete the CRF are known to the sponsor and study-site personnel and are accessible
for verification by the sponsor study-site contact. If electronic records are maintained at the study
site, the method of verification must be discussed with the study-site personnel.
Direct access to source documents (medical records)  must be allowed for the purpose of verifying
that the recorded data are consistent with the original source data. Findings from this review will
be discussed with the study-site personnel. The sponsor expects that, during monitoring visits, the
relevant study-site personnel will be available, the source documents will be accessible, and a
suitable environment will be provided for review of study-related documents. The monitor will
meet with the investigator on a regular basis during the study to provide feedback on the study
conduct.
In addition to on-site monitoring visits, remote contacts can occur. It is expected that during these
remote contacts, study-site personnel will be available to provide an update on the progress of the
study at the site.
Central monitoring will take place for data identified by the sponsor as requiring central review.
ON-SITE AUDITS
Representatives of the sponsor's clinical quality assurance department may visit the study site at
any time during or after completion of the study to conduct an audit of the study in compliance
with regulatory guidelines and company policy. These audits will require access to all study
records, including source documents, for inspection. Participant privacy must, however, be
respected. The investigator and study-site personnel are responsible for being present and available
for consultation during routinely scheduled study-site audit visits conducted by the sponsor or its
designees.
Similar auditing procedures may also be conducted by agents of any regulatory body, either as part
of a national GCP compliance program or to review the results of this study in support of a
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 138
Status: 
Approved,  Date: 25 November 2021regulatory submission. The investigator should immediately notify the sponsor if he or she has
been contacted by a regulatory agency concerning an upcoming inspection.
RECORD RETENTION
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all CRF and
all source documents that support the data collected from each participant, as well as all study
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a Clinical
Trial, and all study documents as specified by the applicable regulatory requirement(s) . The
investigator/institution will take measures to prevent accidental or premature destruction of these
documents.
Essential documents must be retained until at least 2 years after the last approval of a marketing
application in an ICH region and until there are no pending or contemplated marketing applications
in an ICH region or until at least 2 years have elapsed since the formal discontinuation of clinical
development of the investigational product. These documents will be retained for a longer period
if required by the applicable regulatory requirements or by an agreement with the sponsor. It is the
responsibility of the sponsor to inform the investigator/institution as to when these documents no
longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the
responsibility of keeping the study records, custody must be transferred to a person who will accept
the responsibility. The sponsor must be notified in writing of the name and address of the new
custodian. Under no circumstance shall the investigator relocate or dispose of any study documents
before having obtained written approval from the sponsor.
If it becomes necessary for the sponsor or the appropriate regulatory authority to review any
documentation relating to this study, the investigator/institution must permit access to such reports.
STUDY AND SITE START AND CLOSURE
First Act of Recruitment
The first site open is considered the first act of recruitment and it becomes the study start date.
Study Termination
The sponsor reserves the right to close the study site or terminate the study at any time for any
reason at the sole discretion of the sponsor. Study sites will be closed upon study completion. A
study site is considered closed when all required documents and study supplies have been collected
and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time, provided there is reasonable cause and
sufficient notice is given in advance of the intended termination.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 139
Status: 
Approved,  Date: 25 November 2021Reasons for the early closure of a study site by the sponsor or investigator may include but are not
limited to:
 Failure of the investigator to comply with the protocol, the requirements of the IEC/IRB or
local health authorities, the sponsor's procedures, or GCP guidelines
 Inadequate recruitment of participants by the investigator
 Discontinuation of further study intervention development
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 140
Status: 
Approved,  Date: 25 November 202110.4 . Appendix 4 : Adverse Events: Definitions and Procedures for Recording,
Evaluating, Follow-up, and Reporting
ADVERSE EVENT DEFINITIONS AND CLASSIFICATIONS
Adverse Event
An AEis any untoward medical occurrence in a clinical study participant administered a medicinal
(investigational or non-investigational)  product. An AE does not necessarily have a causal
relationship with the intervention. An AE can therefore be any unfavorable and unintended sign
(including an abnormal finding) , symptom, or disease temporally associated with the use of a
medicinal (investigational or non-investigational)  product, whether or not related to that medicinal
(investigational or non-investigational)  product. (Definition per ICH)
This includes any occurrence that is new in onset or aggravated in severity or frequency from the
baseline condition, or abnormal results of diagnostic procedures, including laboratory test
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to All Adverse
Events under Section 8.5.1for time of last AE recording) .
Serious Adverse Event
A SAEbased on ICH and EU Guidelines on Pharmacovigilance for Medicinal Products for Human
Use is any untoward medical occurrence that at any dose:
 Results in death
 Is life-threatening
(The participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically might have caused death if it were more severe.)
 Requires inpatient hospitalization or prolongation of existing hospitalization
 Results in persistent or significant disability/incapacity
 Is a congenital anomaly/birth defect
 Is a suspected transmission of any infectious agent via a medicinal product
 Is Medically Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is also appropriate in
other situations, such as important medical events that may not be immediately life threatening or result in death or
hospitalization but may jeopardize the participant or may require intervention to prevent one of the other outcomes
listed in the definition above. These should usually be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal
relationship between the study intervention and the event (eg, death from anaphylaxis) , the event
must be reported as a serious and unexpected suspected adverse reaction even if it is a component
of the study endpoint (eg, all-cause mortality) .
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 141
Status: 
Approved,  Date: 25 November 2021Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity is not consistent with the applicable
product reference safety information. For JNJ-3989 and JNJ-6379, the expectedness of an adverse
event will be determined by whether or not it is listed in the IB. For ETV, tenofovir disoproxil,
and TAF with a marketing authorization, the expectedness of an adverse event will be determined
by whether or not it is listed in the package insert.
ATTRIBUTION DEFINITIONS
Assessment of Causality
The causal relationship to study intervention is determined by the Investigator. The following
selection should be used to assess all AEs.
Related
There is a reasonable causal relationship between study intervention administration and the AE.
Not Related
There is not a reasonable causal relationship between study intervention administration and the
AE.
The term "reasonable causal relationship" means there is evidence to support a causal relationship.
SEVERITY CRITERIA
An assessment of severity grade will be made by the investigator using the general categorical
descriptors outlined in the DAIDS Toxicity Grading Scale (see Section 10.9, Appendix 9, DAIDS
Table) .
SPECIAL REPORTING SITUATIONS
Safety events of interest on a sponsor study intervention in an interventional studythat may require
expedited reporting or safety evaluation include, but are not limited to:
 Overdose of a sponsor study intervention
 Suspected abuse/misuse of a sponsor study intervention
 Accidental or occupational exposure to a sponsor study intervention
 Medication error, intercepted medication error, or potential medication error involving a
sponsormedicinal product (with or without patient exposure to the sponsormedicinal product,
eg, product name confusion, product label confusion, intercepted prescribing or dispensing
errors)
 Exposure to a sponsor study intervention from breastfeeding
Special reporting situations should be recorded in the CRF. Any special reporting situation that
meets the criteria of a SAE should be recorded on the SAE page of the CRF.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 142
Status: 
Approved,  Date: 25 November 2021PROCEDURES
All Adverse Events
All adverse events, regardless of seriousness, severity, or presumed relationship to study
intervention, must be recorded using medical terminology in the source document and the CRF.
Whenever possible, diagnoses should be given when signs and symptoms are due to a common
etiology (eg, cough, runny nose, sneezing, sore throat, and head congestion should be reported as
"upper respiratory infection") . Investigators must record in the CRF their opinion concerning the
relationship of the adverse event to study therapy. All measures required for adverse event
management must be recorded in the source document and reported according to sponsor
instructions.
In the context of this study, AEs and SAEs associated with/triggered by the liver biopsies,
leukapheresis, or blood collection procedures are to be reported to the sponsor.
For all studies with an outpatient phase, including open-label studies, the participant must be
provided with a "wallet (study)  card" and instructed to carry this card with them for the duration
of the study indicating the following:
 Study number
 Statement, in the local language(s) , that the participant is participating in a clinical study
 Investigator's name and 24-hour contact telephone number
 Local sponsor's name and 24-hour contact telephone number (for medical personnel only)
 Site number
 Participant number
 Any other information that is required to do an emergency breaking of the blind
Serious Adverse Events
All SAEs that have not resolved by the end of the study, or that have not resolved upon
discontinuation of the participant's participation in the study, must be followed until any of the
following occurs:
 The event resolves
 The event stabilizes
 The event returns to baseline, if a baseline value/status is available
 The event can be attributed to agents other than the study intervention or to factors unrelated
to study conduct
 It becomes unlikely that any additional information can be obtained (participant or health care
practitioner refusal to provide additional information, lost to follow-up after demonstration of
due diligence with follow-up efforts)
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 143
Status: 
Approved,  Date: 25 November 2021Suspected transmission of an infectious agent by a medicinal product will be reported as a SAE.
Any event requiring hospitalization (or prolongation of hospitalization)  that occurs during the
course of a participant's participation in a study must be reported as a SAE, except hospitalizations
for the following:
 Hospitalizations not intended to treat an acute illness or adverse event (eg, social reasons such
as pending placement in long-term care facility)
 Surgery or procedure planned before entry into the study (must be documented in the CRF) .
Note: Hospitalizations that were planned before the signing of the ICF, and where the
underlying condition for which the hospitalization was planned has not worsened, will not be
considered SAEs. Any adverse event that results in a prolongation of the originally planned
hospitalization is to be reported as a new SAE.
The cause of death of a participant in a study, whether or not the event is expected or associated
with the study intervention, is considered an SAE.
CONTACTING SPONSOR REGARDING SAFETY
The names (and corresponding telephone numbers)  of the individuals who should be contacted
regarding safety issues or questions regarding the study are listed in the Contact Information
page(s) , which will be provided as a separate document.
PRODUCT QUALITY COMPLAINT HANDLING
A product quality complaint (PQC)  is defined as any suspicion of a product defect related to
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity, quality,
durability, or reliability of a product, including its labeling or package integrity. A PQC may have
an impact on the safety and efficacy of the product. Timely, accurate, and complete reporting and
analysis of PQC information from studies are crucial for the protection of participants,
investigators, and the sponsor, and are mandated by regulatory agencies worldwide. The sponsor
has established procedures in conformity with regulatory requirements worldwide to ensure
appropriate reporting of PQC information; all studies conducted by the sponsor or its affiliates will
be conducted in accordance with those procedures.
Procedures
All initial PQCs must be reported to the sponsor by the study-site personnel within 24 hours after
being made aware of the event.
If the defect is combined with a SAE, the study-site personnel must report the PQC to the sponsor
according to the SAE reporting timelines (refer to Section 8.5.1) . A sample of the suspected
product should be maintained for further investigation if requested by the sponsor.
Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers)  of the individuals who should be contacted
regarding product quality issues are listed in the Contact Information page(s) , which will be
provided as a separate document.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 144
Status: 
Approved,  Date: 25 November 202110.5. Appendix 5: Rash Management
Table 6: Management of Rash Events by Severity Grade
Definition Study
Intervention
ActionActivities by DayaReferral to
Dermatologist and
Dermatology Activities
Grade 
1 rash
(with or
without
pruritus)bErythema Study intervention
intake may be
continued at the
investigator’s
discretionDay 0: optional on site visit for initial rash evaluation may be
perform
ed at the investigator’s discretion.
Safety laboratory assessments may be performed at the investigator’s
discretion (recommended if visit occurs) .
Digital pictures* of skin lesions may be taken at the investigator’s
discretion.
Determine if participant was adhering to the recommended sun-
protective measures. If appropriate, provide sun protection
counseling.
Day 1 and thereafter: appropriate follow-up visits at the investigator’s
discre
tion until resolution of rash.
Safety laboratory assessments and photography (digital pictures* of
skin lesions)  may be performed at the investigator’s discretion.
* Digital pictures to be taken at the clinical site upon consent of the
participant.Not required
Grade 
2 rash
(with or without
pruritus)bDiffuse,
maculopapular rash,
or dry desquamationStudy intervention
intake may be
continued at the
investigator’s
discretionDay 0: required on-site visit (if a visit is not possible, telephone
contac
t with the participant should take place to collect information
and give advice on the necessary measures to be taken) .
Safety laboratory assessments may be performed at the investigator’s
discretion (recommended) .
Digital pictures* of skin lesions may be taken at the investigator’s
discretion. Digital pictures* of skin lesions are recommended in case
consultation of a dermatologist is required. Determine if participant
was adhering to the recommended sun-protective measures. If
appropriate, provide sun protection counseling.
Day 1 and thereafter: appropriate follow-up visits at the investigator’s
discre
tion until resolution of rash or until clinical stability is reached.Referral to dermatologist
at the discretion of the
investigatorc
Biopsy not required, but
may be performed at the
dermatologist’s
discretion
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 145
Status: 
Approved,  Date: 25 November 2021Table 6: Management of Rash Events by Severity Grade
Definition Study
Intervention
ActionActivities by Daya Referral to
Dermatologist and
Dermatology Activities
Safety 
laboratory assessments are required on Day 1 and are required
thereafter only if the previous values were abnormal (but may be
performed at the investigator’s discretion) . If the rash progresses to a
higher grade, safety laboratory assessments of the higher grade should
be followed.
Digital pictures* of skin lesions may be taken at the investigator’s
discretion.
* Digital pictures to be taken at the clinical site upon consent of the
participant.
Grade 
3 rashb Vesiculation, moist
desquamation, or
ulceration OR
Any cutaneous event
with 1 of the
following:
- Elevations in
AST/ALT
>2×baseline
value
- Fever >38°C or
100°F
- Eosinophils
>1.00×103/µL
- Serum sickness-
like reactionMust permanently
discontinue
JNJ-3989; no
rechallenge
allowed
NA treatment may
be discontinued
based on
investigator
judgement in
consultation with
the sponsorDay 0: required on-site visit.
Safety 
laboratory assessments required to be performed.
Digital pictures* of skin lesions may be taken at the investigator’s
discretion (recommended) .
Determine if participant was adhering to the recommended sun-
protective measures. If appropriate, provide sun protection
counseling.
Day 1: required on-site visit.
Safety 
laboratory assessments required to be performed.
Digital pictures* of skin lesions may be taken at the investigator’s
discretion (recommended) .
Further visit(s) : appropriate follow-up required until resolution of rash
or unti
l clinical stability is reached.
Safety laboratory assessments and photography (digital pictures* of
skin lesions)  are recommended to be performed until the rash severity
resolves to grade 2 or grade 1.
* Digital pictures to be taken at the clinical site upon consent of the
participant.Requiredc
Biopsy not required, but
may be performed at the
dermatologist’s
discretion.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 146
Status: 
Approved,  Date: 25 November 2021Table 6: Management of Rash Events by Severity Grade
Definition Study 
Intervention 
Action Activities by Daya Referral to
Dermatologist and
Dermatology Activities
Grade 
4 rash Exfoliative 
dermatitis OR  
Mucous membrane
involvement in at
least 2 distinct sites
OR  
Erythema multiforme
major OR
Stevens-Johnson 
syndrome OR  
Toxic epidermal
necrolysis OR  
Necrosis requiring 
surgery Must permanently 
discontinue
JNJ-3989; no
rechallenge
allowed
NA treatment may 
be discontinued
based on
investigator
judgement in
consultation with 
the sponsorDay 0: required on-site visit. 
Safety 
laboratory assessments required to be performed.
Digital pictures* of skin lesions may be taken at the investigator’s
discretion (recommended) .
Determine if participant was adhering to the recommended sun-
protective measures. If appropriate, provide sun protection
counseling.
Day 1: required on-site visit.
Safety 
laboratory assessments required to be performed.
Digital pictures* of skin lesions may be taken at the investigator’s
discretion (recommended) .
Further visit(s) : appropriate follow-up required until resolution of rash
or unti
l clinical stability is reached.
Safety laboratory assessments and photography (digital pictures* of
skin lesions)  are recommended to be performed until the rash severity
resolves to grade 2 or grade 1.
* Digital pictures to be taken at the clinical site upon consent of the
participant.Requiredc
Biopsy required and to
be performed as soon as
possible after the onset
of the rash.
AE: adv
erse event; ALT: alanine aminotransferase; AST: aspartate aminotransferase; NA: nucleos(t) ide analog.
a Day 0 of the rash is the first day of investigator assessment and not the first day of rash as reported by the participant. The initial visit should be conducted as soon
as possible after the participant contacts the investigator to report the AE (ie, preferably on Day 0) . The initial visit and subsequent visits to manage the rash may
require unscheduled visit(s) .
b The participant should be advised to contact the investigator immediately if there is any worsening of the rash, if any systemic signs or symptoms appear, or if
mucosal involvement develops. In case the rash evolves to a higher grade than that first observed, management of the rash should follow the guidelines indicated
for the higher grade.
c If applicable, dermatologist visit should occur preferably within 24 hours after onset of rash.
Notes:
 L
ocal laboratory assessments are to be used for rash management. The values of the local laboratory assessments need to be transcribed in the eCRF by the study site
personnel.
 Digital pictures that are collected, dermatological consultation reports or biopsy reports that become available, should be de-identified and provided to the sponsor.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 147
Status: 
Approved,  Date: 25 November 202110.6. Appendix 6: Intervention-emergent ALT/AST Elevations
a Additional tests may be considered based on clinical judgement in case of confirmed ALT flares:
 Hepatitis A, D, C, E: IgM anti-HAV; delta IgM, IgG & PCR, HCV RNA, IgM & IgG anti-HEV, HEV RNA
 CMV, HSV, EBV infection: IgM & IgG anti-CMV, IgM & IgG anti-HSV; IgM & IgG anti-EBV, PCR
 HIV
 Ig-electrophoresis

JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 148
Status: 
Approved,  Date: 25 November 202110.7. Appendix 7: Cardiovascular Safety Abnormalities
ECG
All im
portant abnormalities from the ECG readings will be listed.
Abnormality Code ECG parameter
Heart 
Rate PR  QRS QTcorrected
Abnormali
ties on actual values
Abnormal
ly low  <45 bpm  NAP - -
Abnormal
ly high 120 bpm  >220 ms 120 ms -
Borderli
ne prolonged QT - - - 450 ms < QTc ≤480 ms
Prolon
ged QT - - - 480 ms < QTc <500 ms
Pathol
ogically prolonged QT - - - QTc >500 ms
Abnormali
ties on changes f rom baseline ( ∆QTc)
Normal
 QTc change - - - ∆QTc <30 ms
Borderli
ne QTc change - - - 30 ms < ∆QTc <60 ms
Abnormal
ly high QTc change - - - ∆QTc >60 ms
ECG: el
ectrocardiogram; NAP = not applicable
For absolute QTc parameters the categories are defined based on the ICH E14 Guidance Fa
Vital Signsb
The fo
llowing abnormalities will be defined for vital signs:
Abnormality Code Vital Signs parameter
Pulse DB
P SBP
Abnormali
ties on actual values
Abnormal
ly low  45 bpm  50 mmHg 90 mmHg
Grade 
1 or mild - >90 mmHg - <100 mmHg >140 mmHg - <160 mmHg
Grade 
2 or moderate - 100 mmHg - <110 mmHg 160 mmHg - <180 mmHg
Grade 
3 or severe - 110 mmHg 180 mmHg
Abnormal
ly high 120 bpm  - -
DBP: dia
stolic blood pressure; SBP: systolic blood pressure
a The cl
inical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs
CHMP/ICH/2/04, May 2005.
b The classification of AEs related to hypotension and hypertension will be done according to the DAIDS grading
scale.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 149
Status: 
Approved,  Date: 25 November 202110.8. Appendix 8: Contraceptive and Barrier Guidance and Collection of
Pregnancy Information
Participants must follow contraceptive measures as outlined in Section 5.1. Pregnancy information
will be collected and reported as noted in Section 8.5.5 and Section 10.4, Appendix 4 Adverse
Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting.
Definitions
W oman of  Childbearing Potential (W OCBP)
A woman is considered fertile following menarche and until becoming postmenopausal unless
permanently sterile (see below) .
W oman Not of  Childbearing Potential
 premenarchal
A premenarchal state is one in which menarche has not yet occurred.
 postmenopausal
A postmenopausal state is defined as no menses for 12 months without an alternative medical
cause. A high FSH level (>40 IU/L or mIU/mL)  in the postmenopausal range may be used to
confirm a postmenopausal state in women not using hormonal contraception or hormonal
replacement therapy (HRT) , however in the absence of 12 months of amenorrhea, a single
FSH measurement is insufficient. If there is a question about menopausal status in women on
HRT, the woman will be required to use one of the non-estrogen-containing hormonal highly
effective contraceptive methods if she wishes to continue HRT during the study.
 permanently sterile
Permanent sterilization methods include hysterectomy, bilateral salpingectomy, or bilateral
oophorectomy.
Note: If the childbearing potential changes after start of the study (eg, a premenarchal woman
experiences menarche)  or the risk of pregnancy changes (eg, a woman who is not heterosexually
active becomes active) , a woman must begin a highly effective method of contraception, as
described throughout the inclusion criteria.
If reproductive status is questionable, additional evaluation should be considered.
Contraceptive (birth control)  use by men or women should be consistent with local regulations
regarding the acceptable methods of contraception for those participating in clinical studies.
Typical use failure rates may differ from those when used consistently and correctly. Use should
be consistent with local regulations regarding the use of contraceptive methods for participants in
clinical studies.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 150
Status: A
pproved,  Date: 25 November 2021Examples of Contraceptives
EXAMPLES OF CONTRACEPTIVESa ALLOWED DURING THE STUDY  INCLUDE:
USER INDE
PENDENT
Highly Effective Methods That Are User Independent Failure rate of  <1% per year when used
consistently andcorrectly.
 Implant
able progestogen-only hormone contraception associated with inhibition of ovulationb
 Intraut
erine device (IUD)
 Intraut
erine hormone-releasing system (IUS)
 Tubal c
losure (eg, bilateral tubal occlusion, bilateral tubal ligation)
 Azoospe
rmic partner (vasectomized or due to medical cause)
(V asectomized partner is a highly ef f ective contraceptive method provided that the partner is the
sole sexual partner of  the woman of  childbearing potential and the absence of  sperm has been
conf irmed. If  not, additional highly ef f ective method of  contraception should be used.
Spermatogenesis cycle is approximately 74 days.)
USER DEPEN
DENT
Highly Effective Methods That Are User Dependent Failure rate of  <1% per year when used
consistently and corr ectly.
 Combine
d (estrogen- and progestogen-containing)  hormonal contraception associated with
inhibition of ovulationb
 oral
 intravaginal
 transdermal
 injectable
 Progest
ogen-only hormone contraception associated with inhibition of ovulationb
 oral
 injectable
 Sexual 
abstinence
(Sexual abstinence is considered a highly ef f ective method only if  def ined as ref raining f rom
heterosexual intercourse during the entire period of  risk associated with the study intervention.
The reliability of  sexual abstinence needs to be evaluated in relation to the duration of  the study
and the pref erred and usual lif estyle of  the participant.)
a) Typi
cal use failure rates may differ from those when used consistently and correctly. Use should be
consistent with local regulations regarding the use of contraceptive methods for participants in
clinical studies.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 151
Status: 
Approved,  Date: 25 November 202110.9. Appendix 9: DAIDS Table
DIVISION OF AIDS (DAIDS) TABLE FOR GRADING THE SEVERITY  OF ADULT
AND PEDIATRIC ADVERSE EVENTS, VERSION 2.1, PUBLISH DATE:  JULY , 2017
The DAIDS grading table is a descriptive terminology to be utilized for AE reporting in this study.
A grading (severity)  scale is provided for each AE term.
General Instructions
Grading Adult and Pediatric Adverse Events
When a single parameter is not appropriate for grading an AE in both adult and pediatric
populations, separate parameters with specified age ranges are provided. If there is no distinction
between adult and pediatric populations, the listed parameter should be used for grading an AE in
both populations.
Determining Severity Grade f or Parameters Betw een Grades
If the severity of an AE could fall under either 1 of 2 grades (eg, the severity of an AE could be
either grade 2 or grade 3) , sites should select the higher of the 2 grades.
Laboratory normal ranges should be taken into consideration to assign gradings to a laboratory
value.
Definitions
Basic self-care functions Adults: activities such as bathing, dressing, toileting,
transf
er/movement, continence, and feeding
Young 
children: activities that are age and culturally appropriate
(eg, fe
eding self with culturally appropriate eating implements)
Usual 
social & functional 
activities Activities which adults and children perform on a routine basis and
those which are part of regular activities of daily living, for
example:
Adults
: adaptive tasks and desirable activities, such as going to
work, s
hopping, cooking, use of transportation, or pursuing a
hobby
Young 
Children: activities that are age and culturally appropriate
(eg, so
cial interactions, play activities, learning tasks)
Interv
ention Medical, surgical, or other procedures recommended or provided
by a healthcare professional for the treatment of an AE.
Estimat
ing Severity Grade f or Parameters not Identif ied in the Grading Table
The functional table below should be used to grade the severity of an AE that is not specifically
identified in the grading table. In addition, all deaths related to an AE are to be classified as grade
5.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 174
Status: 
Approved,  Date: 25 November 202110.10. Appendix 10: Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located
directly before the Table of Contents (TOC) .
Amendment 5 (01 October 2021)
Overall Rationale for the Amendment: The primary reasons for this amendment are to remove JNJ-6379
as study intervention, to add a new nucleos(t) ide analog (NA)  re-treatment criterion for participants who
discontinued NA treatment during follow-up, and to include more frequent monitoring for participants who
discontinued NA treatment during follow-up.
Based on emerging data from recent interim analyses of the REEF-1 (73763989HPB2001)  and REEF-2
(73763989PAHPB2002)  studies, the benefit-risk profile of JNJ-6379 in combination with JNJ-3989+NA
is unfavorable compared to JNJ-3989+NA.
In the primary REEF-1 analysis (Week 48, end of treatment)  the mean reduction of hepatitis B surface
antigen (HBsAg)  in the triple arm (JNJ-6379+JNJ-3989 100mg+NA)  appeared to be less than in the dual
arm (JNJ-3989 100mg+NA) . More recent interim results of the REEF-2 study (Week 48, end of treatment)
confirmed this observation when the effect of JNJ-6379+JNJ-3989 200mg+NA on mean HBsAg level
reduction in REEF-2 study is compared to JNJ-3989 200mg+NA in the REEF-1 study. To match with the
REEF-2 population, this cross-study comparison focused on the REEF-1 subpopulation of hepatitis B e
antigen (HBeAg)  negative, virologically suppressed participants with chronic hepatitis B.
Pharmacokinetic-pharmacodynamic modelling analyses accounting for variability in baseline
characteristics further support this observation. Therefore, a negative impact of JNJ-6379 on the HBsAg
lowering effect of JNJ-3989+NA is suspected.
From a safety perspective, transient reductions of eGFR based on creatinine (eGFRcr)  in JNJ-6379
containing treatment arms with fast recovery after end of treatment had been described in the Jade study
(56136379HPB2001)  and was confirmed in the REEF-1 study. In absence of a pattern of increased
biomarkers of proximal tubulo-toxicity (the beta-2microglobulin/creatinine and the retinol binding
protein/creatinine ratios) , the eGFRcr reduction during treatment was interpreted as transporter inhibition
at the level of creatinine excretion from the proximal tubule rather than renal toxicity.
Recent data from REEF-2 confirm the transient pattern of eGFRcr declines but, in addition, show an
increase of the beta-2microglobulin/creatinine and the retinol binding protein/creatinine ratios in some
participants when tenofovir disoproxil fumarate (TDF)  treatment was continued and combined with JNJ-
6379+JNJ-3989. These new data are suggesting that JNJ-6379 in combination with TDF may contribute to
renal tubulo-toxicity. There was no apparent increase in the beta-2-microglobulin/creatinine or retinol
binding protein/creatinine ratios in participants receiving ETV (active or control arm) , nor in participants
receiving TDF+placebo.
The negative impact of JNJ-6379, when combined with JNJ-3989 + NA, on HBsAg reduction taken
together with the adverse renal profile leads to conclusion of an unfavorable benefit-risk balance of JNJ-
6379 in combination with JNJ-3989+NA, compared to JNJ-3989+NA alone. Therefore, the Sponsor has
decided to discontinue treatment with JNJ-6379 in all ongoing clinical studies effective immediately.
Participants currently on treatment with JNJ-6379 will be contacted and requested to stop taking JNJ-6379,
while continuing treatment with NA, JNJ-3989 and optional PegIFN-α2a. For newly enrolled participants,
JNJ-6379 will be no longer included in the treatment regimen. 
In addition, a new NA re-treatment criterion and more frequent monitoring for participants who
discontinued NA treatment during follow-up were added. The reason for these changes is a severe clinical
alanine aminotransferase (ALT)  flare that was reported following discontinuation of NA treatment in a
virologically suppressed HBeAg negative participant on long-term TDF treatment who was randomized to
the control arm (placebo + placebo + NA)  in the REEF-2 study. The participant presented with hepatitis B
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 175
Status: 
Approved,  Date: 25 November 2021virus (HBV)  DNA levels that increased rapidly, before any relevant changes in liver markers were noted.
Discontinuation of NA treatment followed the protocol-defined criteria and was in line with recent
European Association for the Study of the Liver (EASL)  treatment guidelines.5 Flares following NA
discontinuation are not unexpected, but the rapid evolution and clinical deterioration seen in this participant
who was anti-HBe antibody positive at screening and had no history or evidence of liver cirrhosis was
unforeseeable. Therefore, to protect safety of participants, the protocol was amended as detailed below.
In addition, based on Health Authority request, it has been clarified that the follow-up phase of 48 weeks
will be extended to ensure that all study participants have at least one year of follow-up after NA treatment
cessation.
Furthermore, the eligibility criteria, the PegIFN-α2a discontinuation criteria, and the monitoring of
neuropsychiatric adverse events during PegIFN-α2a treatment were amended to be consistent with the
PegIFN-α2a prescribing information.
Other changes, clarifications and corrections were also made as detailed below.
Description of Change Brief Rationale Section Number and Name
Throug
hout the protocol, JNJ-
6379 has been removed as
study intervention.
Participants enrolled before
Protocol Amendment 5 and
who are being treated with
JNJ-3989+JNJ-6379+NA (Arm
1 in Panel 1 and Panel 2)  had to
stop JNJ-6379 treatment
immediately. They will
continue with JNJ-3989+NA
treatment up to the end of the
48-week open-label study
intervention phase and will then
enter the follow-up phase
during which they stop
treatment with JNJ-3989 and
NA if completion criteria are
met. Throughout the protocol,
elements specific for JNJ-6379
have been modified.Based on emerging data
from recent interim analyses
of the REEF-1 and REEF-2
studies, showing that the
benefit-risk profile of JNJ-
6379 in combination with
JNJ-3989+NA is
unfavorable compared to
JNJ-3989+NA.1.1 Synopsis
1.2 Schema
1.3.1 Schedule of Activities   Screening and
Study Intervention Phase
2 INTRODUCTION
2.1 Study Rationale
2.2 Background
2.3 Benefit-Risk Assessment
2.3.2.2.2 Potential Risks for JNJ-6379
2.3.3 Benefit-risk Assessment for Study
Participation
3 OBJECTIVES AND ENDPOINTS
4.1 Overall Design
4.2 Scientific Rationale for Study Design
4.3 Justification for Dose
4.3.2 JNJ-6379
5.1 Inclusion Criteria
5.2 Exclusion Criteria
6.1 Study Intervention(s)  Administered
6.2
Preparation/Handling/Storage/Accountability
6.3 Measures to Minimize Bias:
Randomization and Blinding
6.4 Study Intervention Compliance
6.5 Concomitant Therapy
6.6 Dose Modification
6.6.1 Study Intervention Completion at Week
48
7.1 Discontinuation of Study Intervention
8 STUDY ASSESSMENTS AND
PROCEDURES
8.4.4 Clinical Safety Laboratory
Assessments8.5.5 Pregnancy8.5.6 Adverse
Events of Special Interest
8.5.7 Other Toxicities
8.6 Treatment of Overdose
8.7 Pharmacokinetics
8.7.1 Evaluations
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 176
Status: 
Approved,  Date: 25 November 20218.7.3 Pharmacokinetic Parameters and
Evaluations
8.8 Pharmacokinetics/Pharmacodynamics
9.2 Sample Size Determination
9.3 Populations for Analyses
9.4 Statistical Analyses
9.4.1 Analysis ofEfficacy and Antiviral
Activity
9.4.2 Safety Analyses
9.4.3 Other Analyses
10.1 Appendix 1: Abbreviations and
Definitions of Terms
10.5 Appendix 5: Rash Management
10.6 Appendix 6: Intervention-emergent
ALT/AST Elevations
A new 
NA re-treatment 
criterion was added for 
participants who discontinued 
NA treatment during follow-up. To ensure that participants 
with significant HBV DNA 
increases during treatment- 
free follow-up are monitored 
at least weekly and/or
immediately re-start NA
treatment irrespective of
ALT levels. 1.1 Synopsis
1.3.2 Schedule of Activities   Follow-up Phase
4.2 Scientific Rationale for Study Design
6.6.2 NA Re-treatment Criteria During Follow-
up
7.1 Discontinuation of Study Intervention
8.5.6.2 Intervention-emergent ALT/AST
Elevations
10.12 Appendix 12: NA Re-treatment During
Follow-up
Partic
ipants who discontinue 
NA treatment during follow-up, 
will be monitored more 
frequently, with a study visit at 
least once every 4 weeks. 
The visit frequency for 
participants who continue NA 
treatment or have restarted NA
treatment during the follow-up
period and for whom the HBV
DNA and ALT values are
stable remains at least once
every 12 weeks.
For participants with increased
follow-up, the total blood
volume to be collected during
the study will increase.To further protect the safety 
of participants. 1.3.2 Schedule of Activities   Follow-up Phase
2.3.2.2 Potential Risks
6.7 Study Intervention After the End of the
Study
7.1 Discontinuation of Study Intervention
8 STUDY ASSESSMENTS AND
PROCEDURES
A note
 has been added to 
clarify that the follow-up phase 
of 48 weeks will be extended 
with a maximum of 24 weeks 
(ie, up to Follow-up Week 72)  
to ensure that all study 
participants have at least one 
year of follow-up after NA 
treatment cessation. 
The end of study definition and 
study completion definitions
were updated to include this
possible extension.
For participants with extended
follow-up, the total bloodUpon Health authority 
request. 1.1 Synopsis
1.2 Schema
1.3.2 Schedule of Activities   Follow-up Phase
4.1 Overall Design
4.2 Scientific Rationale for Study Design
4.4 End of Study Definition
6.6.1 Study Intervention Completion at Week
48
8 STUDY ASSESSMENTS AND
PROCEDURES
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 177
Status: 
Approved,  Date: 25 November 2021volume to be collected during
the study was updated.
The Peg
IFN-α2a 
discontinuation criteria were 
updated to clarify that 
participants with moderate or 
severe depression or other 
psychiatric symptoms should 
immediately discontinue
PegIFN-α2a treatment.
In addition, participants will be
closely monitored for
neuropsychiatric adverse events
during the optional PegIFN-α2a
treatment period.
Participants who develop a
neuropsychiatric adverse event
during optional PegIFN-α2a
treatment will be monitored
closely until the
neuropsychiatric adverse event
resolves, with frequent (at least
weekly)  follow-up phone calls.
Furthermore, exclusion
criterion 31 was amended to
exclude participants with a
history of a severe psychiatric
disorder.Upon Health Authority 
request and to be consistent 
with the PegIFN-α2a 
prescribing information 1.3.1 Schedule of Activities   Screening and
Study Intervention Phase
1.3.3 Schedule of Activities –Optional
PegIFN-α2a Treatment
5.2 Exclusion Criteria
7.1 Discontinuation of Study Intervention
The Co
ntraceptive and Barrier 
Guidance and Collection of 
Pregnancy Information section 
was updated: the list of 
examples which are not
allowed as sole method of
contraception during the study
and the footnote concerning
possible interaction between
hormonal contraception and the
study intervention have been
removed. Additional
clarifications were also made.Upon Health Authority 
request and to align with the 
latest version of the 
sponsor’s protocol template. 5.1 Inclusion Criteria
10.8 Appendix 8: Contraceptive and Barrier
Guidance and Collection ofPregnancy
Information
Recomm
endations regarding 
the use of live vaccines during 
the study were added. Clarification considering the 
second dose concerns a life- 
attenuated virus.6.5 Concomitant Therapy
10.11 Appendix 11: Covid Appendix
It was
 clarified that venous 
blood samples will be collected 
for measurement of JNJ-3989, 
NA, and PegIFN-α2a. 
However, bioanalysis of NA
and PegIFN-α2a is optional at
the discretion of the sponsor.
Bioanalysis of JNJ-6379 may
also be done on samplesClarification. 1.1 Synopsis
1.3.1 Schedule of Activities   Screening and
Study Intervention Phase
3 OBJECTIVES AND ENDPOINTS
8.7 Pharmacokinetics
8.7.1 Evaluations
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 178
Status: 
Approved,  Date: 25 November 2021collected from participants who
received JNJ-6379 up to
Protocol Amendment 4.
Exclus
ion criterion 1 was 
adapted to clarify that 
participants with a positive
HIV-1 or HIV-2
antibody/antigen test at
screening should have a
confirmatory HIV RNA test, to
rule out false positive results.
They can be enrolled if they
have a negative HIV RNA test
at screening.
It was also clarified that
participants with evidence of
HIV-1 or HIV-2 infection who
are on antiretroviral treatment
are excluded. Clarification upon Health 
Authority request5.2 Exclusion Criteria
It was
 clarified that the use of 
low-dose aspirin is allowed 
with exception of 7 days prior 
to biopsies. Clarification upon 
investigator’s request. 1.1 Synopsis
6.5 Concomitant Therapy
8.1 Liver Biopsy and Fine Needle Aspiration
Biopsy
Minor e
rrors were corrected 
and minor clarifications were
made.Correction and clarification. Throughout the protocol
Amendm
ent 4 (30 July 2021)
Overall Rationale for the Amendment: The primary reason for this amendment is to offer participants
optional treatment with PegIFN-α2a for either 12 or 24 weeks starting after the Week 40 biopsy (or after
the optional leukapheresis if applicable) , to investigate whether addition of PegIFN-α2a towards the end of
the treatment regimen may enhance response to treatment. This change is based on the availability of
preliminary 48-week treatment data from the Phase 2b study REEF-1 (73763989HPB2001)  and new data
presented during the European Association for the Study of the Liver (EASL)  conference of 2021 showing
that HBsAg declines with siRNA treatment can be increased when combined with PegIFN.43
The REEF-1 study is evaluating the efficacy of 3 doses of JNJ-3989 (40, 100, or 200 mg Q4W)  + NA, of
JNJ-3989 100 mg Q4W + JNJ-6379 + NA, of JNJ-6379 + NA, and of NA alone. Data showed that all
regimens were safe and well-tolerated through end of treatment at Week 48. The JNJ-3989 200 mg dose
achieved the highest response rate (19.1%)  for the primary endpoint of meeting the NA treatment
completion criteria at Week 48 (ie, ALT <3x ULN, HBV DNA <LLOQ, HBeAg-negative [<LLOQ], and
HBsAg <10 IU/mL) . No participant in the JNJ-6379 + NA arm and 1 participant in the NA alone arm
achieved the primary endpoint. The largest mean (SD)  decline at Week 48 of 3.56 (1.328)  log 10 IU/mL was
observed in the JNJ-3989 200 mg + NA arm in the HBeAg positive currently not treated participants. The
mean HBsAg decline followed a biphasic pattern, with a steeper decline during the first 24 weeks followed
by a more shallow decline between Week 24 and Week 48. At Week 48, a limited number of participants
reached HBsAg seroclearance.
This amendment will allow to investigate whether addition of PegIFN-α2a for 12 or 24 weeks at or after
the Week 40 biopsy increases the participant’s chances to achieve HBsAg loss.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 179
Status: 
Approved,  Date: 25 November 2021Description of Change Brief Rationale Section Number and Name
In add
ition to the study 
intervention participants are 
randomized to, they may also 
receive optional treatment with 
PegIFN-α2a after the Week 40 
biopsy (or after the optional 
leukapheresis if applicable)  but
before the Week 48 visit. The 
duration (either 12 or 24 
weeks)  will be at the 
investigator’s discretion. To investigate whether 
addition of PegIFN-α2a 
towards the end of the 
treatment regimen increases 
the participant’s chances to
achieve HBsAg loss.1.1 Synopsis
1.2 Schema
1.3.3 Schedule of Activities –Optional
PegIFN-α2a Treatment
2 INTRODUCTION
2.1 Study Rationale
2.2.1.3 Combination of JNJ-3989 with
PegIFN-α2a
2.2.1.4 Combination of JNJ-6379 with
PegIFN-α2a
2.2.2.3 Combination of JNJ-3989 and JNJ-
6379 with PegIFN-α2a
2.3 Benefit-Risk Assessment
3 OBJECTIVES AND ENDPOINTS
4.1 Overall Design
5.2 Exclusion Criteria
6.1 Study Intervention(s)  Administered
6.2
Preparation/Handling/Storage/Accountability
6.4 Study Intervention Compliance
6.5 Concomitant Therapy
6.6 Dose Modification
7.1 Discontinuation of Study Intervention
8 STUDY ASSESSMENTS AND
PROCEDURES
8.5.6 Adverse Events of Special Interest
8.6 Treatment of Overdose
8.7 Pharmacokinetics
8.8 Pharmacokinetics/Pharmacodynamics
9.4.3 Other Analyses
10.1 Appendix 1: Abbreviations and
Definitions of Terms
10.2 Appendix 2: Clinical Laboratory Tests
10.3 Appendix 3: Regulatory, Ethical, and
Study Oversight Considerations
10.11 Appendix 11: Covid Appendix
11 REFERENCES
ALT el
evations were added as 
a potential risk and the section 
on management of ALT 
elevations was updated. To ensure the safety of 
participants during treatment 
with JNJ-3989, based on 
emerging data from studies 
REEF-1 and REEF-D.2.3.2.2.1 Potential Risks for JNJ-3989
8.5.6.1 Injection Site Reactions
10.6 Appendix 6: Intervention-emergent
ALT/AST Elevations
Update
s were made to the 
assumed statistical distribution 
and model-based approach that 
will be used in the analysis of 
the primary efficacy endpoint
and also used to justify the
planned sample size.For increased precision of 
the estimation of the 
primary efficacy endpoint 
and its variability. 1.1 Synopsis
9.2 Sample Size Determination
9.4.1.1 Analysis of the Primary Endpoint
11 REFERENCES
Remova
l of the mITT 
population. The same approach for 
complete case analysis can 
be implemented using the 
ITT population (including 1.1 Synopsis
9.3 Populations for Analyses
9.4.1 Analysis of Efficacy and Antiviral
Activity
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 180
Status: 
Approved,  Date: 25 November 2021all panels)  and therefore
mITT can be removed.
Descri
ption of efficacy and 
antiviral activity analyses were 
added to clarify the
explorations of interest which
include the statistical analyses
overall for the entire study
population, the comparisons
between panels regardless of
intervention arm, between
intervention arms within panel,
and between intervention arms
across panels.For clarification and 
completeness. 9.4.1 Analysis of Efficacy and Antiviral
Activity
Update
s were made to the 
clinical background section as 
more data have become 
available. For completeness. 2.2.2.1 JNJ-3989 and JNJ-6379
2.2.2.2 Combination of JNJ-3989 and JNJ-
6379 with Entecavir, Tenofovir Disoproxil, or
Tenofovir Alafenamide
2.3.3 Benefit-risk Assessment for Study
Participation
11 REFERENCES
Update
 of follow-up procedures 
and criteria for re-initiation of 
NA treatment. For clarification. 4.2 Scientific Rationale for Study Design
6.6.2 NA Re-treatment Criteria During Follow-
up
10.12 Appendix 12: NA Re-treatment During
Follow-up
A stud
y intervention 
discontinuation criterion was
added for participants who
withdraw consent.For completeness. 7.1 Discontinuation of Study Intervention
Study i
ntervention 
discontinuation criteria on 
hepatic decompensation and
eGFR cr abnormality were
updated.For clarification. 7.1 Discontinuation of Study Intervention
8.5.6.4 Renal Complications
The st
udy intervention 
discontinuation criterion on
virologic breakthrough was
updated.For completeness. 7.1 Discontinuation of Study Intervention
Local 
platelet aggregation 
testing was added to the 
schedule of activities instead of 
only mentioned in a footnote.Correction. 1.3.1 Schedule of Activities   Screening and
Study Intervention Phase
1.3.2 Schedule of Activities   Follow-up Phase
The fo
otnotes related to HBeAg 
testing were corrected. Correction. 1.3.1 Schedule of Activities   Screening and
Study Intervention Phase
Langua
ge on urine pregnancy 
testing for at-home use was 
updated. To provide additional 
guidance on urine pregnancy 
testing at home.1.3.2 Schedule of Activities   Follow-up Phase
10.11 Appendix 11: Covid Appendix
Exclus
ion criterion 1 
(concerning evidence of HIV-1
or HIV-2 infection at
screening)  and criterion 2 were
updated.For clarification. 5.2 Exclusion Criteria
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 181
Status: 
Approved,  Date: 25 November 2021It was clarified that JNJ-3989 
should preferably be 
administered via subcutaneous
injection in the abdomen.For clarification. 1.1 Synopsis
6.1 Study Intervention(s)  Administered
Head, n
eck, and thyroid were 
added to complete physical
examination.For completeness. 8.4.1 Physical Examinations
Langua
ge was added on 
medical encounters.For completeness. 8.11 Medical Encounters
Manage
ment ofrash and acute 
systemic allergic reactions were 
moved under a separate 
subheader. For correction and 
clarification as rash and
acute systemic allergic
reactions are not considered
AESIs for JNJ-3989 or JNJ-
6379.8.5.6 Adverse Events of Special Interest
Minor e
rrors were corrected 
and minor clarifications were
made.Correction and clarification. Throughout the protocol
Amendm
ent 3 (14 August 2020)
Overall Rationale for the Amendment: The sample size justification section was updated.
Section Number and Name Description of Change Brief Rationale
9.2 Sample
 Size Determination 
11 REFERENCES More details were added on the 
justification for sample size
determinationFor clarification
1.3.2 Sche
dule of 
Activities - Follow-up Phase Optional biopsy was delinked from 
the leukapheresis procedure The leukapheresis procedure was
incorrectly linked with the optional
biopsy
10.11 Appe
ndix 11: Covid 
Appendix Guidance on study conduct during 
the COVID-19 pandemic was 
added Options for study-related
participant management are being
provided in the event of disruption
to the study conduct due to the
COVID-19 pandemic
Amendm
ent 2 (07 May 2020)
Overall Rationale for the Amendment: Following Health Authority (HA)  feedback the protocol was
amended as specified below
Section Number and Name Description of Change Brief Rationale
1.1 Synop
sis, 9.3 Populations for 
Analyses An additional population (mITT)  
was added. Per HA request, the modified ITT
(mITT)  analysis set, restricted to
participants with biopsy data at
both Baseline and Week 40, was
defined as the primary analysis
population for consistency with the
planned observed cases analysis of
the primary efficacy endpoint
described in section 9.4.1.1.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 182
Status: 
Approved,  Date: 25 November 20219.4.1 Analysis of Efficacy and 
Antiviral Activity, 9.4.1.1 Analysis 
of the Primary Endpoint, 9.4.1.2 
Analysis of Secondary Endpoints, 
9.4.1.3 Analysis of Exploratory 
EndpointsThe mITT analysis set was added to 
the ITT set for the purpose of the 
efficacy analyses. Per HA request, in order to evaluate
the potential bias in using complete
case analysis, both mITT as
primary analysis set and ITT as
secondary analysis set will be used.
Title 
page and footer Updated confidentiality statement In line with the latest protocol
template
Amendm
ent 1 (10 April 2020)
Overall Rationale for the Amendment: Following Health Authority (HA)  feedback the protocol was
amended as specified below
Section Number and Name Description of Change Brief Rationale
9.4.1.1 Ana
lysis of the Primary 
Endpoint Methods for handling missing data 
were added to the protocol. Per HA request the approach to
handle missing data in the primary
analysis of the primary endpoint
was added.
2.3.2.3.1 Potent
ial Risks and 
Inconvenience Associated with the 
Liver Biopsy Procedures 
8.5.6.3 Complications From Liver
BiopsyThe risk language regarding 
possible serious complications of 
liver biopsies has been updated.  Per HA request the complications
from a liver biopsy are now
described in the protocol.
1.3.1 Sched
ule of 
Activities - Screening and Study 
Intervention Phase 
Schedule of Activities - Follow-up
PhaseAdditional timepoints were added 
for whole blood single cell
profiling.Correction
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 183
Status: 
Approved,  Date: 25 November 202110.11. Appendix 11: Covid Appendix
GUIDANCE ON STUDY  CONDUCT DURING THE COVID-19 PANDEMIC
It is recognized that the Coronavirus Disease 2019 (COVID-19)  pandemic may have an impact on
the conduct of this clinical study due to, for example, self-isolation/quarantine by participants and
study-site personnel; travel restrictions/limited access to public places, including hospitals; study-
site personnel being reassigned to critical tasks.
In alignment with recent health authority guidance, the sponsor is providing options for study-
related participant management in the event of disruption to the conduct of the study. This guidance
does not supersede any local or government requirements or the clinical judgement of the
investigator to protect the health and well-being of participants and site staff and maintain
oversight of delegated trial activities. If, at any time, a participant’s safety is considered at risk,
study intervention will be discontinued, and study follow-up will be conducted.
Scheduled visits that cannot be conducted in person at the study site will be performed to the extent
possible remotely/virtually or delayed until such time that on-site visits can be resumed. At each
contact, participants will be interviewed to collect safety data. Key efficacy endpoint assessments
should be performed if required and as feasible. Participants will also be questioned regarding
general health status to fulfill any physical examination requirement.
Every effort should be made to adhere to protocol-specified assessments for participants on study
intervention, including follow-up. Modifications to protocol-required assessments may be
permitted via COVID-19 Appendix after consultation with the participant, investigator, or the
sponsor. Missed assessments/visits will be captured in the clinical trial management system for
protocol deviations. Discontinuations of study interventions and withdrawal from the study should
be documented with the prefix “COVID-19-related” in the CR) .
The sponsor will continue to monitor the conduct and progress of the clinical study, and any
changes will be communicated to the sites and to the health authorities according to local guidance.
If a participant has tested positive for COVID-19, the investigator should contact the sponsor’s
responsible medical officer to discuss plans for study intervention and follow-up. Modifications
made to the study conduct as a result of the COVID-19 pandemic should be summarized in the
clinical study report.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 184
Status: 
Approved,  Date: 25 November 2021GUIDANCE SPECIFIC TO THIS PROTOCOL
The following emergency provisions are meant to ensure participant safety on study while site
capabilities are compromised by COVID-19 related restrictions. Remote medical consultation and
alternatives to study intervention dispensing, administration, and clinical laboratory assessments
may allow continued study participation for participants in this trial. Before implementing any of
these emergency provisions, the sponsor should be consulted to perform a benefit-risk analysis
and to ensure the measures are executed and documented correctly.
As restrictions are lifted and the acute phase of the COVID-19 pandemic resolves, sites should
revert to original protocol conduct as soon as feasible and in accordance with any country-specific
regulatory requirements.
Dispensing/administration of study intervention:
 For participants able to visit the study site, but who request to reduce visit frequency, or for
whom limited access to the site is expected, an additional supply of oral study intervention can
be provided.
 For participants unable to visit the study site, direct-to-patient (DTP)  shipment or handover to
a caregiver or delegate of oral study intervention may be implemented, where allowed per local
regulations and if requested by the treating study physician. Where DTP shipments or handover
to delegates are deemed necessary, the process must be coordinated between the site and
sponsor staff following standard DTP procedures for arranging shipment and adhering to
associated approvals and documentation requirements.
 JNJ-3989 should always be administered by a nurse at the study site or, if site visits are not
possible, at the participant’s home. Per the protocol, if a scheduled injection of JNJ-3989 was
missed, the injection should be given as soon as possible but within 3 weeks after the scheduled
time. Otherwise, the injection should be skipped and the next injection should be given at the
next scheduled time point per the initial injection schedule.
Continuation of study intervention:
 Any issue with continuation and/or provision of study intervention should be discussed with
the sponsor and should be well documented.
 Study intervention should be continued if, in the assessment of the investigator, it does not
result in risk to the participant. If at any time the participant’s safety is considered at risk due
to study intervention, study intervention will be temporarily or permanently discontinued,
while every effort should be made to maintain follow-up on study. The benefit of continuing
study intervention should be assessed by the investigator for each individual participant,
considering the potential impact of reduced direct clinical supervision on participant safety.
 If a participant develops a SARS-CoV-2 infection, the investigator should contact the sponsor
to discuss plans for study intervention and follow-up. A decision to continue study intervention
should be made by the investigator depending on symptoms and concomitant medication(s)
used for the treatment of COVID-19. Study intervention must be discontinued if prohibited
medication is used.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 185
Status: 
Approved,  Date: 25 November 2021 When a participant, for whom study intervention has been interrupted, recovers from suspected
or confirmed SARS-CoV-2 infection or related disease and all AEs related to SARS-CoV-2
infection improve to Grade ≤1, the investigator should discuss with the sponsor about resuming
study intervention.
COVID-19 vaccination during the study:
Local guidelines on the use of live vaccines in participants receiving PegIFN-α2a should be
followed, including for the second dose of Sputnik V (which contains rAd5, with a theoretical risk
of replication competence) . Sputnik Light, which is the first dose of Sputnik V (with rAd26)  is not
considered a live vaccine. See below for further guidance on the use of COVID-19 vaccines.
Locally approved COVID-19 vaccines (including those that received emergency use authorization
or conditional marketing authorization)  are allowed throughout the study. For participants
receiving PegIFN-α2a, the following recommendations should be applied to accommodate
COVID-19 vaccination during PegIFN-α2a treatment:
 COVID-19 vaccine and PegIFN-α2a should not be administered on the same day.
 If required, PegIFN-α2a injection can be delayed with 2 days. The next PegIFN-α2a injection
should be performed at the scheduled time.
 If required, skipping a PegIFN-α2a injection may be considered after consultation with the
Sponsor.
 Vaccination with Sputnik V should take above-mentioned consideration about live vaccines
into account.
All COVID-19 vaccination-related data (eg, COVID-19 vaccination, AEs, AE management)
should be appropriately captured in the CRF and source documents. Refer to the COVID-19
vaccine and/or PegIFN-α2a prescribing information for more details.
Study visits and assessments:
 If possible, central laboratory testing as outlined in the Schedule of Activities is to be
continued. If central laboratory tests cannot be performed, the use of a local laboratory is
allowed for study evaluations. A copy of the local laboratory report should be reviewed by the
investigator and filed with the source documents, along with reference ranges.
 To safely maintain participants on study intervention while site capabilities are compromised
by COVID-19-related restrictions, study visits may be performed by a nurse (who received
study-specific training)  at the patient’s home (home health nurse)  until such time that on-site
visits can be resumed. The following activities may be completed as required per the Schedule
of Activities and as feasible:
 Sampling, processing and shipping of laboratory samples (as described above)
 Checking study compliance: medication diary (if available) , intake of oral study
intervention, storage of oral study intervention
 Performing ECGs
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 186
Status: 
Approved,  Date: 25 November 2021 If JNJ-3989 is administered at the patient’s home, it will need to be done by a nurse (who
received study-specific training)
 Delivering oral study interventions and urine pregnancy tests for at-home use
 Any data related to adverse events (AEs) , concomitant medication, vital signs, and ECGs will
be reviewed and assessed by the investigator.
 In addition, participants may have tele-health visits conducted by qualified site personnel via
phone or video conversation as per local regulation. Assessments may include review of AEs
(including ISRs) , concomitant medications, and study intervention accountability. Participants
will also be questioned regarding general health status to fulfill any physical examination
requirement.
 Procedures and timings should follow the Schedule of Activities as closely as possible.
Standard AE/SAE reporting requirements apply.
 Ultrasound (and Fibroscan where applicable)  should be done as close as possible to the time
points specified in the Schedule of Activities . However, if this is not possible due to COVID-
19 related restrictions, the imaging test should be performed as soon as possible.
Informed consent:
 Consenting and re-consenting of participants (including also remote consenting by phone or
video consultation)  will be performed as applicable for the measures taken and according to
local guidance for informed consent applicable during the COVID-19 pandemic. The process
is to be documented in the source documents.
Source data verification/monitoring:
 In case on-site monitoring visits are not possible, the site monitor may contact the investigator
to arrange monitoring activities remotely (in accordance with site and local requirements) .
Additional on-site monitoring visits may be needed in the future to catch up on source data
verification.
Site audits:
 During the COVID-19 pandemic and at the impacted sites, study site GCP audits with direct
impact/engagement from the investigator and study-site personnel would not be conducted in
order to comply with national, local, and/or organizational social distancing restrictions.
Additional quality assurance activities such as remote audits or focused review of study-related
documents may take place with limited impact/engagement if possible.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDE
NTIAL –FOIA Exemptions Apply in U.S. 187
Status: 
Approved,  Date: 25 November 202110.12. Appendix 12: NA Re-treatment and Monitoring After Stopping of NA

JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 188
Status: A
pproved,  Date: 25 November 202111. REFERENCES
1. American Red Cross Blood donor eligibility requirements. Available from:
http:\\www.redcrossblood.org\donating-blood\eligibility-requirements. Accessed 28 March 2019.
2. Burak KW, Sherman M. Hepatocellular carcinoma: Consensus, controversies and future directions. A report
from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Can J
Gastroenterol Hepatol. 2015;29(4) :178 84.
3. Cohen SM, Johansson SL, Arnold LL, Lawson TA. Urinary tract calculi and thresholds in carcinogenesis.
Food and Chem Toxicol. 2002;40;793-799.
4. Dusheiko G, Wang B, Carey I. HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy.
Hepatol Int. 2016;10:727 729.
5. European Association for the Study of the Liver (EASL)  clinical practice guidelines on the management of
chronic hepatitis B virus infection. J Hepatol. 2017;67:370-398.
6. European Medicines Agency (EMA) . Assessment report Vemlidy (Tenofovir alafenamide) .
https://www.ema.europa.eu/documents/assessment-report/vemlidy-epar-public-assessment-report en.pdf. 10
November 2016. Accessed 29 January 2019.
7. Fang Z, Li J, Yu X, et al. Polarization of monocytic myeloid-derived suppressor cells by hepatitis B surface
antigen is mediated via ERK/IL-6/STAT3 signaling feedback and restrains the activation of T cells in chronic
hepatitis B virus infection. J Immunol. 2015;195(10) :4873-4483.
8. Gane E, et al. Dose Response with the RNA Interference Therapy JNJ-3989 Combined with Nucleos(t) ide
Analogue Treatment in Expanded Cohorts of Patients with Chronic Hepatitis B. The Liver Meeting,
Boston 2019, Poster 0696.
9. Gehring AJ, Protzer U. Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection.
Gastroenterology. 2019 Jan;156(2) :325-337.
10. Gill US, Pallett LJ, Kennedy PTF, et al. Liver sampling: a vital window into HBV pathogenesis on the path to
functional cure. Gut 2018;67:767-775.
11. Gill US, Pallett LJ, Thomas N, et al. Fine needle aspirates comprehensively sample intrahepatic immunity. Gut
2019;68:1493-1503.
12. Henry SP, Johnson M, Zanardi TA, Fey R, Auyeung D, Lappin PB, Levin AA. Renal uptake and tolerability of
a 2’-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715)  in monkey. Toxicology. 2012;301(1
3) :13-20.
13. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for
Human Use. ICH Harmonized Tripartite Guideline E14: Clinical evaluation of QT/QTc interval prolongation
and proarrhythmic potential for non-antiarrhythmic drugs. ICH 12 May 2005.
14. Investigator’s Brochure: JNJ-56136379 Edition 6. Janssen Research & Development (February 2021) .
15. Investigator’s Brochure: JNJ-73763989 Edition 5. Janssen Research & Development (April 2021) .
16. Investigator’s Brochure: JNJ-73763989 Edition 5, Addendum 1. Janssen Research & Development (July
2021) .
17. Janas MM, Harbison CE, Perry VK, et al. The nonclinical safety profile of GalNac-conjugated RNAi
therapeutics in subacute studies. Toxicol. Pathol. 2018;46(7) :735-745.
18. Janssen HLA, Arif A. Averting hepatocellular carcinoma in chronic hepatitis B with antiviral therapy: tipping
the balance or not yet? Gastroentology. 2014;147:24 26.
19. Jeng W-J, Chen Y-C, Chien R-N, Sheen I-S, Liaw Y-F. Incidence and predictors of hepatitis B surface antigen
seroclearance after cessation of nucleos(t) ide analogue therapy in hepatitis B e antigen-negative chronic
hepatitis B. Hepatology. 2018;68:425-434.
20. Li H, Zhai N, Wang Z, et al. Regulatory NK cells mediated between immunosuppressive monocytes and
dysfunctional T cells in chronic HBV infection. Gut. 2018;67(11) :2035-2044.
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 189
Status: A
pproved,  Date: 25 November 202121. Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. J
Hepatol. 2017;67(4) :847-861.
22. Magalhães-Costa P, Lebre L, Peixe P, Santos S, Chagas C. Hepatocellular carcinoma in chronic hepatitis B
patients on third generation nucleos(t) ides analogs: Risk factors and performance ofa risk score. GE Port J
Gastroenterol. 2016;23:233-242.
23. Memorandum to Advisory Committee Members and Guests from Entecavir Review Team. Briefing document
for NDA 21-797, entecavir 0.5 and 1 mg tablets and NDA 21-798, entecavir oral solution 0.05 mg/mL, 10
February 2005.
24. Memorandum to Advisory Committee Members and Guests from Tenofovir Review Team. Background
Package for NDA 21-356: VIREAD (tenofovir disoproxil fumarate) , 6 September 2001.
25. Papatheodoridis GV, Chan HLY, Hansen BE, et al. Risk of hepatocellular carcinoma in chronic hepatitis B:
Assessment and modification with current antiviral therapy. J Hepatol. 2015;62:956 967.
26. Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, et al. DARING-B: discontinuation of effective
entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg
negative chronic hepatitis B. Antivir Ther. 2018;23(8) :677-685.
27. PEGASYS Summary of Product Characteristics.
http://www.ema.europa.eu/docs/en GB/document library/EPAR -
Product Information/human/000395/WC500039195.pdf. Accessed 22 November 2019
28. Polaris Observatory Conservatory. Global prevalence, treatment, and prevention of hepatitis B virus infection
in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018;3:383– 403.
29. Rehermann B, Thimme R. Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C
Virus Infection. Gastroenterology. 2019;156(2) :369– 383.
30. Sarin KS, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis
B: A 2015 update. Hepatol Int. 2016;10:1-98.
31. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings
from the global burden of disease Study 2013. Lancet. 2016;388(10049) :1081-1088.
32. Tannehill-Gregg SH, Dominick MA, Reisinger AJ, et al. Strain-related Differences in Urine Composition of
Male Rats of Potential Relevance to Urolithiasis. Toxicol Pathol. 2009;37:293-305.
33. Terrault NA, Bzowej NH, Chang K, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology.
2016;63(1) :261 283.
34. Wang S, Chen Z, Hu C, et al. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12
production in monocytes/macrophages by interfering with JNK activation. J Immunol. 2013;190(10) :5142
5151.
35. Wooddell CI, Yuen MF, Chan HL, et al. RNAi-based treatment of chronically infected patients and
chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci. Transl. Med. 2017; 9:
409.
36. Yuen MF, Chen DS, Dusheiko GM, et al. Hepatitis B virus infection. Nat Rev Dis Prim. 2018; 4: Article
number 18035.
37. Yuen MF, et al. First Clinical Experience with RNA Interference-based Triple Combination Therapy in
Chronic Hepatitis B: JNJ-3989, JNJ-6379 and a Nucleos(t) ide Analogue. The Liver Meeting, Boston 2019, LB
Poster 4.
38. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven
methods. Stat Med. 1998; 17, 873-890.
39. Investigator’s Brochure: JNJ-56136379 Edition 6, Addendum 1. Janssen Research & Development (July
2021) .
40. Kassahun W, Neysens T, Molenbergh G, Faes C, Verbeke G. Modeling overdispersed longitudinal binary data
using a combined beta and normal random-effects model. Arch Public Health. 2012;70(1) :7
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 190
Status: A
pproved,  Date: 25 November 202141. PEGASYS Summary of Product Characteristics. Roche Registration GmbH. Revised July 2020. Available at
https://www.ema.europa.eu/en/documents/product-information/pegasys-epar-product-information en.pdf.
Accessed 4 September 2020.
42. PEGASYS United States Prescribing Information. Hoffmann-La Roche, Inc. Revised October 2017. Available
at https://www.accessdata.fda.gov/drugsatfda docs/label/2017/103964s5270lbl.pdf. Accessed 4 September
2020.
43. Yuen MF, et al. Preliminary on-treatment data from a phase 2 study evaluating VIR-2218 in combination with
pegylated interferon alfa-2a in participants with chronic hepatitis B infection. EASL 2021. PO-824
JNJ-73763989 and JNJ-56136379 Clinical Protocol 73763989HPB2003
AMENDMENT 6
CONFIDEN
TIAL –FOIA Exemptions Apply in U.S. 191
Status: A
pproved,  Date: 25 November 2021INVESTIGATOR AGREEMENT
I have read this protocol and agree that it contains all necessary details for carrying out this study. I will
conduct the study as outlined herein and will complete the study within the time designated.
I will provide copies of the protocol and all pertinent information to all individuals responsible to me who
assist in the conduct of this study. I will discuss this material with them to ensure that they are fully informed
regarding the study intervention, the conduct of the study, and the obligations of confidentiality.
Coordinating Investigator (where required):
Name (typed or printed) :
Institution and Address:
Signatur
e: Date:
(Day Mo
nth Year)
Principa
l (Site) Investigator:
Name (typed or printed) :
Institution and Address:
Telephon
e Number:
Signatur
e: Date:
(Day Mo
nth Year)
Sponsor's
 Responsible Medical Officer:
Name (typed or printed) : 
Institution: Janssen Research & Development
Signatur
e: electronic signature appended at the end of the protocol Date:
(Day Mo
nth Year)
Note: If 
the address or telephone number of the investigator changes during the study, written notification will be
provided by the investigator to the sponsor, and a protocol amendment will not be required.
PPD
Signature
User Date Reason
 
 25-Nov-2021 
10:27:57
(GMT)Document Approval
PPD